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Summary 
Posttranslational modification of cell cycle regulators with ubiquitin chains is 
essential for eukaryotic cell division. Such chains can be connected through 
seven lysine residues or the amino-terminus of ubiquitin, thereby allowing the 
assembly of eight homogenous and multiple mixed or branched conjugates. 
While functions of homogenous chain types have been described, physiological 
roles of branched structures are unknown. The anaphase-promoting complex 
(APC/C) catalyzes degradation of key regulators during the cell cycle causing 
proper transition through the cell cycle.   
Here, I report that the APC/C efficiently synthesizes substrate-attached branched 
conjugates and enhances recognition of ubiquitylated substrates by the 
proteasome, thereby driving the degradation of cell cycle regulators during early 
mitosis. I showed several APC/C-substrates require the ubiquitin-conjugating 
enzyme E2 S (Ube2S) for degradation, e.g. the Never in mitosis A-related kinase 
2 (Nek2A). The reconstitution of Nek2A ubiquitylation revealed that Ube2S does 
not simply extend a conjugate, but instead branches multiple lysine11-linked 
chains off the ubiquitin chains produced by the ubiquitin-conjugating enzyme E2 
C (Ube2C). 
Therefore, I identified an enzyme and substrates for modification with branched 
ubiquitin chains, which points to an important role of these conjugates in 
providing an improved signal for proteasomal degradation. Compared to 
homogenous chains, branched conjugates synthesized by the APC/C increase 
the efficiency of proteasomal substrate recognition, and accordingly, are required 
for the degradation of cell cycle regulators at times of limited APC/C activity such 
as prometaphase. Hence, the APC/C is an enzyme that synthesizes branched 
ubiquitin chains, which provide an improved signal for proteasomal degradation.  
 
 
 
 
Zusammenfassung 
Posttranslationale Modifikation von Regulatoren des Zellzyklus mit 
Ubiquitinketten ist essentiell für Zellteilung. Diese Ketten können durch sieben 
verschiedene Lysine oder den Amino-Terminus von Ubiquitin verknüpft sein, 
welches die Formierung von acht homogenen und vielen gemischten oder 
verzweigten Konjugaten erlaubt. Funktionen für homogene Kettenarten sind 
bereits beschrieben worden, während die physiologische Bedeutung der 
verzweigten Strukturen unbekannt ist. Der Anaphase fördernde Komplex 
(APC/C) katalysiert die Degradierung von wichtigen Regulatoren innerhalb des 
Zellzyklus, was zu einem geordneten Ablauf des Zellzyklus führt.   
Ich berichte hier, dass der APC/C verzweigte, substratgekoppelte Ubiquitinketten 
effizient synthetisiert, was die Bindung von ubiquitinierten Substraten durch das 
Proteasom verstärkt und wodurch der Abbau von Zellzyklusregulatoren in früher 
Mitose vorangetrieben wird. Ich habe aufgedeckt, dass mehrere APC/C-
Substrate das ubiquitinkonjugierende Enzym E2 S (Ube2S) für ihre Degradierung 
benötigen, z.B. die Niemals in Mitose A verwandte Kinase 2 (Nek2A). Die 
Rekonstitution der Nek2A-Ubiquitinierung zeigt, dass Ube2S nicht nur ein 
Konjugat verlängert, sondern stattdessen mehrere Lysin11-geknüpfte Ketten 
verzweigt, welche von Ubiquitinketten ausgehen, die durch das 
ubiquitinkonjugierende Enzym E2 C (Ube2C) produziert worden sind.   
Daher habe ich ein Enzym und Substrate identifiziert, welche mit verzweigten 
Ketten modifiziert sind, was auf eine wichtige Rolle dieser Konjugate als ein 
stärkeres Abbausignal hinweist. Verglichen mit homogenen Ketten steigt die 
Effizienz der vom APC/C-produzierten, verzweigten Ketten im Bezug auf 
proteasomale Substraterkennung und deshalb sind verzweigte Ubiquitinketten 
für die Degradierung von Zellzyklusregulatoren zuzeiten limitierter APC/C-
Aktivität erforderlich, wie in Prometaphase. Infolgedessen ist der APC/C ein 
Enzym, das verzweigte Ubiquitinketten synthetisiert, welche ein verstärktes 
Abbausignal durch das Proteasom darstellen. !
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1. Introduction 
Living organisms known to date rely on three kinds of large molecules for 
basically all their biological functions. These molecules consist of 
deoxyribonucleic acids (DNA), ribonucleic acids (RNA) and proteins, and are 
known as biological macromolecules (Berg et al., 2002). Proteins are responsible 
for vital processes such as metabolism, growth, environmental interaction, 
morphology and motility. Half the mass of the bacterium Escherichia coli consists 
of proteins, underlying their importance and complexity (Voet and Voet, 2011). 
An organism needs to be capable of regulating the abundance of myriads of 
proteins to function properly. Both the synthesis and the destruction of proteins 
are tightly controlled. On a cellular level the degradation of proteins is mainly 
carried out by trafficking into lysosome organelles or by degradation through the 
proteasome, which both can be achieved by a posttranslational modification 
called ubiquitylation (Ciechanover, 2005). The following will mainly explain how 
ubiquitylation occurs and what its consequences are during the cell cycle 
mediated by the enzyme called anaphase-promoting complex/cyclosome 
(APC/C). 
 
1.1. The posttranslational modification with ubiquitin called ubiquitylation 
Ubiquitylation controls critical signaling pathways in eukaryotes and is essential 
for cell proliferation, differentiation, and survival (Deshaies and Joazeiro, 2009; 
Schulman and Harper, 2009). It achieves this by targeting proteins to the 
proteasome for degradation or signaling endocytosis and lysosomal degradation 
(Figure 1). Furthermore ubiquitylation is not only involved in the degradation of 
proteins. In several signaling pathways it controls the interactions of key proteins 
(Komander and Rape, 2012).  
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Figure 1: Overview of cellular functions regulated by ubiquitylation. (a) In the nucleus, 
ubiquitylation signals for proteasome-independent regulation of DNA repair. Histones and 
Proliferating cell nuclear antigen (PCNA) are examples of nuclear targets of 
ubiquitylation.(b) Ubiquitylation functions in kinase activation by acting as a scaffold to bring 
kinases and their substrates together to enable the activation of kinase cascades, as exemplified 
by the activation of inhibitor of kappa B kinase (IKK) by Transforming growth factor beta activated 
kinase-1 (TAK1). The E3 Tumor necrosis factor receptor-associated factor 6 (TRAF6) 
ubiquitylates several proteins including nuclear factor-kappa-B essential modulator (NEMO) and 
itself upon ligand stimulation. TAK1 and IKK complexes interact with each other upon binding 
these ubiquitin chains with their ubiquitin-binding subunits (TAB2 and NEMO, respectively). IKK is 
thus activated by TAK1 and competent to phosphorylate Inhibitor of kappa B (IκB), which leads to 
its ubiquitylation and proteasomal degradation (i). IκB degradation releases nuclear factor-kappa-
B (NF-κB) into the nucleus, thereby activating gene transcription. (c) Proteasome-mediated 
degradation (i) regulates many cellular processes through targeted degradation of key regulatory 
proteins. (d) Ubiquitylation signals for protein quality control to degrade misfolded proteins. 
Protein quality control of endoplasmic reticulum (ER) proteins occurs through the ER-associated 
protein degradation (ERAD) pathway by proteasomal degradation (i), whereas some large protein 
aggregates are eliminated through the autophagy (Av, autophagic vesicles)-lysosome route (ii). 
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Polyubiquitylation acts as a signal for autophagy targeting. (e) Ubiquitylation signals for vesicular 
trafficking between membrane compartments. (iii) Ligand-bound plasma membrane proteins 
internalized into early endosomes (EE). (iv) Proteins are sorted into multivascular bodies 
(MVB). (v) Newly synthesized membrane proteins are sorted from the trans-Golgi network (TGN) 
to the MVB. (f) Ubiquitin signaling regulates gene transcription (BARD1: BRCA1-associated RING 
domain protein 1; BRCA1: breast cancer type 1 susceptibility protein; ESCRT: endosomal sorting 
complexes required for transport; H2AX: histone 2 A histone family member, family X; H3: histone 
3; Lys: lysine; p62: ; Polη: DNA polymerase η; RAP80: receptor-associated protein 80; modified 
after Liu and Walters, 2010). 
Because of its key roles in proteolysis and signaling, misregulated ubiquitylation 
is involved in a plethora of human diseases and disorders: cancer (Kirkin and 
Dikic, 2011; Lipkowitz and Weissman, 2011; Micel et al., 2013; Shi and 
Grossman, 2010; Yerlikaya and Yöntem, 2013), autoimmune diseases 
(Fierabracci, 2012; Ma and Malynn, 2012; Wang and Maldonado, 2006), cardiac 
diseases (Carrier et al., 2010; Pagan et al., 2013; Powell et al., 2012), metabolic 
disorders (Genschik et al., 2013; Vu and Sakamoto, 2000; Zungu et al., 2011), 
neurodegeneration (Bossy-Wetzel et al., 2004; Ihara et al., 2012; Nijholt et al., 
2011), mental disorders (Donohue, 2002; Seelaar et al., 2011) or even 
pneumonia (Wang et al., 2012a). Because ubiquitylation participates in so many 
different processes a lot of studies have been conducted to understand the 
mechanisms behind it.  
Ubiquitin itself is a highly conserved 76 amino acid protein, that becomes 
covalently attached to another protein through the formation of an isopeptide 
bond between ubiquitin’s C terminal carboxyl function and in most studied cases 
the ε-amino group of a lysine residue within the other protein (Figure 2A; Hershko 
and Ciechanover, 1998). In eukaryotes, ubiquitin is fairly abundant with levels 
around 0.1-5% of total proteins; it is expressed from two genes as a tetramer or 
octamer in a head-to-tail configuration and from two other genes as single 
ubiquitin moiety fusions to ribosomal proteins (Kimura and Tanaka, 2010). These 
four precursors are processed into the final monomeric ubiquitin molecules by 
ubiquitin hydrolases. Ubiquitin forms a globular structure and is very stable 
(Kimura and Tanaka, 2010).  
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Figure 2: Ubiquitin structure and different ubiquitylation topologies. A. Ubiquitin structure 
and linkages. Ubiquitin is a globular protein with a flexible C-terminus. Polyubiquitylation can 
occur through any of the seven lysine residues  (blue: ε-amino group) and the N-terminus (M1) of 
ubiquitin (PDB 1UBQ). B. Monoubiquitylation and multiple monoubiquitylation. The transfer of a 
single ubiquitin to one (monoubiquitylation) or multiple (multiple monoubiquitylation) sites can 
recruit binding partners, inhibit interactions, change protein localizations or modulate protein 
activities. C. Heterogenous polyubiquitylation. A single substrate can get ubiquitylated with chains 
containing distinct linkages within a single chain or homogenous chains at different sites within 
the substrate. Branched or forked ubiquitin chains result from the attachment of two ubiquitin 
molecules to two different lysine residues in a ubiquitin that is already linked to a substrate and 
are therefore a subtype of mixed ubiquitin chains. If heterogenous chains are responsible for 
certain cellular functions is unknown. D. Homogenous polyubiquitylation. K48- and K11-linked 
ubiquitin chains target proteins for degradation by the 26S proteasome. K63-linked chains usually 
mediate the recruitment of binding partners, which can lead to activation of NF-κB, orchestration 
of different steps during DNA repair or targeting of the modified protein to the lysosome. All other 
ubiquitin chains have been detected in vitro or in vivo, but substrates or enzymes responsible for 
their assembly are poorly defined (green: substrate (PDB 1VIN), red: ubiquitin (PDB 1UBQ); 
modified after Ye and Rape, 2009). 
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The transfer of a single ubiquitin to a substrate, a reaction referred to as 
monoubiquitylation, typically alters interactions, localization, or activity of the 
modified protein (Figure 2B; Dikic et al., 2009).  
Conversely, the attachment of multiple ubiquitin molecules results in polymeric 
chains, that depending on their connectivity could have unique functions. 
Ubiquitin chain formation can occur through seven lysine residues  (K6, K11, 
K27, K29, K33, K48 and K63) or the N-terminus of ubiquitin (M1), leading to the 
assembly of multiple chains with distinct topology; the use of different lysine 
residues leads to more complex ubiquitin topologies  (Figure 2C,D; Komander 
and Rape, 2012). All linkages have been detected in cells, and their abundance 
changes during the cell cycle or cell differentiation (Peng et al., 2003; Xu et al., 
2009). 
 
1.1.1. The enzymatic ubiquitylation cascade of E1-E2-E3 
Most ubiquitylation reactions occur through the subsequent actions of an 
adenosine triphosphate (ATP)-dependent enzymatic cascade consisting of 
ubiquitin activating enzymes (E1), ubiquitin conjugating enzymes (E2) and 
ubiquitin ligases (E3). Two ubiquitin specific E1s exist in vertebrates called UBA1 
and UBA6. While UBA1 is the more extensively investigated E1 working with 
most E2s, UBA6 was recently discovered and seems to work exclusively with a 
single E2 named UBA6 specific E2 (USE1) (Jin et al., 2007; Schulman and 
Harper, 2009). Therefore UBA1 is referred to E1 from here on. The human 
genome contains about 40 E2s; some of them do not interact with ubiquitin or 
show no catalytic activity on their own (Deshaies and Joazeiro, 2009). More than 
600 distinct E3s ensure the regulated modification of specific substrates within 
human cells (Deshaies and Joazeiro, 2009). About 85 deubiquitinating enzymes 
(DUBs) can reverse ubiquitylation making it a highly dynamic process, which can 
be regulated on multiple levels (Komander et al., 2009).  
The initial step in the ubiquitylation cascade is the binding of Mg•ATP and 
ubiquitin to E1. Next, ubiquitin is adenylated by E1 under release of 
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pyrophosphate (PPi) at its C-terminus (Figure 3A; Haas and Rose, 1982; Haas et 
al., 1982, 1983). E1’s catalytic cysteine sulfhydryl group attacks the ubiquitin 
adenylate bond leading to discharge of adenosine monophosphate (AMP) and 
the formation of a thioester between E1 and ubiquitin’s C terminal carboxyl group 
(Ciechanover et al., 1981, 1982; Haas and Rose, 1982; Haas et al., 1982). 
Another round of ubiquitin adenylation leads to a complex of E1 bound to the 
activated ubiquitin adenylate and the thioester ubiquitin intermediates (Haas and 
Rose, 1982; Haas et al., 1982). This single E1 bound to two activated ubiquitin 
species binds E2s with nanomolar affinities (Haas et al., 1988). Ubiquitin is then 
transferred to the catalytic site cysteine residue of the respective E2 in a 
transthioesterification reaction (Figure 3B; Haas and Bright, 1988; Haas et al., 
1982, 1988; Hershko et al., 1983; Pickart and Rose, 1985).  
Figure 3: The enzymatic cascade 
responsible for ubiquitin transfer. 
A. E1-catalyzed reaction. Step 1, 
ubiquitin adenylate formation; step 
2, transfer of ubiquitin from 
adenylate to cysteine (product not 
shown); step 3, second round of 
adenylate formation to yield fully 
loaded enzyme, modified after 
(Pickart, 2004). B. Schematic 
representation of the different 
modifications occurring at the 
carboxyl end of ubiquitin during 
ubiquitylation. (i) RING (really 
interesting new gene) mediate the 
direct transfer of ubiquitin from the 
E2 onto the substrate; (ii) an 
additional transthioesterification 
step is mediated by HECT 
(homologous to E6-AP carboxyl 
terminus) before substrate ubiquitylation, modified after (Kleiger and Mayor, 2014). 
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The ubiquitin charged E2 dissociates from E1, which now can undergo another 
cycle of ubiquitin thioester and subsequent ubiquitin adenylate formation. An E3 
will bind an E2 loaded with ubiquitin and catalyze ubiquitin transfer from the E2’s 
active site onto the substrate forming a stable isopeptide bond between 
ubiquitin’s C terminal carboxyl group and an ε-amino group of a lysine residue of 
the respective substrate (Ye and Rape, 2009). This process can be repeated 
multiple times resulting in the formation of polyubiquitin chains on a substrate; 
engagement of the substrate already modified with ubiquitin by an E3 causes the 
addition of another ubiquitin moiety from an E2 leading to formation of a covalent 
bond between the C-terminus of E2 bound ubiquitin and a lysine residue of the 
substrate attached ubiquitin (Hochstrasser, 2006). E3 binding sites in substrates 
are called degrons, if the E3 causes substrate degradation. The determinants of 
E2/E3 pairs are further elaborated below. E3s can be divided in two major 
classes: really interesting new gene (RING) and homologous to E6-AP carboxy 
terminus (HECT) ligases. While RING E3s permit transfer of ubiquitin from E2 
directly to the substrate, HECT E3s have a catalytic side cysteine residue within 
their HECT domain. Due to transthioesterification ubiquitin becomes transferred 
from the E2 on to the HECT E3. Binding of a substrate to a charged HECT E3 
results in modification of the substrate with ubiquitin. If E3s are mentioned here 
generally RING E3s are meant. Ubiquitin ligases that further ubiquitylate 
oligoubiquitylated substrates are called E4s (Hoppe, 2005; Koegl et al., 1999).  
 
1.1.2. E2s specify ubiquitin chain linkage and E2-E3 interaction  
An increasing number of studies show that E2s are often the deciding force 
behind ubiquitin topology specificity of E3s (Komander and Rape, 2012; Wenzel 
et al., 2011a). HECT E3s are the exception as the C-terminal lobe of the HECT 
domain decides linkage specificity (Wang et al., 2006). In general the last 
enzyme in the ubiquitylation cascade carrying ubiquitin via a thioester bond 
seems to determine what kind of chain is constructed.  
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Figure 4: Mechanism of linkage-specific ubiquitin chain assembly and RING interaction by 
E2s. A. Heterodimeric Ube2N-Ube2V2 (Ubc13-Mms2 in S.cerevisiae) recognizes acceptor 
ubiquitin through the UBC-variant domain of Ube2V2. This positions the acceptor K63 to the 
active site of charged Ube2N. B. Monomeric Ube2S catalyzes linkage formation through 
substrate-assisted catalysis. Ube2S recognizes the so-called TEK-box (Jin et al., 2008) of 
acceptor ubiquitin. Activation of the acceptor K11 requires a ubiquitin residue, E34. Thus, the 
correct surface of the acceptor ubiquitin, which includes K11 and E34, must be exposed to the 
catalytic cysteine of charged Ube2S in order for the active site to be completed and for linkage 
formation to occur. C. Comparison of different E2-E3 interactions: UBE2L3–casitas B-lineage 
lymphoma (CBL) (PDB 1FBV44), UBE2N–carboxy terminus of HSC70 interacting protein (CHIP; 
also known as STUB1) (PDB 2C2V46), UBE2D2–CNOT4 (CCR4–NOT transcription complex, 
subunit 4) (PDB 1UR645) and UBE2N–TNF receptor associated factor 6 (TRAF6) (PDB 
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3HCT47). All E2s use loop 1, loop 2 and α-helix 1 to interact with E3s. The side chains of the 
residues involved in E3 recognition are colour-coded (residues in loop 1 are yellow, in loop 2 are 
red and in α-helix 1 are cyan). Note that for CBL and TRAF6, E3 elements outside the RING 
domain (shown in green) participate in E2 binding. The CNOT4–UBE2D2 structure is an NMR 
model, whereas the others were solved by crystallography. The RING finger (or the U-Box for 
CHIP) is in orange, and the cognate E2s are in blue. D. E2 binding domains other than the RING 
modulate ubiquitylation by binding to the ‘backside’ of E2s. Structures of the Postreplication repair 
protein Rad18 (R6BD, 2YBF); Autocrine motility factor receptor, called gp78 (G2BR, PDB 3H8K); 
binding to the ‘backside’ of their respective E2s (labeled and shown in green). The catalytic 
cysteine of each E2 is highlighted in yellow. E. Ubiquitin chain formation proceeds through an 
initiation step, during which a substrate lysine residue is modified, and elongation, during which 
ubiquitin molecules are added to the growing chain. (Modified after Komander and Rape, 2012; 
Metzger et al., 2014; Ye and Rape, 2009) 
In the case of RING E3s this is achieved by proper orientation of E2 active site 
and target ubiquitin lysine residue. Two major orientation mechanisms have been 
observed, as either an E2 binding protein helps to orient the acceptor ubiquitin or 
surfaces on the E2 itself that are distinct from the catalytic site bind and orient 
acceptor ubiquitin. Donor ubiquitin is the ubiquitin molecule, which is attached to 
the E2 via its C-terminus, while the ubiquitin molecule, which becomes modified 
via its lysine residue, is called acceptor ubiquitin (Figure 4A,B). In the resulting 
polyubiquitin chain donor ubiquitin would be the proximal ubiquitin moiety, while 
the acceptor ubiquitin would be the distal ubiquitin. The E2 Ube2N is able to use 
Ube2V1/2 for acceptor ubiquitin orientation (Figure 4A; Eddins et al., 2006). 
Ube2K possesses a ubiquitin-associated domain (UBA), binding and orienting 
the acceptor ubiquitin (Wilson et al., 2011). On the other hand Ube2S, Ube2G2 
and Ube2R1 can orient acceptor ubiquitin via binding to the core E2 itself (Figure 
4B; Liu et al., 2014; Suryadinata et al., 2013; Wickliffe et al., 2011a). Domains 
within an E3 like the RING itself might contribute to orientation of acceptor 
ubiquitin, which needs to be further determined.  
While it is important to know what kind of linkage-specificity is encoded by an E2, 
it is equally important to understand which E3s and E2s are able to interact in a 
productive manner. All E2s have an evolutionary conserved ubiquitin conjugating 
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domain (UBC) of about 150 amino acids with extensions N- or C-terminal of the 
UBC and within the UBC (Wenzel et al., 2011a). Generally every E2 interacts 
with an E3 through its UBC. Certain loops have been identified in the UBC as 
essential for productive RING or HECT interaction (Figure 4C). Replacement of 
residues in these loops tested in combination with different E3s indicate a certain 
degree of E3 specificity encoded in these loop regions (Wenzel et al., 2011a; Xu 
et al., 2008). As only few functional E2/E3 pairs are known and have been tested 
this way, generalizations regarding E2/E3 compatibility should be met with 
caution. The N-or C-terminal extensions of the UBC can provide specific 
interaction with their E3s (Kleiger et al., 2009; Summers et al., 2008). 
Additionally, elements outside the RING domain in E3s seem to be involved in 
binding to their cognate E2s via the UBC (Figure 4C,D; Bailly et al., 1997; Das et 
al., 2009; Li et al., 2009). Moreover, productive interaction of an E2 with an E3 
can be based on the class of the E3 (Wenzel et al., 2011b).  
Furthermore different E2s are able to work sequentially with a given E3. One E2 
initiates chain formation by monoubiquitylation and subsequently another E2 
elongates the single ubiquitin moiety with more ubiquitin molecules in form of 
chains (Figure 4E; Rodrigo-Brenni and Morgan, 2007).  
 
1.1.3. How much information is encoded by the different ubiquitin linkages? 
The first chain types to be discovered, termed canonical ubiquitin chains, have 
distinct consequences for the modified protein: while chains connected through 
K48 of ubiquitin promoted proteasomal degradation (Chau et al., 1989; Johnson 
et al., 1995), K63 linked chains regulated the assembly of oligomeric complexes 
(Figure 2D; Spence et al., 2000; Wang et al., 2001). Based on these 
observations, it was hypothesized that diverse ubiquitylation marks might trigger 
unique biological outcomes, reminiscent of a code. Since then many more 
physiological ubiquitylation events have been characterized in terms of K48 or 
K63 linkages. Just to name a few, K48-linked chains are used for degradation of 
proteins involved in the cell cycle (Mocciaro and Rape, 2012; Petroski and 
Introduction 
 !
! -22-!
Deshaies, 2005), tumor suppression (Chen et al., 2013a; Wang et al., 2013, 
2012b), tumorigenesis (Chandra et al., 2013; Lin et al., 2013; Narisawa-Saito and 
Kiyono, 2007; Wang and Pickart, 2005), development (Latres et al., 1999; Ro 
and Dawid, 2009; Wodarz and Nusse, 1998), apoptosis (Gonzalvez et al., 2012; 
Guicciardi et al., 2014; van de Kooij et al., 2013; Yeh and Bratton, 2013), 
transcription (Chang et al., 2011; Chen et al., 2013b; Lei et al., 2013; Liu et al., 
2012; Yuan et al., 2012) or in clearance of misfolded proteins at the endoplasmic 
reticulum (ER) (Bagola et al., 2013; Li et al., 2007b; Smith et al., 2011). On the 
other hand more examples have been found, where K63-linked chains modulate 
composition of protein complexes with functions such as DNA repair (Doil et al., 
2009; Al-Hakim et al., 2010; Huang et al., 2009; Sobhian et al., 2007; Stewart et 
al., 2009), cell proliferation (Davies et al., 2013; Linares et al., 2013; Peschiaroli 
et al., 2010; Tauriello et al., 2010), immune response (Conze et al., 2008; Hou et 
al., 2011; Xia et al., 2009; Zeng et al., 2010) protein trafficking (Hao et al., 2013; 
Huang et al., 2013; Kramer et al., 2010; Stawiecka-Mirota et al., 2007), splicing 
(Bellare et al., 2008; Song et al., 2010) and translation (Spence et al., 2000). At 
this point it should be mentioned that trafficking of proteins regulated by K63-
linked chains often leads to their degradation in lysosomes (Figure 1; Barriere et 
al., 2007; Tofaris et al., 2011; Varghese et al., 2008). 
Other ubiquitin linkages have been detected in cells and some of them are 
attributed to E2/E3 pairs and their biological functions (Komander and Rape, 
2012). Several of these linkages can mediate proteasomal degradation, but the 
reason for this redundancy is unclear (Jin et al., 2008; Johnson et al., 1995; 
Koegl et al., 1999; Xu et al., 2009).  
Linear ubiquitin chains or M1-linked chains have been reported to function 
similarly to K63-linked chains in regulating formation of protein complexes often 
even in the same pathway as K63 chains (Rieser et al., 2013; Walczak et al., 
2012). Again the redundancy for different chain types fulfilling very similar 
functions remains elusive. 
Conjugates of more complex topology, such as mixed chains, are formed during 
endocytosis or immune signaling (Figure 2C; Boname et al., 2010; Emmerich et 
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al., 2013). Furthermore, in vitro reconstitution of several E2/E3 pairs showed that 
a single ubiquitin molecule embedded within a chain can be modified at two 
lysine residues, a process that leads to the assembly of branched conjugates 
(Figure 2C; Kim et al., 2007). These branched conjugates were also found in 
cells (Peng et al., 2003; Tagwerker et al., 2006). 
Many of the identified E3/substrate pairs still have to be investigated regarding 
their linkage specificity especially in vivo. Another way to determine linkage 
specificity is in vitro reconstitution of the respective reaction. Unfortunately only 
few physiological E2/E3 pairs have been identified. Studies that address ubiquitin 
linkages generally report the linkage used by a certain E3 and what function this 
linkage specific substrate ubiquitylation has. Hence these studies pair a certain 
linkage and its impact on substrates in a purely correlative way. Future studies 
are needed to show the outcomes of changing linkage specificity to gain further 
insights into the ubiquitin code. 
 
1.1.4. The 26S proteasome and other ubiquitin binding proteins 
The human 2.5 MDa 26S proteasome is responsible for ubiquitin dependent 
protein degradation in the ubiquitin proteasome system (UPS; Figure 5; Finley, 
2009). It consists of the proteolytic 20S core particle (CP) and a 19S regulatory 
particle (RP). The CP consists of 28 subunits encoded by 14 different genes and 
is shaped like a barrel in a symmetrical manner (Borissenko and Groll, 2007; 
Groll et al., 1997). The interior of the barrel is coated with six peptidase active 
sites, which together are able to hydrolyze a wide range of proteins into 
oligopeptides (Borissenko and Groll, 2007). Entry into the inner chamber of the 
CP is regulated by the RP (Finley, 2009). The RP consists of 19 subunits in yeast 
and can be further subdivided into base and lid. Six different ATPases 
responsible for CP-RP complex formation, two scaffold proteins and two ubiquitin 
binding proteins, the 26S proteasome regulatory subunits Rpn10/S5a and 
Rpn13, also called ubiquitin receptors, make up the base. ATP binding to the 
ATPases is necessary for proper assembly of the proteasome (Smith et al., 
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2005). ATP hydrolysis is required for protein unfolding and translocation of the 
unfolded polypeptide via a channel into the proteolytic chamber of the CP (Finley, 
2009).  
 
Figure 5: Schematic representation of the degradation cycle of the ubiquitin proteasome 
system. Proteins are targeted to the proteasome by a two-part degradation signal or degron. It 
consists of a disordered region within the substrate and a reversibly attached polyubiquitin tag 
(Ubn). The proteasome recognizes its substrates at the ubiquitin tag through ubiquitin receptors 
(Rpn10/S5A and Rpn13; green) (top) and initiates degradation at the unstructured region (right). 
Once the proteasome has engaged its substrate, it unravels the protein by translocating it into a 
central cavity in the core particle, where the protein is proteolysed (bottom). The polyubiquitin tag 
is cleaved off by the intrinsic DUB Rpn11 (skyblue) as unfolding and degradation begins 
(modified after  Inobe and Matouschek, 2014). 
The only assigned function for one of the nine lid subunits is the deubiquitinating 
activity of Rpn11, which is important for proteasome activity cleaving off a 
ubiquitin chain in one step at the proximal ubiquitin (Gallery et al., 2007; Maytal-
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Kivity et al., 2002; Verma et al., 2002; Yao and Cohen, 2002). Consequently the 
concerted actions of CP and RP enable the 26S proteasome to bind a 
ubiquitylated protein via its ubiquitin receptors, to unfold the protein with its 
ATPases, to cleave off ubiquitin with its DUB and to translocate the unfolded 
protein into the inside of the CP, where its peptidases hydrolyze the proteins. 
Several other proteins bind the proteasome, regulating its function. Most relevant 
here are the so-called proteasomal shuttle or delivery factors that bind and 
protect ubiquitylated proteins from DUBs, while supposedly recruiting them to the 
proteasome by direct binding (Finley, 2009). The homologues of S5A/Rpn10 and 
human UV excision repair protein RAD23 homolog A (HHR23A), one of the 
proteasomal delivery factors, are both crucial in mice (Hamazaki et al., 2007; Ng 
et al., 2003) and were therefore mostly used as a readout for proteasomal 
ubiquitin binding in this study. 
The ATP-driven chaperone valosin-containing protein/p97 (p97) has been 
implicated in targeting ubiquitylated proteins to the proteasome as well (Kim et 
al., 2004; Richly et al., 2005). In complex with its cofactors, which have ubiquitin 
binding domains, p97 is able to interact with ubiquitylated proteins (Alexandru et 
al., 2008; Richly et al., 2005). Using its so-called “segregase” activity, p97 can 
extract proteins from the ER or the mitochondrial membrane as well as chromatin 
for proteasomal degradation; it has also been shown to be involved in the 
clearance of intracellular protein aggregates, in autophagy and in endosomal 
trafficking (Meyer et al., 2012). Hence, p97 is an important hub in the cell for 
ubiquitin dependent processes and was used as another readout for ubiquitin 
binding experiments. 
 
1.2. The basics of the cell cycle  
For the human organism to survive, grow and reproduce its cells have to undergo 
cell division. The separation of a single cell into two cells and the simultaneous 
distribution of its content into the daughter cells is called cell division. Proteins, 
RNA, ribosomes and organelles such as mitochondria, peroxisomes or 
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lysosomes are constantly synthesized and present in multiple copies in a cell; 
therefore division of a cell can simply distribute them into daughter cells. Other 
cellular compartments like the Golgi apparatus, the ER and the nuclear 
membrane disintegrate into fragments, which can be separated into daughter 
cells and are able to reform the mature structures in the progeny. Most 
importantly, the DNA of a cell needs to be duplicated before cells undergo 
division. Also the centrosome, the organelle responsible for microtubule-
organization and for the establishment of the DNA separating machinery, is 
another component, which needs to be duplicated before cell division (Figure 6A; 
Morgan, 2007).  
To ensure proper separation into daughter cells, distribution of cell components 
and ability for further cell divisions, a program was established during evolution 
called the cell cycle. In general the cell cycle consists of four different phases. 
The replication of the genome occurs in the synthesis or S phase. Chromatin is 
replicated and the resulting copies, called sister chromatids are held together by 
cohesin protein complexes (Nasmyth et al., 2000). The separation of the DNA 
duplicates, known as nuclear division, and separation of daughter cells, known 
as cytokinesis, occur in mitosis (M phase). Mitosis is further subdivided into other 
phases (Figure 6A). In metaphase sister chromatids are aligned in the middle of 
a bipolar microtubule array emanating from centrosomes (Bailly and Bornens, 
1992; Bornens, 2002). Transition from metaphase into anaphase leads to 
cleavage of cohesin and transport of the separated sister chromatids towards the 
spindle poles. The period from the end of one M phase until the start of another 
M phase is referred to as interphase. In between M and S phases are so-called 
gap or G1 and G2 phases. Cells progress through G1 phase, before they enter S 
phase. They can also exit the cell cycle from G1 and enter the G0 phase. Cells in 
G0 are often called quiescent cells, which do not proliferate until certain 
conditions signal them to start dividing again. Three major checkpoints are in 
place to ensure error free division (Hartwell and Weinert, 1989; Murray and 
Kirschner, 1989). Enough resources and proliferation signals have to be present 
to pass the G1/S checkpoint.  
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Figure 6: Major events of the cell cycle are connected to changes in cyclin levels. A. 
Diagram of the cell cycle in metazoans (2014a). B. Changes of cyclin levels during the cell cycle 
(2014b). 
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Cells progress through the G2/M checkpoint, if the genome was accurately 
copied during S phase. Otherwise cells persist in G2 until inhibitory signals such 
as DNA damage are successfully eliminated. The last checkpoint before final 
division is at the metaphase-to-anaphase transition and is also known as mitotic 
checkpoint, metaphase checkpoint, spindle checkpoint or spindle assembly 
checkpoint. Only if every sister chromatid pair is attached to opposing 
centrosomes via microtubules and consequently under bipolar tension, will the 
APC/C become active and cause the cleavage of cohesin and progression 
through mitosis (Morgan, 2007; Musacchio and Salmon, 2007). 
Cyclin dependent kinases (Cdks) are of outmost importance to catalyze 
biochemical reactions, which drive accurate progression through the cell cycle. 
Cdks become active upon binding to cyclins. While the amount of a certain cyclin 
oscillates during the cell cycle dependent on the kind of cyclin, Cdk levels stay 
constant throughout the cell cycle (Figure 6B; Morgan, 1997). Cdk4/6 and cyclin 
D trigger entry into the cell cycle in G1 (Lucibello et al., 1993; Matsuoka et al., 
1994). Cdk2 together with cyclin E is mainly responsible for transition through the 
G1/S checkpoint, but also for duplication of centrosomes and formation of DNA 
pre-replication complexes. Cdk2/1 and cyclin A initiate DNA replication and early 
mitotic events e.g. upregulation of cyclin B levels starting in S phase and 
enhancement of Cdk1/cyclin B activity. Active Cdk1 and cyclin B cause 
condensation of DNA, nuclear envelope breakdown (NEBD), and subsequently 
the formation of the mitotic spindle and alignment of sister chromatids at the 
spindle midzone (Hunt, 1989; Nigg, 2001; Takizawa and Morgan, 2000). 
Therefore cyclin B has to be destroyed in order to progress through mitosis and 
for cells to ultimately divide. Thus the rise and fall of cyclin levels in the cell 
regulates accurate progression through the cell cycle (Morgan, 2007). 
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1.2.1. The anaphase-promoting complex 
The APC/C is a conserved RING E3 ubiquitin ligase of about 1.5 MDa with more 
than a dozen core subunits (Peters, 2006). Most of these subunits, like Cell 
division control protein 27 (Cdc27; name of Anaphase-promoting complex 
subunit APC3 in S.cerevisiae), APC5, Cdc16/APC6, APC7 or APC8, are 
responsible for scaffolding using tetratricopeptide repeat (TPR) motifs for protein-
protein interactions (Figure 7A; Barford, 2011). The Cullin-like subunit APC2 and 
the RING subunit APC11 build similar to the modular Skp1-Cul1-F-box (SCF) 
ligases the catalytic center of the APC/C (Tang et al., 2001). The core APC/C is 
expressed at constant levels throughout the cell cycle, but depending on the cell 
cycle stage it interacts with two different coactivators, Cdc20 and Cdh1, for 
substrate recognition comparable to F-box proteins (Zhang et al., 2014). The 
core subunit APC10 binds substrates cooperatively with Cdh1 (Figure 7B; da 
Fonseca et al., 2011; Matyskiela and Morgan, 2009). Another subunit APC15 
seems to be important for inactivating Cdc20 to control APC/C activity in mitosis 
(Primorac and Musacchio, 2013). The APC/C is mainly studied for its essential 
functions in mitosis, but has also been reported to be important in meiosis; 
additionally it has been implicated in post-mitotic neurobiology and metabolism 
(Barford, 2011). APC/C-mediated polyubiquitylation of its substrates leads to 
their proteasomal degradation (King et al., 1995; Sudakin et al., 1995). Securin, 
cyclin A, cyclin B and geminin are some of the most prominent APC/C substrates 
(Peters, 2006). Securin has to be degraded in order to release active separase, 
which then cleaves cohesin and allows for separation of sister chromatids 
(Nasmyth, 2001). Cdt1 is kept inactive by geminin binding; once geminin is 
removed free Cdt1 is available as a replication factor necessary in S phase 
(McGarry and Kirschner, 1998; Quinn et al., 2001; Tada et al., 2001; 
Wohlschlegel et al., 2000). Degradation of the cyclins renders Cdks inactive 
allowing for timely progression through the cell cycle.  
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Figure 7: Structure and functional mechanism of the APC/C. A. Schematic representation of 
the APC/C. A pseudoatomic model was generated by fitting known high-resolution structures 
(currently available only for a subset of the APC/C subunits or for closely related sequences) into 
an ∼10-Å cryo-EM map of the APC/CCdh1–D box ternary complex from S. cerevisiae (Schreiber et 
al., 2011). The subunits are labeled with both the yeast and vertebrate names. The approximate 
expected position of Mnd2/Apc15, for which a molecular model is currently missing, is indicated 
(marked therefore with an asterisk). PDB accession numbers for deposited high-resolution 
models are as follows: Apc10/Doc1, 1JHJ; APC7 N-terminal domain, 3FFL; Cdc26–Apc6 
complex, 3HYM; Apc10/Doc1, 1GQP; Cdc16/Cut9–Cdc26/Hcn1 complex, 2XPI; Apc8/Cdc23, 
3ZN3; and Cdc27, 3KAE. B. Negative stain EM reconstruction of APC/CCdh1 from S. cerevisiae 
(da Fonseca et al., 2011) with densities assigned to Cdh1 and Apc10. C. Ubiquitin (Ub) is first 
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activated by an E1 enzyme, transferred to a chain-initiating E2 (E2I; Ube2C in H.sapiens; Ubc4 in 
S.cerevisiae), and transferred to a substrate (S; cyclin B or securin). The creation of poly-Ub 
chains by the APC/C requires an elongating E2 (E2E; Ube2S in H.sapiens; Ubc1 in S.cerevisiae). 
The substrate is presented to the RING-E3 ligase APC/C by a coactivator (Cdc20 or Cdh1); 
modified after Primorac and Musacchio, 2013); (EM: electron microscopy). 
But many more APC/C substrates have been identified so far, such as the 
spindle assembly factors HURP, NuSAP and Tpx2, the mitotic kinases Nek2A, 
Aurora A and Plk1, or the Cdk inhibitor p21 (Meyer and Rape, 2011; Zhang et al., 
2014). The best-understood APC/C degrons are the so-called destruction box or 
D box (RxxL; Glotzer et al., 1991) and the KEN box (Pfleger and Kirschner, 
2000). Other binding motifs have been described as well. In metazoans (with 
exception to organisms such as Caenorhabditis elegans) the best-characterized 
E2s for the APC/C are Ube2C and Ube2S (Meyer and Rape, 2011). E2s of the 
Ube2D family have also been reported to work with the APC/C in vitro 
(Aristarkhov et al., 1996; Yu et al., 1996). Ube2C catalyzes the initiation of 
polyubiquitin chain formation by modifying the substrate with single ubiquitin 
moieties or short ubiquitin chains (Figure 7C; Kirkpatrick et al., 2006). The K11 
specific Ube2S elongates these chains rapidly allowing processive 
polyubiquitylation of APC/C substrates by concerted action of Ube2C and Ube2S 
(Garnett et al., 2009; Williamson et al., 2009a; Wu et al., 2010). Ube2C requires 
the presence of an interaction motif (IM) besides the canonical degron within a 
substrate for processive ubiquitylation (Williamson et al., 2011). As the functions 
of the APC/C during the cell cycle are of such great importance it is not surprising 
that its temporal activity is controlled by several intertwined mechanisms. 
 
1.2.2. Regulation of the anaphase-promoting complex 
The orderly destruction of substrates is crucial for accurate cell division. 
Therefore, inherent attributes of APC/C substrates differ and cause their 
sequential degradation, based on how processiveley they are ubiquitylated by 
the APC/C (Rape et al., 2006; Williamson et al., 2011). APC/C’s coactivators and 
E2s are simultaneously substrates of the APC/C, which leads to changes of their 
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levels and autonomous regulation of APC/C activity (Peters, 2006; Williamson et 
al., 2009a).  
Besides this intrinsic regulation, APC/C is controlled by many other cell cycle 
components. While the APC/C limits cyclin levels, Cdk activity itself influences 
APC/C activity. Cdk1 promotes formation of APC/CCdc20 by phosphorylation of 
Cdc20 and other APC/C subunits (Barford, 2011). Cdk2/cyclin A phosphorylates 
Cdh1, which inhibits Cdh1 binding to the APC/C and creates a Cdh1 
phosphodegron leading to its destruction by SCFSkp2 (Peters, 2006). The F-box 
protein Emi1 inhibits the APC/C by binding and altering its conformation; it can 
interact with both APC/CCdc20 in S and G2 phases and APC/CCdh1 at the G1/S 
transisition (Zhang et al., 2014). Inhibition of ACP/CCdc20 in G2 by Emi1 is 
necessary for an increase in cyclin B levels and prevention of premature mitotic 
division. Inactivation of APC/CCdh1 in G1 by Emi1 allows for accumulation of 
geminin and cyclin A to start and finish DNA replication. Emi1 is phosphorylated 
by Plk1 and subsequently degraded by SCFß-TrCP (Hansen et al., 2004; Moshe et 
al., 2004). Plk1 is at the same time a substrate of the APC/C and thereby closing 
the cycle (Lindon and Pines, 2004).  
The most complex and probably most important inhibitor of the APC/C is the 
spindle assembly checkpoint (SAC), which ensures that transition into anaphase 
does not occur, until biorientation of chromosomes on the spindle is complete 
(Foley and Kapoor, 2013; Lara-Gonzalez et al., 2012). Hence, improperly 
attached kinetochores and a lack of tension activate the SAC. Kinetochores are 
large protein structures assembled on chromosomes at their centromeres, where 
microtubules emanating from the centrosomes attach to chromatids. The SAC is 
conserved in eukaryotes and includes budding uninhibited by benomyl 1 (Bub1), 
the serine/threonine kinases monopolar spindle protein 1 (Mps1) as well as the 
non-kinase components mitotic arrest deficient 1 (Mad1), Mad2, Bub3 and 
the probably pseudo-kinase Bub1-related 1 (BubR1; the human orthologue of 
yeast Mad3) (Figure 8A; Foley and Kapoor, 2013). Mps1-dependent 
phosphorylation leads to recruitment of Mad1 and Bub1 to unattached 
kinetochores (Figure 8B; Lara-Gonzalez et al., 2012).  
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Figure 8: Regulation 
of the Mad2 template 
mechanism. A. The 
key components, 
including Mad2 in the 
open (O) and closed 
(C) conformations, 
which can dimerise; 
Mad1, the kinetochore 
receptor for Mad2, is a 
ligand for C-Mad2; the 
APC/C activator 
Cdc20 is also a ligand 
for C-Mad2; p31comet 
which binds C-Mad2 
at the dimerisation 
interface; and Mps1, a 
protein kinase which 
can dimerise and 
transphosphorylate. 
B. Mad2 binds Mad1 to form the Mad1–C-Mad2 core complex. In interphase, and when not 
bound to kinetochores, this core complex is ‘capped’ by p31comet. Upon kinetochore binding, 
p31comet is somehow released, allowing recruitment of O-Mad2 via Mad2 dimerisation. O-Mad2 
is then ‘handed over’ to Cdc20, and in doing so closes to form a C-Mad2-Cdc20 subcomplex, 
which then binds BubR1-Bub3, thereby forming the MCC. Mps1 plays a two-step role: (i) upon 
mitotic entry, Mps1 activity is required to recruit Mad1–C-Mad2 to the kinetochore; (ii) Mps1 
activity is also required continuously during mitosis to promote its own release from kinetochores 
and in doing so allow recruitment of O-Mad2 to Mad1–C-Mad2 (Lara-Gonzalez et al., 2012).  
 
According to the “Mad2 template” model, Mad2 converts from an open cytosolic 
conformation to a closed conformation upon interaction with kinetochore-bound 
Mad1/Mad2 heterodimers (Mapelli and Musacchio, 2007). Cdc20 subsequently is 
bound by closed Mad2, which serves as a template for further conversion of 
open Mad2 into its closed state. Therefore closed Mad2/Cdc20 complexes would 
pose a diffuse signal explaining how a single unattached kinetochore can prolong 
metaphase until proper orientation is achieved.  
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Mad2/Cdc20 together with BubR1 and Bub3 build the mitotic checkpoint complex 
(MCC), which inhibits APC/C activity (Figure 9A; Primorac and Musacchio, 
2013). Cdc20 still interacts with the APC/C, when it is sequestered into the MCC. 
But Cdc20 is not able to engage substrates, as its substrate binding site is 
shielded by BubR1 (Figure 9A) and it gets displaced from its usual position within 
the active APC/CCdc20 complex (Figure 9B; Chao et al., 2012). Binding of MCC to 
Cdc20 also triggers autoubiquitylation of Cdc20 by the APC/C leading to Cdc20 
degradation and further inactivation of the APC/C (Foley and Kapoor, 2013).  
 
Figure 9: Organization of the 
MCC. A. Schematic 
organization and cartoon 
model of the Mad2–
BubR1/Mad3–Cdc20 complex. 
The KEN1 motif of 
BubR1/Mad3 binds on the 
Cdc20 propeller. Mad2 binds 
to the MIM motif and makes 
extensive contacts with 
BubR1/Mad3. The Cdc20 
linker between the MIM and 
the entry point in the propeller 
was disordered in the crystal 
structure (Chao et al., 2012). 
The KEN2 motif of 
BubR1/Mad3 was not included 
in the crystallized construct.  
Cartoon model of the MCC 
(PDB 4AEZ). An enlargement of the area boxed in C and showing the interaction of the KEN1 
motif with Cdc20. The KEN motif lies within a folded region. B. A series of EM reconstructions 
showing APC/C devoid of coactivator or MCC subunits (APC/Capo), APC/CCdc20, and APC/CMCC 
(Herzog et al., 2009). The position and orientation of Cdc20 varies significantly in the presence of 
the MCC (Primorac and Musacchio, 2013). 
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After bi-oriented microtubule attachment to kinetochores is achieved, and proper 
tension is established, SAC components loose their kinetochore-localization and 
no longer propagate MCC formation. Cdc20 is released from MCC by APC/C-
dependent autoubiquitylation or by p31comet binding (Lara-Gonzalez et al., 2012). 
Some APC/C substrates, such as Nek2A, Cdc20, cyclin A and p21 seem to bind 
the APC/C even in the presence of SAC (Amador et al., 2007; den Elzen and 
Pines, 2001; Foley and Kapoor, 2013; Geley et al., 2001; Hames et al., 2001; 
Hayes et al., 2006). They therefore get targeted for proteasomal degradation in 
prometaphase. Nek2A and cyclin A bind to APC/CMCC through motifs distinct 
from the canonical degrons. Nek2A binds through its C terminal MR residues 
similar to Cdc20, Cdh1 and APC10 with their C terminal IR tail (Hayes et al., 
2006). Cyclin A interacts with APC/CMCC via another binding partner (Wolthuis et 
al., 2008; van Zon et al., 2010). Other APC/C substrate such as HOXC10, E2F1 
and RASSF1A seem to be degraded before transition into anaphase in the 
presence of an active SAC (Chow et al., 2012; Gabellini et al., 2003; Peart et al., 
2010).  
The best understood function of Nek2 activity is separation of centrosomes; the 
duplicated centrosomes are held together by a proteinaceous structure (O’Regan 
et al., 2007). Nek2 localizes to the centrosome and causes the dissolution of this 
proteinaceous structure in late G2, thus allowing separation of the centrosomes. 
Centrosome disjunction is necessary for the formation of the bipolar spindle 
apparatus. However, Nek2 has also been implicated in the SAC, chromatin 
condensation and NEBD (Fry et al., 2012). Why these substrates are degraded, 
before APC/C inhibition by the SAC is relieved, is not very well understood. 
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1.3. Aims 
The APC/C provides a powerful model to test for functions of atypical chains. 
While yeast APC/C modifies its substrates with canonical K48-linked chains 
(Rodrigo-Brenni and Morgan, 2007), the metazoan APC/C assembles atypical 
K11-linked conjugates to drive proteasomal degradation and mitotic exit (Jin et 
al., 2008). The abundance of K11 linkages rises dramatically during mitosis, 
when the APC/C is active, and this boost in K11-linked chain formation is 
dependent on Ube2S (Matsumoto et al., 2010; Wickliffe et al., 2011a). This study 
aims to determine the physiological meaning of K11-linked chains. Therefore 
substrates only degraded in the presence of Ube2S and cellular processes 
relying on Ube2S activity are to be identified. The ubiquitylation of the identified 
substrates needs to be reconstituted and the reaction products are to be 
investigated in terms of binding to ubiquitin receptors and degradation by the 
proteasome regarding their ubiquitin topologies. For further characterization of 
the ubiquitylated substrates, tools need to be developed and implemented to 
compare the influence of different ubiquitin topologies on identical substrates. !
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2. Materials 
2.1. Equipment and software 
Equipment Provider 
Autoclave Consolidate MK II Stills&Sterilizers 
Automated fluorescence microscope ImageXpress 
Micro  Molecular Dynamics 
Automatic film processor Konica SRX-101 Diagnostic Imaging Inc 
Biosafety cabinet Logic Labconco 
Biosafety cabinet SterilGARD The Baker Company 
Blotting apparatus Mini Trans-Blot cell Bio-Rad 
Centrifuge Allegra X-30R Beckman-Coulter 
Centrifuge CL10 Thermo Scientific 
Centrifuge RC-3B Sorvall Instruments 
Centrifuge Sorvall Legend Micro 21R Thermo Electron Corp. 
Centrifuge Sorvall Legend RT+, RC 3BP+, RC 6+ Thermo Scientific 
Centrifuges 5415C, 5417C, 5415R, 5424 Eppendorf 
Charged-couple device camera Andor technology 
Confocal microscope Revolution XD spinning disk Olympus, Yokogawa 
Customized electrophoresis apparatus Midi Maxi 
sized gels R. Shadel Inc. 
Epifluorescence microscope IX71 Olympus 
Flow Cytometer EPICS XL Beckman-Coulter 
Gel dryer model 583 Bio-Rad 
Heating block Dry bath Fisher Scientific 
Incubator AutoFlow Nu-5510 NuAire 
Incubator innova 42 New Brunswick scientific 
Incubator Isotemp Fisher Scientific 
Incubator NAPCO 8000 DH Thermo Electron Corp. 
Laser imaging device Pharos FX Plus Bio-Rad 
Laser imaging device Typhoon 9400 GE Healthcare 
Microscope Invertoskop 40 C Zeiss 
Mini Protean II electrophoresis appartus  Bio-Rad 
PCR machine MyCycler Bio-Rad 
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PCR machine PTC-200 MJ Research 
Power supple Power Pac HC Bio-Rad 
Power supply FisherBiotech™ Electrophoresis 
1000V Fisher Scientific 
Power supply Model 494 Isco 
qRT-PCR machine Mx3000P Stratagene 
Scanner V700 Photo Epson 
Sonicator Q700 Qsonica 
Sonicator W185D Ultrasonics Inc. 
Spectrometer Ultraspec III Pharmacia 
Spectrophotometer NanoDrop 2000c  Thermo Scientific 
Tank Blotting Unit TE62 Hoefer  Fisher Scientific 
Thermomixer Eppendorf 
Vacuum pump FisherBiotech™ Vacuum System Fisher Scientific 
Vacuum pump HydroTech Bio-Rad 
Water bath Isotemp 220 and 202 Fisher Scientific 
Water purifier Milli Q Synthesis A10 Millipore 
 
Software Provider 
CellProfiler Broad Institute 
CellProfiler Analyst Broad Institute 
Epson Scan Epson 
ImageJ National Institutes of Health 
MetaMorph Molecular Devices 
MxPro Stratagene 
NanoDrop 2000 Thermo Scientific 
Oligo Perfect Designer Invitrogen 
Photoshop Adobe 
Prism6 GraphPad Software 
Protparam expasy.org 
PyMol DeLano Scientific 
Quantity One Bio-Rad 
QuickChange Primer Design Agilent Technologies 
Materials 
 !
! -39-!
Translate expasy.org 
Typhoon control GE Healthcare 
Word, PowerPoint, Excel Microsoft  
Zotero zotero.org 
 
2.2. Kits and other lab consumables 
Name Provider 
10-MWCO columns  Millipore 
30 MWCO Microcon filters Millipore 
Black polystyrene 384-Well Clear-Bottom Plates Corning 
Chromatography paper 0.35mm Fisher Scientific 
Dialysis cassettes Thermo Scientific 
Disposable chromatography columns 10 ml Bio-Rad 
Maxima SYBR Green qPCR Master Mixes Fermentas 
Nitrocellulose membrane 0.45µm Bio-Rad or Fisher Scientific 
QIAGEN Plasmid Plus Midi Qiagen 
QIAprep Spin Maxiprep Qiagen 
QIAprep Spin Miniprep Qiagen 
QIAquick Gel Extraction Qiagen 
RevertAid First Strand cDNA Synthesis Fermentas 
RNeasy Mini Qiagen 
Sterile filters 0.22-0.45µm Millipore 
Tissue culture dishers VWR 
TnT-Quick Coupled tranlation/transcription 
Systems Promega 
X-ray film Kodak or PhenixResearch Products 
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2.3. Chemicals, reagents and enzymes 
All chemicals, reagents and enzymes were purchased from Sigma-Aldrich, 
Fisher Scientific, National Diagnostics, BD Biosciences, Invitrogen, New England 
Biolabs (NEB), Pierce, Gibco, Gold Shield Chemical Corporation, HyClone, MP 
Biomedicals, Fermentas, Millipore, Apex, Roche, BostonBiochem, Boehringer, 
Qiagen, Agilent, Bio-Rad, Alfa Aesar and Ubiquitin-Proteasome Biotechnologies 
unless marked otherwise. 
2.4. Cell lines 
Name Provider 
Flp-In™ T-REx™ 293 Invitrogen 
Flp-In™ T-REx™ 293-Ube2G2CTP this work 
HEK 293T Ann Fisher 
HeLa Michael Rape 
HeLa S3 Michael Rape 
HeLa-HR this work 
HeLa-mcherryH2B-GFPtubulin Rebecca Heald 
HeLa-Ube2G2CTP  this work 
HeLa-Ube2G2CTP  this work 
HeLa-Ube2S (Wickliffe et al., 2011) 
T98G Ann Fisher 
ES SF9, SF9 Ann Fisher 
BL21(DE3) pRIL Michael Rape 
DH5α Michael Rape 
XL1blue Michael Rape 
Michael Rape and Rebecca Heald – MCB, UC Berkeley 
Ann Fisher – Manager of the tissue culture facility at UC Berkeley 
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2.5. DNA oligonucleotides for qRT-PCR 
Target gene Right Left 
actin GCCGCCAGCTCACCATGGAT CACCATCACGCCCTGGTGCC 
ANAPC2 GTGTGCTTCCAACTGAGGGT CCTTCAAGGACGAGAAGCTG 
Cdc16 CCCACGGAGGTGAAATAATG CATTGGTGATTCTGAAGCTTATATTG 
Cdc20 TGTAATGGGGAGACCAGAGG ATTCGCATCTGGAATGTGTG 
cyclin B1 CAGATGTTTCCATTGGGCTT GAACCTGAGCCAGAACCTGA 
Nek2A TCCCCACTGAAATGAACTTTCT CAGCTTGCTAAAGGAACGGA 
Pkn1 AGCTGCTGCTGTACCCCG AGGACATGGCCAGCGAC 
securin GAGAGGCACTCCACTCAAGG AAAGCTCTGTTCCTGCCTCA 
Ube2C GCTGGTGACCTGCTTTGAGT AGCAGGAGCTGATGACCCTC 
Ube2S GCCGCATACTCCTCGTAGTT GTGCTCAAGAGGGACTGGAC 
 
2.6. Plasmids  
The human coding sequence of the listed genes was cloned into the respective 
vector backbone. If not otherwise specified the construct was made by the 
author. 
Ube2G2 - NM_003343; OTU7B - BC072681; Nek2A - NM_002497; p97 - 
BC110913; FAF1 - BC004970; FAF2 - BC014001; p47 - BC002801; UBXD7 - 
NP_056377.1; SAKS1 - BC000902; S5A - BC002365; Usp37 - AM392929, 
TRAF6 - BC031052; gp78 - BC069197 
Vector Insert Restriction sites Details 
pCDNA3.1(+)hy
gro empty no Insert see vector map (Invitrogen) 
pCDNA3.1(+)hy
gro empty Ube2G2
CTP BamHI/NotI 
untagged, as tagged version is supposedly less 
active, generated by fusing full-length human 
Ube2G2 to residues 186-222 of Ube2S 
pCDNA3.1(+)hy
gro empty Ube2G2
CTP-C89S BamHI/NotI see above and mutation of active site C89 to S 
pCDNA3.1(+)hy
gro empty Ube2S BamHI/NotI 
untagged, as tagged version is supposedly less 
active (Wickliffe et al., 2011) 
pCS2 UbK29R,K48R-cyclin A FseI/AscI 
K29R, K48R mutations in ubiquitin inhibit UFD 
activity in reticulocyte lysate, ubiquitin is missing 
the C-terminal GG to inhibit DUB activity, ubiquitin 
is fused to cyclin A by the linker GSLVPRGSG 
(thrombin cleavage site) 
pCS2 no Insert originally Marc Kirschner lab, Harvard, MA 
pCS2 6xHisubiquitin64TEV/Flag FseI/AscI NLYFQGSDYKDDDDKG was inserted after after E64 
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pCS2 
6xHisubiquitin64TEV/Flag 
-K11R,K48R,K63R FseI/AscI see above and mutation of K11, K48 and K63 to R 
pCS2 6xHisubiquitin-K0 FseI/AscI all K in ubiquitin are mutated to R (Lingyan Jin) 
pCS2 6xHisubiquitin-K11 FseI/AscI all K in ubiquitin are mutated to R except K11 (Jin et al., 2008) 
pCS2 
6xHisubiquitin-
K6,K11 FseI/AscI 
all K in ubiquitin are mutated to R except K6 and 
K11 
pCS2 cyclinA2 FseI/AscI (Rape and Kirschner, 2004) 
pCS2 Flagubiquitin53TEV FseI/AscI SENLYFQGS was inserted after G53 
pCS2 
Flagubiquitin53TEV-
K11R,K48R,K63R FseI/AscI see above and mutation of K11, K48 and K63 to R 
pCS2 geminin FseI/AscI (Rape and Kirschner, 2004) 
pCS2 geminin∆DBOX FseI/AscI (Williamson et al., 2011) 
pCS2 geminin∆IM FseI/AscI (Williamson et al., 2011) 
pCS2-HA Cdh1 FseI/AscI (Rape and Kirschner, 2004) 
pCS2-HA Nek2A272-445 FseI/AscI aa 272-445 were used meaning kinase domain is missing 
pCS2 6xHisubiquitin FseI/AscI (Jin et al., 2008) 
pCS2 NuSAP FseI/AscI (Song and Rape, 2010) 
pCS2 securin FseI/AscI (Rape and Kirschner, 2004) 
pCS2 securin∆DBOX FseI/AscI Olaf Stemmann 
pCS2 Ube2C-C114S FseI/AscI (Rape and Kirschner, 2004) 
pCS2 Ube2G2CTP FseI/AscI see above 
pCS2 Ube2G2 CTP-C89S FseI/AscI see above 
pCS2 Ube2S-C95S FseI/AscI Katherine Wickliffe 
pEGFP-C1  no Insert see vector map (Clontech Laboratories) 
pET28a 6xHisubiquitin NcoI/AscI (Jin et al., 2008) 
pET28a 6xHisubiquitin53TEV NcoI/AscI see above 
pET28a 
6xHisubiquitin53TEV-
K11R,K48R,K63R NcoI/AscI see above 
pET28a 6xHisubiquitin64TEV/Flag NcoI/AscI see above 
pET28a 
6xHisubiquitin64TEV/Flag 
-K11R,K48R,K63R NcoI/AscI see above 
pET28a 6xHisubiquitin71TEV NcoI/AscI GSENLYFQGS was inserted after L71 
pET28a 6xHisubiquitin-K0 NcoI/AscI Lingyan Jin 
pET28a 6xHisubiquitin-K11 NcoI/AscI see above 
pET28a 6xHisubiquitin-K11R NcoI/AscI Lingyan Jin 
pET28a 6xHisubiquitin-K48 NcoI/AscI all K in ubiquitin are mutated to R except K48 
pET28a 
6xHisubiquitin-
K6,K11 NcoI/AscI see above 
pET28a 6xHisubiquitin-K6 NcoI/AscI all K in ubiquitin are mutated to R except K6 
pET28a-His Cezanne (OTU7B) FseI/AscI  
pET28a-His cyclin A2 FseI/AscI (Rape et al., 2006) 
pET28a-His Emi1299-447 FseI/AscI (Rape et al., 2006) 
pET28a-His FAF1 FseI/AscI  
pET28a-His FAF2 FseI/AscI  
pET28a-His Nek2A272-445 FseI/AscI see above 
pET28a-His p47 FseI/AscI  
pET28a-His SAKS1 FseI/AscI  
pET28a-His securin FseI/AscI (Rape and Kirschner, 2004) 
pET28a-His Ube2V1 FseI/AscI Lingyan Jin 
pET28a-His UBXD7 FseI/AscI  
pET28a Ub-cyclin A6xHis NcoI/AscI see above 
pET28a Ub-cyclin AHA/6xHis NcoI/AscI see above 
Materials 
 !
! -43-!
pET28a Ub-Ub-cyclin AHA/6xHis NcoI/AscI 
ubiquitin is missing C-terminal GG to inhibit DUB 
activity, Ub is fused by the linker GSLVPRGSG 
(thrombin cleavage site) to cyclin A, ubiquitin is 
fused to ubiquitin via the linker GSEDLYFQSG 
(TEV cleavage site) 
pET28a Ub-K0-cyclin AHA/6xHis NcoI/AscI 
all K in ubiquitin are mutated to R, otherwise see 
above 
pET28a Ub-K11R-cyclin AHA/6xHis NcoI/AscI 
K11 in ubiquitin is mutated to R, otherwise see 
above 
pET28a Ub-K11R-Ub-cyclin AHA/6xHis NcoI/AscI 
K11 in the distal ubiquitin is mutated to R, 
otherwise see above 
pET28a Ube2C6xHis NcoI/AscI (Jin et al., 2008) 
pET28a Ube2C6xHis-C114S NcoI/AscI (Jin et al., 2008) 
pET28a Ube2G26xHis NcoI/AscI  
pET28a Ube2G2CTP-6xHis NcoI/AscI see above 
pET28a Ube2G2
CTP-6xHis-
C89S NcoI/AscI see above 
pET28a Ube2G2
CTP-6xHis-
∆acidic loop NcoI/AscI 
aa A95-A107 of Ube2G2 are deleted, otherwise 
see above 
pET28a Ube2G2
CTP-6xHis-
I92E NcoI/AscI see above and mutation of catalytic site I92E 
pET28a Ube2G2
CTP-6xHis-
K118A NcoI/AscI 
see above and mutation of RING interating network 
residue K118 to A 
pET28a Ube2G2
CTP-6xHis-
L66D NcoI/AscI see above and RING interaction site L66 to D 
pET28a Ube2G2
CTP-6xHis-
Q114A NcoI/AscI 
see above and mutation of RING interating network 
residue Q114 to A 
pET28a Ube2G2
CTP-6xHis-
V113E NcoI/AscI 
see above and mutation of RING interating network 
residue V113 to E 
pET28a Ube2N6xHis NcoI/AscI cut and paste from pET28a-His-F/A Michael Rape 
pET28a Ube2S6xHis NcoI/AscI (Wickliffe et al., 2011) 
pET30a(+) no Insert see vector map invitrogen 
pET30a(+) Ub-Ub-Ub-CycAHA/6xHis NdeI/NotI 
synthetically made Ub-Ub-Ub sequence is listed 
below (Life Technologies) 
pET30a(+) Ub-Ub-Ub-Nek2A272-445-HA/6xHis NdeI/NotI see above 
pFastBac Ube1 SalI/HindIII (Wickliffe et al., 2011) 
pFastBac Usp37 BamHI/KpnI  
pFastBac TRAF6 SalI/NotI  
pGEX gp78C6xHis FseI/AscI cytosolic domain of gp78, residues 309–643 
pGEX HHR23A; UBA domains  (Raasi et al., 2004) 
pMAL-TEV CTP6xHis FseI/AscI residues 186-222 of Ube2S 
pMAL-TEV HHR23A6xHis FseI/AscI Michael Rape 
pMAL-TEV p976xHis FseI/AscI  
pMAL-TEV S5a FseI/AscI  
pMAL-TEV Ube2G2 FseI/AscI  
pMAL-TEV Ube2G2CTP FseI/AscI see above 
pMAL-TEV TEV6xHis FseI/AscI Katherine Wickliffe 
Michael Rape – MCB, UC Berkeley 
Olaf Stemmann – Department of Genetics, University of Bayreuth 
Katherine Wickliffe and Lingyan Jin – former member of the Rape Lab 
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Ubiquitin sequence: 
ATGCAGATTTTCGTGAAAACCCTTACGGGGAAGACCATCACCCTCGAGGTTGAACCCTCGGATACGATA
GAAAATGTAAAGGCCAAGATCCAGGATAAGGAAGGAATTCCTCCTGATCAGCAGAGACTGATCTTTGCT
GGCAAGCAGCTGGAAGATGGACGTACTTTGTCTGACTACAATATTCAAAAGGAGTCTACTCTTCATCTT
GTGTTGAGACTTCGTGGTGGTTAA 
 
Triple ubiquitin sequence with restriction sites underlined:  
ATGCAGATCTTTGTTAAAACCCTGACCGGTAAAACCATTACCCTGGAAGTTGAACCGAGCGATACCATT
GAAAATGTGAAAGCCAAAATCCAGGACAAAGAAGGTATTCCGCCTGATCAGCAGCGTCTGATTTTTGCA
GGTAAACAGCTGGAAGATGGTCGTACCCTGAGCGATTATAACATTCAGAAAGAAAGCACCCTGCATCTG
GTTCTGCGTCTGCGTGGTACCGCACAGATTTTTGTGAAAACACTGACAGGCAAAACAATCACACTGGAA
GTAGAGCCGTCAGATACAATCGAAAACGTCAAAGCGAAAATTCAAGATAAAGAGGGCATCCCTCCGGA
TCAGCAACGCCTGATCTTTGCTGGCAAACAACTGGAAGATGGACGCACACTGTCAGATTACAATATCCA
GAAAGAATCAACACTGCACCTGGTGCTGCGCCTGCGGGTCGACGCCCAGATTTTCGTAAAAACGCTGA
CGGGAAAAACGATTACACTGGAAGTGGAACCTTCCGATACGATTGAGAACGTTAAAGCAAAAATCCAGG
ATAAAGAGGGAATTCCACCGGACCAACAGCGGCTGATCTTTGCCGGAAAACAGCTGGAAGATGGCCGT
ACGCTGTCTGACTATAACATCCAAAAAGAGTCTACGCTGCATCTGGTACTGCGCCTGCGTGGATCC 
 
2.7. Peptides 
Name Sequence Provider 
3xFLAG (MDYKDHDGDYKDHDIDYKDDDDK)3 Sigma 
3xHA (YPYDVPDYA)3 Biosynthesis Inc 
biotin-
CTP 
biotin-
KKHAGERDKKLAAKKKTDKKRALRRL  Elim Biopharmaceuticals 
G2BR SADERQRMLVQRKDELLQQARKRFLNKS Elim Biopharmaceuticals 
 
2.8. Antibodies 
Antibody dilutions are provided for western blot analysis unless marked for 
immunofluorescence (IF). 
Target Species Dilution Source ID 
α-tubulin mouse 1:5000 (WB)/1:200 (IF) Calbiochem DM1A 
APC4 rabbit 1:2000 Santa Cruz H-298 
APC5 rabbit 1:3000 Santa Cruz H-300 
APC7 rabbit 1:4000 Santa Cruz H-300 
Aurora A rabbit 1:2000 Abcam ab12875 
β-actin mouse 1:10000 MP Biomedicals 3G4-F9 
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BubR1 mouse 1:5000 Millipore 8G1 
CD3 mouse IP only Santa Cruz C415.9A 
Cdc16/APC6 rabbit 1:1000 Santa Cruz H-175 
Cdc20 rabbit 1:2000 Santa Cruz H-300 
Cdc27/APC3 mouse 1:2000 Santa Cruz AF3.1 
cyclin A2 rabbit 1:2000 Santa Cruz C-19 
cyclin B1 rabbit 1:2000 Santa Cruz H-20 
FLAG rabbit 1:3000 Sigma F7425 
geminin rabbit 1:2000 Santa Cruz FL-209 
GFP rabbit 1:1000 Achim Werner  
human influenza 
hemagglutinin (HA) rabbit 1:3000 Cell Signalling C29F4 
HURP rabbit 1:3000 Bethyl Laboratories A300-853A 
IgG mouse IP only Santa Cruz 2027 
K11 human 1:1000 (Matsumoto et al., 2010) 
K48 human 1:4000 (Newton et al., 2008) 
Kif18A rabbit  1:2000 Abcam ab72417 
Mad2 mouse 1:2000 BD Biosciences 48/Mad2 
Nek2A mouse 1:3000 BD Biosciences 20/Nek2 
NuSAP rabbit 1:3000 Proteintech 12024-1-AP 
p21 rabbit 1:1000 Santa Cruz C-19 
phospho-Histone 
H3 (Ser10) rabbit 1:2000 Millipore 06-570 
Tpx2 rabbit 1:300 (IF) Novus Biologicals NB500-179 
Ube2G2 mouse 1:1000 BostonBiochem AB-230 
Ube2S rabbit 1:5000 Novus Biologicals 22570002 
ubiquitin rabbit 1:50 Santa Cruz P4D1 
HRP-coupled secondary    
human goat 1:10000 Jackson ImmunoResearch 109-486-098  
mouse goat 1:5000 Sigma A5906 
rabbit goat 1:5000 Sigma A6154  
Fluorophore-coupled secondary   
mouse (Alexa 
568) goat 1:500 (IF) Invitrogen A-11004  
rabbit (Alexa 
488) goat 1:500 (IF) Invitrogen A-11034 
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2.9. RNA oligonucleotide sequences for siRNA 
Custom-made small interfering RNAs were ordered with UU overhangs as 
duplexes in lyophilized form. They were resuspended in RNAse-free water 
according to the manufacturer’s guidelines and stored in small aliquots at 20µM 
at -80°C. 
Target gene Antisense (5’→3’) 
Control (Dharmacon) UAGCGACUAAACACAUCAA 
Ube2C (Dharmacon) GUAUAGGACUCUUUAUCUU 
Ube2S (Dharmacon) GGCACUGGGACCUGGAUUU 
Ube2S (Qiagen) CCCGAUGGCAUCAAGGUCU 
GAAGAUUGGUUUCGACCCA 
UUUAAAGGCUUCCGCGAGU 
GGUAUGAGAAGUCCGAAGA p31
comet smartpool (Dharmacon) 
GGACACUAGUACCGCGAGU 
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3. Methods 
3.1. Molecular biology techniques 
3.1.1. Preparation of chemically competent bacteria  
Chemically competent E.coli were prepared using a rubidium chloride based 
protocol from a 3L growing culture in LB (1% (w/v) tryptone, 1% (w/v) NaCl, 0.5% 
yeast extract) with an optical density of 0.3 at 600nm. Bacteria were incubated on 
ice for 10min and harvested by centrifugation at 5000g and 4°C. The cell pellet 
was resuspended in 90ml ice-cold sterile TFB-I buffer (30mM potassium acetate, 
100mM RbCl2, 10mM CaCl2, 50mM MnCl2, 15% (v/v) glycerol, pH6.5) followed 
by incubation on ice for 2 h. Cells were again collected at 5000g and 4°C, 
resuspended in 18ml of sterile, cold TFB-II buffer (10mM 3-(N-
morpholino)propanesulfonic acid (MOPS), 75mM CaCl2, 10mM RbCl2, 15% (v/v) 
glycerol, pH6.5), flash frozen as 200µl aliquots in liquid nitrogen, and stored at -
80°C.  
 
3.1.2. Transformation of chemically competent E.coli 
Chemically competent E.coli were thawed on ice and incubated with 0.1-1µg 
plasmid DNA for 30min on ice. Incorporation of the DNA was achieved by heat-
shock at 42°C for 60s, followed by brief incubation on ice. To recover the 
tranformed bacteria, they were supplemented with 250µl LB and incubated in a 
thermomixer (Eppendorf) at 37°C for 1h in case of ampicillin- and 2h in case of 
kanamycin- or chloramphenicol-resistance. Transformed cells were plated on LB 
agar plates (1% (w/v) tryptone, 1% (w/v) NaCl, 0.5% yeast extract, 1.5% (w/v) 
agar) supplemented with the respective antibiotic for the transformed plasmid. 
Final concentrations of antibiotics in plates or in liquid cultures were 34µg/ml 
chloramphenicol, 0.1mg/ml ampicillin or 25µg/ml kanamycin. 
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3.1.3. Isolation of plasmid DNA from bacteria 
Single colonies or suspensions of transformed cells were used to inoculate LB 
overnight cultures (5ml for Mini, 50ml for Midi, 500ml for Maxi). The next day 
cells were harvested by centrifugation at 4000g for 10min. The DNA was isolated 
from the cells using kits according to the manufacturer’s instructions (Qiagen). If 
sterile DNA was required for tissue culture, the DNA containing solution was 
sterile filtered with 0.22µm filters (Millipore). To assess the DNA’s concentration 
and purity, its optical density (OD) was measured at 260nm and 280nm using a 
NanoDrop spectrophotometer (Thermo Scientific). Elution occurred in 50µl, 200µl 
or 600µl for Mini, Midi or Maxi preparations. 
 
3.1.4. Cloning 
The enzymes and buffer systems of New England Biolabs (NEB) were used for 
DNA restrictions. Reaction conditions were chosen according to the 
manufacturer’s instructions (NEB). To create linearized vector for cloning, 5µg 
DNA was digested in a volume of 20µL with 2-10 units of enzyme at 37°C for 1-
2h; to test for successful cloning 0.5-1µg DNA in a volume of 10µL was digested 
with 1-5 units of enzyme for 1h.  
FastAP alkaline phosphatase (Fisher) catalyzes the removal of 5’phospate from 
DNA to reduce the amount of linearized vector religating without annealing to the 
PCR fragment, as the phosphate group is required by T4 ligase for successful 
ligation. The cut DNA was incubated with the phosphatase (1 U/µg DNA) for 
30min at 37°C and the phosphatase was subsequently heat inactivated by an 
incubation at 75°C for 5min.  
DNA fragments of different sizes were separated by agarose gel electrophoresis. 
Depending on the fragment size, 0.5-2% (w/v) agarose, 0.005% (v/v) 
ethidiumbromide (Fisher), TAE (40mM Tris, 20mM acetic acid, and 1mM EDTA 
pH8.0) gels were used to separate DNA samples supplemented with 6x DNA 
loading dye (NEB) at 120V and visualized with UV light of 365nm. Desired DNA 
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was extracted from gel pieces using the QIAquick Gel Extraction (Qiagen) 
according to the manufacturer’s instructions. DNA was typically eluted in 30µL. 
Ligations were performed using 50-100ng of vector in a molar vector to insert 
ratio ranging from 1:3 to 1:9. Reactions were performed in a total volume of 10µL 
containing 400 units T4 DNA ligase (NEB) and 1x ligation buffer (NEB). The 
ligation reaction was typically performed at 23°C for 1h and half the reaction was 
transformed into DH5α cells.  
Amplification of specific DNA fragments using 5’- and 3’-flanking primers was 
performed by polymerase chain reaction (PCR) according to Mullis et al., 1986. 
Reactions were set up in a final volume of 50µL with 100ng template, 25 pmol of 
each forward and reverse primer, 1x Pfu buffer (Agilent), 500µM dNTP-mix 
(Fermentas), 2 units Taq polymerase (NEB) and 1 unit PfuUltra polymerase 
(Agilent). Addition of up to 10% DMSO (Sigma) for GC-rich regions in the DNA 
was optional. Primers were designed using Oligo Perfect Designer (Invitrogen). 
An elongation time of 30s/kb was generally assumed. PCR reactions were 
carried out by denaturating the DNA template at 94°C for 2min, going through 25-
30 cycles of 94°C for 30s, 42-55°C for 30s and 68°C for 30s/kb, and final 
elongation at 68°C for 10min. 
To fuse two DNA fragments by PCR, reactions were performed to first amplify 
the two fragments individually and purify them subsequently. Overlapping 
sequences were introduced in the first round of PCR via the respective primers. 
In a second PCR the two synthesized fragments with overlapping sequences are 
mixed and amplified using only the two distal primers of the fused construct. 
Site-directed mutagenesis of plasmids was performed according to the 
QuickChange Site-Directed Mutagenesis Protocol from Stratagene. QuickChange 
Primer Design (Agilent) was used to design mutagenesis primers. Mutagenesis 
PCR reactions were normally performed in 25µL final volume containing 50ng 
plasmid DNA, 7.5 pmol of forward and reverse primer, 0.4mM dNTP-mix 
(Fermentas), 1x Pfu buffer (Agilent) and 2 units PfuUltra DNA polymerase 
(Agilent). Mutagenesis PCR reactions were carried out by denaturating the DNA 
template at 94°C for 2min, going through 18 cycles of 94°C for 30s, 53°C for 
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1min and 68°C for 12min. The reaction products are incubated with 5 units DpnI 
(NEB) for 1h at 37°C afterwards to cleave parental DNA. 5µL of the product is 
transformed into XL1blue cells. 
All plasmids constructed via these PCR reactions were verified by DNA 
sequencing carried out at the sequencing facility in the Department of Molecular 
and Cell Biology, University of California, Berkeley or at Quintara Biosciences in 
Richmond, CA.  
 
3.1.5. Real Time quantitative Reverse Transcription PCR 
Real Time quantitative Reverse Transcription PCR (qRT-PCR) measures PCR 
product accumulation through a dual-labeled fluorogenic probe to quantify gene 
copies (Heid et al., 1996). The reaction was carried out using total RNA as 
template to assess the quantities of certain genes in HeLa cells. Total RNA was 
isolated using a RNeasy Mini kit (Qiagen) according to the manufacturer’s 
instructions. For the synthesis of first strand cDNA, 2µg isolated RNA was used 
with the RevertAid First Strand cDNA Synthesis kit (Fermentas) following the 
manufacturer’s instructions. Then, 0.5µl of the reaction product were used with 
Maxima SYBR Green qPCR Master Mix according to the manufacturer’s 
instructions (Thermo). Reactions were carried out using a qRT-PCR machine 
Mx3000P (Stratagene) with a 95°C-10min initial denaturation step, 40 cycles of 
30s-95°C,60s-55°C,60s-72°C followed by 1min of 95°C, 30s of 55°C and 30s of 
95°C. Analysis was carried out relative to actin mRNA copies in the cell. 
 
 
3.2. Biochemical techniques 
3.2.1. Measurement of protein concentration 
Protein concentrations of solutions were determined via measurement of 
absorption at 280nm using a NanoDrop. The aromatic amino acids 
phenylalanine, tyrosine, and disulfide bonds lead to absorption of energy at 
280nm. Proteins were kept under reducing conditions using 2mM dithiothreitol 
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(DTT) supposedly preventing the formation of disulfide bonds under these 
conditions. Extinction coefficient and MW of a protein based on its amino acid 
sequence were determined using an algorithm (http://web.expasy.org/protparam) 
for calculation of protein concentration based on the absorption at 280nm. 
Absorption at 280nm was also used for normalization of cell extracts to equalize 
cell lysate samples for western blot analysis.  
 
3.2.2. Sodium dodecyl sulfate (SDS) polyacrylamide gel electrophoresis (SDS 
PAGE) 
Separation of proteins was performed by SDS PAGE (Laemmli, 1970). Different 
gels with a range of 8% to 20% acrylamide were used in a Mini, Midi or Maxi 
format. Acrylamide solutions with distinct acrylamide to bisacrylamide ratios were 
used, as a ratio of 29:1 was beneficial for resolution of small proteins like 
ubiquitin compared to a 37.5:1 ratio generally used for larger protein separation. 
For resolving gels the desired percentage (w/v) of polyacrylamide solutions in 
0.2M Tris-HCl pH8.8, 0.05% (w/v) SDS were prepared. Polymerization was 
started by adding 0.1% (w/v) ammonium persulfate (APS) and 0.02% (v/v) 
tetramethylethylenediamine (TEMED). The solutions were filled into the casting 
chambers and overlaid with 2-propanol to even the surface. After polymerization 
of the separating gel, 2-propanol was removed and the stacking gel consisting of 
5% (w/v) polyacrylamide, 125mM Tris-HCl pH6.8, 0.1% (w/v) SDS, 0.1% (w/v) 
APS and 0.1% (v/v) TEMED was poured on top of the separation gel. After 
insertion of combs gels were allowed to polymerize. The gels were run with SDS-
glycine (25mM Tris Base, 192 mM glycine, 0.1% (w/v) SDS) or SDS-tricine 
(100mM Tris Base, 100mM tricine, 0.1% (w/v) SDS) running buffer at 150V for 
Mini, 250V for Midi or 300V for Maxi gels at room temperature. Tricine running 
buffer was used for separation of small ubiquitin fragments. Before loading, 
samples were supplemented with SDS-loading buffer (62.5mM Tris-HCl pH6.8, 
2% (w/v) SDS, 0.1% (w/v) bromophenol blue, 25% glycerol, 5%  (v/v) β-
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mercaptoethanol) and boiled at 95 °C for a few minutes. Prestained molecular 
markers (Bio-Rad) were used as standards. Separated proteins were stained by 
Coomassie, transferred onto a nitrocellulose membrane or dried onto 
chromatography paper (Fisher) for autoradiography (see below).  
 
3.2.3. Coomassie staining of gels after SDS PAGE  
Separated proteins were visualized by their binding to the Coomassie Brilliant 
Blue R-250, short Coomassie. After SDS PAGE the disassembled gel was 
incubated in Coomassie staining solution for 1-24 hours (10% (v/v) ethanol, 10% 
(v/v) acetic acid, 0.25% (w/v) Coomassie). Next the gel was washed with 
destaining solution (10% (v/v) acetic acid) until excess dye was removed. Last 
the gel was scanned for documentation. If higher detection sensitivity was 
needed, gels were stained with a different method, as described previously 
(Neuhoff et al., 1985). In short, gels were incubated in a fixing solution (40% (v/v) 
ethanol, 10% (v/v) acetic acid) for 20 minutes, rehydrated in water and stained 
with another Coomassie solution (1.6% (v/v) ortho-phosphoric acid, 8% (w/v) 
ammonium sulfate, 4% (v/v) methanol and 0.08% Coomassie G-250). Excess 
dye was washed off with water and the gel was scanned subsequently. 
 
3.2.4. Western blot analysis 
Proteins separated by SDS PAGE were transferred onto a nitrocellulose 
membrane (Bio-Rad or Fisher) according to Stott et al., 1985. After SDS-PAGE, 
the separating gel, the membrane and two chromatography papers were 
immersed in blotting buffer (25mM Tris, 192mM glycine, 20% (v/v) methanol). A 
sandwich, consisting of a chromatography paper, a nitrocellulose membrane, a 
gel and another chromatography paper was assembled between the two 
electrodes of a tank transfer blotting apparatus with the gel facing the negative 
and the membrane the positive electrode and submerged in blotting buffer. The 
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standard blotting conditions were 75V for two hours at 4°C regarding Mini and 
80V for four hours regarding Midi or Maxi gels at 4°C. For ubiquitin linkage 
specific western blots the conditions were 30V for 2h at 23°C. Transferred 
proteins were visualized by staining with ATX Ponceau S (Sigma) for one minute 
before excess dye was removed by washing with water. The stained membrane 
was optionally scanned for documentation. 
Membranes were transferred into 5% (w/v) dry milk (Safeway, Alco) in PBST or 
TBST (PBS (137mM NaCl, 2.7mM KCl, 10mM Na2HPO4, 1.8mM KH2PO4, pH7.4) 
or TBS (50mM Tris-HCl, pH 7.5, 150mM NaCl) with 0.1% (v/v) Triton X-100). 
PBST was only used for ubiquitin linkage antibodies. The primary antibodies 
were added and incubated with the membranes at 4°C for 18 hours. Membranes 
were washed in PBST or TBST three times and incubated with secondary 
antibody coupled to horseradish peroxidase (HRP) in 5% (w/v) dry milk in PBST 
or TBST. After incubation at 23°C for one hour the membranes were washed 
three times with PBST or TBST. The western blots were coated with 
chemiluminescent HRP substrate solution (Millipore) for one minute and the 
resulting chemiluminescent signal was detected with X-ray films (Kodak or 
PhenixResearch Products), which were developed in an automatic film processor 
(Diagnostic Imaging Inc).  
 
3.2.5. Autoradiography 
To detect proteins by autoradiography they were labeled with a radioactive 
isotope. Master mix of the SP6 quick coupled transcription/translation system 
(IVT/T, Promega) supplemented with about 0.1mCi/ml L-Methionine, [35S] and L-
Cysteine, [35S] (MP Biomedicals) was added to 2µg plasmid DNA encoding for 
the desired protein under control of a SP6 promotor with a final volume of about 
27µl. After incubation for 1.5-2h at 30°C the 35S-radiolabeled protein was used 
for binding or ubiquitylation experiments in vitro. The samples were analyzed by 
SDS PAGE and the resulting gel was placed in fixing solution (20% (v/v) ethanol, 
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6% (v/v) acetic acid) for 0.5-18h or stained with Coomassie. The fixed gel was 
subsequently placed between a wet chromatography paper and plastic wrap, and 
placed in a vacuum dryer (Bio-Rad). The gel was dried for 0.5-2h at 72°C using a 
vacuum pump (Bio-Rad or Fisher). After exposing the gel to a phosphorimager 
screen (Bio-Rad or Molecular Dynamics) for 2-96h the signal was scanned with a 
laser imaging device (Typhoon scanner from GE Healthcare or Pharos from Bio-
Rad). Stained gels were also documented with a regular scanner. 
 
3.2.6. Isolation of recombinant proteins from bacteria  
For protein expression BL21(DE3) pRIL E.coli cells were transformed with the 
plasmid encoding the desired protein by heat shock. The resulting cells were 
grown for 18h at 37°C in LB in the presence of 34µg/ml chloramphenicol and 
0.1mg/ml ampicillin (pMAL, pGEX) or 25µg/ml kanamycin (pET28a, pET30a) 
depending on the used plasmid. These initial cultures were diluted 1:150 into LB 
containing appropriate antibiotics and incubated at 37°C until an OD of 0.5 at 
600nm was reached. In the presence of 0.5mM isopropyl β-D-1-
thiogalactopyranoside (IPTG) further incubation was performed at 23°C for 18h. 
The consequent steps were performed at 4°C and all used solution were cooled 
to a temperature of 4°C. Bacterial cultures expressing His-tagged proteins were 
centrifuged at 4000g for 10min and pellets were resuspended in lysis buffer 
(50mM NaH2PO4, 500mM NaCl, 10mM imidazole, pH8.0). 200mg/ml lysozyme 
(Sigma) was added and cells were incubated for 20min. Resuspensions were 
sonicated twice for 2min. The resulting lysates were supplemented with 0.1% 
(v/v) Triton X-100 and cleared by centrifugation at 12500rpm for 30min. In 
general for a 1.5l culture 0.5-1ml NiNTA slurry was used. The slurry was washed 
twice with lysis buffer by centrifugation at 3000rpm. Beads were added to cleared 
lysates and incubated for 3-4h. NiNTA agarose was pelleted at 3000rpm and 
washed twice with 20-fold bead volume of lysis buffer plus 0.1% (v/v) Triton X-
100 and placed in 10ml column. After two more washes with lysis buffer, proteins 
Methods 
 !
! -55-!
were eluted in 200mM imidazole, 50mM NaH2PO4, 500mM NaCl, pH8.0 and 
dialyzed overnight into PBS with 2mM DTT. The protein solution was aliquoted 
and shock frozen in liquid nitrogen. 
Maltose binding protein (MBP) tagged proteins were isolated according to the 
steps above with a different lysis buffer (20mM Tris, pH 7.5, 500mM NaCl), 
amylose resin (NEB) instead of NiNTA agarose and elution into 20mM maltose, 
20mM Tris, pH 7.5, 500mM NaCl. 
Following the steps above Glutathione-S-transferase (GST) tagged proteins were 
purified with Glutathione Sepharose 4B (GE Healthcare) instead of NiNTA 
agarose with lysis in 50mM Tris, pH7.4, 250mM NaCl, 5mM EDTA. GST-tagged 
proteins were eluted with 20mM glutathione, 50mM Tris, pH7.4, 250mM NaCl, 
5mM EDTA. 
 
3.2.7. Isolation of recombinant proteins from insect cells 
To introduce the DNA encoding the recombinant protein of interest into insect 
cells baculoviruses were used. Generation of baculoviruses followed the 
instructions of the Bac-to-Bac Baculovirus Expression system (Invitrogen, 
(Luckow et al., 1993)). In short, the pFastBac donor plasmid was transformed 
into DH10Bac E.coli cells, which contain the bacmid with a mini attTn7 target site 
and the helper plasmid. The mini Tn7 element (containing the sequence of the 
recombinant protein) on the pFastBac donor plasmid transposes to the mini-
attTn7 site on the bacmid in the presence of transposition proteins provided by 
the helper plasmid. Colonies positive for the introduced DNA were distinguished 
from those containing unaltered bacmids by blue-white screening (insertion of the 
mini Tn7 element into the bacmid disrupts the lacZ gene). High molecular weight 
DNA was then isolated from positive clones via the mini prep kit. The bacmid 
DNA was transfected into ES SF9 (Expression Systems) cells with CellfectinII 
(Invitrogen) according to the manufacturer’s guidelines. After 72 h cells showed 
signs of late viral infection, indicating virus budding and release into the media. 
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The medium of the infected cells (P1 viral stock) was harvested and cleared from 
cell debris via centrifugation. For virus titer amplification, P2 and P3 viral stocks 
were generated by using the P1 (or P2) viral stock in a 1:10 dilution for infection 
of ES SF9 cells for 72 h followed by collection of the medium as described 
above. Viral stocks (in general P2) were stored protected from light at 4°C (for 
short term storage) or flash frozen in liquid nitrogen and stored at -80°C (for long 
term storage). For isolation of protein from ES SF9 cells generally 1-2l of ES SF9 
cells were infected with fresh P3 for 72h and harvested at 1500rpm for 5min. 
After resuspension in NP40 lysis buffer (20mM Tris-HCl pH7.5, 150mM NaCl, 1% 
(v/v) Nonident P-40 (NP40)) cells were further broken apart with a dounce 
homogenizer. The lysate was cleared at 12500rpm for 30min and incubated with 
NiNTA agarose for 3-4h. The resin was washed with 20mM Tris-HCl pH7.5, 
500mM NaCl, 20mM imidazole, 10% (v/v) glycerol first with, and later without 
0.5% (v/v) NP40. Protein was eluted with 20mM Tris-HCl pH7.5, 10% (v/v) 
glycerol and 250mM imidazole, and dialyzed into PBS, 2mM DTT, 10% (v/v) 
glycerol. 
 
3.2.8. In vitro APC/C binding assay 
Binding of radiolabeled APC/C-subunits to MBP-tagged proteins was performed 
as published (Wickliffe et al., 2011a). For binding of APC/C-subunits to 
biotinylated CTP, 35S-labeled APC/C-subunits were synthesized by IVT/T. 1mg 
biotin-CTP was immobilized on streptavidin-agarose (Thermo) in 50mM HEPES, 
pH 7.5, 1.5mM MgCl2, 5mM KCl, 150mM NaCl, 0.1% Triton, and 100mg/ml BSA 
for 2h at 4°C. 35S-labeled subunits were added to the beads and incubated for 3h 
at 4°C. After extensive washes, bound proteins were eluted with SDS sample 
buffer, separated by SDS-PAGE, and analyzed by autoradiography. 
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3.2.9. In vitro ubiquitylation of recombinant or radiolabeled substrates with 
immunoprecipitated APC/C 
35S-labeled substrates were synthesized by IVT/T as described above. 
UbK29R,K48R-cyclin A was synthesized to inhibit the UFD-pathway, which is active 
in reticulocyte lysate as part of the IVT/T system. To purify 35S-UbK29R,K48R-cyclin 
A, HisCdk2 was bound to NiNTA. IVT/T was added to beads for 3h at 4°C. Beads 
were eluted with PBS, 200mM imidazole, and UbK29R,K48R-cyclin A/HisCdk2-
complexes were concentrated with 30 MWCO Microcon filters. 
Human APC/C was purified from extracts of HeLa S3 cells synchronized in M 
(APC/CCdc20) or G1 (APC/CCdh1), as described (Rape et al., 2006; Williamson et 
al., 2009b), using αCdc27 antibodies and Protein G agarose (Roche). 500mM 
NaCl and 0.1% (v/v) Triton X-100 were added during the immunoprecipitation to 
wash off endogenous Ube2S. Washed beads were incubated with 100nM HisE1, 
60µM wt-ubiquitin or mutants, 3mM ATP, 22.5mM creatine phosphate, 10mM 
DTT, and substrate. Ube2S, Ube2G2, Ube2G2CTP and its mutants were used at 
10µM. Ube2C in combination with Ube2S or Ube2G2CTP was used at a 
concentration of 150nM; when used by itself, Ube2C was at 1µM. Recombinant 
substrate was used at about 1µM. Ubiquitylation assays were usually incubated 
for 30-60min at 25, 30 or 37°C at 800rpm in a Thermomixer depending on the 
respective experiment.  
 
3.2.10. In vitro degradation of ubiquitylated Nek2A with human proteasome 
35S-labeled HANek2A272-445 was purified after IVT/T by binding to HA-affinity 
matrix (Sigma) and elution with 3xHA-peptide (Biosynthesis Inc). The 
concentrated radiolabeled protein was ubiquitylated as described above at 30°C 
for 30 minutes with APC/CCdc20. The ubiquitylation reactions were supplemented 
with reagents to stabilize 26S proteasome (10% (v/v) glycerol, 0.5mM EDTA, 
5mM ATP, 20mM creatine phosphate and ~0.08mg/ml bovine creatine kinase 
(Sigma)). Human 26S proteasome (BostonBiochem) was diluted to achieve 
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noted concentrations in 60mM HEPES pH7.5, 50mM KCl, 50mM NaCl, 10% (v/v) 
glycerol, 5mM MgCl2, 0.5mM EDTA, 1mM DTT, 0.5mM ATP and added to the 
ubiquitinylation reactions. After an additional 45 minutes the reactions were 
stopped by boiling in SDS-loading buffer, resolved by SDS PAGE, detected by 
autoradiography and quantified with ImageJ.  
 
3.2.11. In vitro reconstitutions of sequential ubiquitylation events by the APC/C 
To separate Ube2G2CTP- from Ube2S-dependent ubiquitylation, recombinant Ub-
cyclin AHAHis was incubated with APC/CCdh1, Ube2G2CTP, and 10µM ubiquitin for 
4min at 25°C. An excess of 400µM ubiR48 was added and incubated at 25°C for 
10min. After addition of Ube2S, the reaction was incubated for 50min at 30°C. 
Reactions were stopped in SDS-loading buffer and analyzed by SDS PAGE and 
αK11 or αK48 western blot. 
To purify conjugates synthesized by both Ube2G2CTP and Ube2S, Ub-cyclin 
AHAHis was incubated with APC/CCdh1, Ube2G2CTP, 8µM ubiquitin, and 2µM 
FLAGubiquitin for 4min at 25°C. An excess of 400µM ubiR48 was added and 
reactions were incubated at 25°C for 10min. Next, Ube2S was added and 
reactions were incubated for further 50min at 30°C. The supernatant containing 
reaction products was incubated with FLAG-M2-affinity resin (Sigma) for 2hr at 
4°C. FLAG-beads were extensively washed and eluted three times with 
100µg/mL 3xFLAG-peptide (Sigma). Eluates were pooled and concentrated by 
centrifugation through 10-MWCO columns (Millipore). Samples were boiled in 
SDS-loading buffer and analyzed by SDS PAGE and αK11 western blot.  
To separate Ube2C- from Ube2S-dependent ubiquitylation, Ub-cyclin AHAHis was 
incubated with APC/CCdh1, 1µM Ube2C, 20µM ubiquitin for 20min at 30°C. An 
excess of 50µM Ube2CC114S and 600µM methylubiquitin was added. The reaction 
was either stopped in SDS-loading buffer or continued for 30min at 30°C with 
either PBS or 5µM Ube2S. Reactions were stopped in SDS-loading buffer and 
analyzed by αHA western blot. 
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3.2.12. Identification of ubiquitin linkages by mass spectrometry 
For analysis of ubiquitin conjugates on Nek2A by mass spectrometry 5µM 
recombinant HisNek2A272-445 was incubated with immunopurified APC/CCdc20, 
100nM E1, 3mM ATP, 22.5mM creatine phosphate, 10mM DTT, various Ube2C- 
and Ube2S-concentrations, 50µM ubiquitin for variable times at 30°C or 37°C. 
After SDS PAGE gel slices in the MW range of 37-250 kDA were excised. Tryptic 
digest of samples occurred in 25mM NH4HCO3 after 45mM DTT- and 100 mM 
iodoacetamide-treatment. Peptides were extracted with acetonitrile, exposed to 
formic acid and dried. Samples were analyzed by the Vincent J. Coates 
Proteomics/Mass Spectrometry Laboratory at UC Berkeley. 
 
3.2.13. Detection of ubiquitin branches with ubiquitinTEV derivatives 
To detect branched ubiquitin signatures in vitro on Nek2A, 5µM recombinant 
HisNek2A272-445 was incubated with APC/CCdc20, 100nM E1, 3mM ATP, 22.5mM 
creatine phosphate, 10mM DTT, 10µM Ube2C, 10µM Ube2S, 60µM 
ubiquitin53TEV and 60µM ubiquitin64TEV/Flag for 30min at 37°C. 4 µg Tobacco Etch 
Virus nuclear inclusion a endopeptidase (TEV) protease was added in excess 
over substrate and incubated for 1h at 34°C. After removal of the supernatant 
reactions were resolved by tricine SDS PAGE on a 20% gel and ubiquitin 
branches were detected by αFlag western blot analysis. 
To detect branched ubiquitin signatures on endogenous APC/C-substrates or 
HA-Nek2A in vivo, Flagubiquitin53TEV and Hisubiquitin64TEV/Flag were expressed in 
293T cells using calcium phosphate in the presence or absence of HANek2A. 
After 48h, cells were harvested, and lysates were subjected to 
immunoprecipitation by protein G-coupled αCdc27 antibody or αHA-resin. After 
several washes, TEV protease was added in excess and incubated for 1h at 
34°C. Reactions were resolved by tricine SDS PAGE on a 20% gel and ubiquitin 
branches were detected by αFlag western blot analysis. 
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3.2.14. In vitro reconstitution of ubiquitylated APC/C substrate binding to ubiquitin 
receptors 
MBP-tagged proteins were coupled to amylose resin (NEB) in 50mM HEPES 
pH7.5, 1.5mM MgCl2, 5mM KCl, 150mM NaCl, 0.1% (v/v) Triton X-100, 100µg/ml 
BSA for 2h at 4°C. 35S-labeled or recombinant cyclin A or Ub-cyclin A were 
ubiquitylated as described. Bait proteins and ubiquitylated cyclin A were 
incubated for 2h at 4°C. After washes, bound proteins were eluted by boiling in 
SDS-loading buffer and analyzed by autoradiography or western blot. Equal 
coupling of ubiquitin binding proteins was detected by Ponceau or Coomassie 
staining. 
 
3.2.15. HeLa cell extract-based in vitro degradation assay 
Extracts of HeLa S3 cells synchronized in mitosis by thymidine and nocodazole 
treatment, in early G1 phase by 2h release from thymidine and nocodazole 
treament or extracts of serum starved T98G cells were prepared as described 
(Jin et al., 2008; Reddy et al., 2007). Radiolabeled substrates were incubated in 
extracts supplemented with ATP, creatine phosphate and ubiquitin as described 
(Jin et al., 2008). Reactions were incubated for indicated times at 23°C or 30°C 
and for endpoint assays containing GST-UBA and/or 200µM MG132 (Boston 
Biochem) for 2h at 23°C. Reactions were stopped in SDS-loading buffer and 
analyzed by autoradiography or western blot.  
 
3.2.16. Isolation of ubiquitylated proteins from cells 
To purify endogenous ubiquitylated proteins from cells in prometaphase 
dependent on the presence of Ube2S, HeLa cells were transfected with 5nM 
Ube2S siRNA using Lipofectamine RNAimax (Invitrogen) according to the 
manufaturer’s protocol and 18h later with His-tagged ubiquitin or empty vector 
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using calcium phosphate as described below. After 21h cells were treated with 
100ng/mL nocodazole for 16h and 15µM MG132 for the last 2h of the 
nocodazole treatment. Cells were harvested, washed with PBS, resuspended in 
8M Urea, 300mM NaCl, 0.5% (v/v) NP40, 50mM Na2HPO4, 50mM Tris-HCl 
pH8.0 and lysed by sonication. Inputs were removed and Hisubiquitin-conjugates 
were purified with NiNTA agarose (Qiagen). Bound proteins were eluted by 
boiling in SDS-loading buffer. Ubiquitylated endogenous APC/C substrates were 
detected by western blot analysis using the respective antibodies against the 
substrate.  
To purify ubiquitylated proteins from cells, 293T cells were transiently transfected 
with APC/C-substrates and His-tagged wt- or mutant ubiquitin using calcium 
phosphate or TransIT-293 Transfection Reagent (Mirus). Cells were harvested 
and washed with PBS. 10% of cells were lysed for direct sample processing as 
described. The remaining cells were resuspended in 6M guanidine hydrochloride 
(GdHCl),! 0.1M Na2HPO4/NaH2PO4, 10mM imidazole pH8.0 and lysed by 
sonication. Hisubiquitin-conjugates were purified by NiNTA agarose (Qiagen), 
washed with 25mM Tris-HCl, 20mM imidazole pH6.8 and eluted by boiling in 
SDS-loading buffer. Ubiquitylated APC/C substrates were detected by western 
blot using the respective antibodies against the substrate or against the tag of the 
transfected APC/C substrate.  
To detect ubiquitin conjugates in cells expressing Ube2G2CTP, HeLa cells were 
transfected with geminin, Hisubiquitin, Ube2G2CTP and the dominant negative 
versions of Ube2G2CTP, Ube2C and Ube2S by calcium phosphate. 6h post 
transfection, 2mM thymidine was added for 24h. After a 3h release, cells were 
treated with 100ng/ml nocodazole for 11h. Mitotic cells were harvested by shake-
off, washed, released for 30min into fresh medium, and then incubated in the 
presence of 15µM MG132 for 2h. Cell lysates were analyzed by αK11 western 
blot. 
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3.2.17. Immunoprecipitations of proteins from cells 
293T or HeLa cells were either grown without synchronization or synchronized in 
mitosis by a thymidine and nocodazole treatment as described above. Cells were 
lysed in 50mM HEPES pH7.5, 1.5mM MgCl2, 5mM KCl by double freeze/thaw in 
liquid nitrogen and multiple passages through a 25G5/8 needle. Cell debris was 
pelleted by centrifugation at 20000g and the remaining lysates were normalized 
according to their absorption at 280nm. Inputs were removed from the lysates 
and boiled in SDS-loading buffer. Lysates were incubated with mouse IgG, 
αCD3- or αCdc27-antibody coupled to protein G agarose for 4h at 4°C. Beads 
were washed and eluted in SDS-loading buffer. Samples were analyzed by 
western blot using the relevant antibodies. 
 
3.3. Cell biology techniques 
3.3.1. Cultivation of adherent and suspension cells  
Adherent HeLa, HeLa S3 and 293T cells were propagated in Dulbecco's Modified 
Eagle Medium (DMEM; Gibco) supplemented with 10% (v/v) fetal bovine serum 
(FBS; HyClone) at 37°C and 5% CO2 in incubators (NuAire, Thermo). Flp-In 293 
T-REx cell lines were supplemented with certified tetracycline-negative FBS 
(HyClone) instead of regular FBS. Usually cells were split at a 1/10 ratio just 
before reaching confluency, when cells were washed with sterile PBS, detached 
from the culture dishes with 0.25% trypsin/1mM EDTA (Gibco) and diluted with 
fresh medium. To grow HeLa S3 cells in large quantities spinner flasks (Bellco) 
were used adding antibiotics/antimycotics (Gibco) and rotating at about 60rpm at 
37°C and 5% CO2. 
ES SF9 cells were propagated in ESF-921 medium (Expression Systems) 
supplemented with 1% (v/v, HyClone) and 1x antibiotic/antimycotic (Gibco) at 
26°C and shaking at 140rpm. 
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To freeze cells exponentially growing cells were trypsinized, diluted in serum- 
containing medium, and collected by centrifugation at 100g for 5 min. Cells were 
then resuspended in DMEM, 20% (v/v) FBS supplemented with 10 % DMSO 
(v/v, Sigma), aliquoted and slowly frozen enclosed in a 2-propanol insulation 
chamber at -80°C. For long-term storage, cells were transferred to -150°C.  
 
3.3.2. Transient transfection of human cells with plasmid DNA 
HEK 293T or HeLa cells were transfected with plasmid DNA using calcium 
phosphate DNA precipitates (Graham and van der Eb, 1973). Up to 77µg 
plasmid DNA was dissolved in 1.3ml of HBS (21mM HEPES, 136mM NaCl, 0.1% 
(m/v) dextrose, 50mM KCl, 0.7mM Na2HPO4, pH7.1, sterile filtered by 0.22 µm 
membrane) per 15cm dish of cells. 0.06ml of a sterile 2.5M CaCl2 solutions was 
added and mixed. After 20min the mixture was added drop-wise to the cells. The 
medium was replaced 24h later in most cases. Cells were generally harvested 
after 48h. 
HeLa cells were transfected with Lipofectamine 2000 (Invitrogen) according to 
the manufacturer’s instructions.  
HEK 293T cells were transfected with TransIT-293 Transfection Reagent (Mirus) 
according to the manufacturer’s instructions. 
 
3.3.3. Transient transfection of human cells with siRNA 
To downregulate different genes (e.g. Ube2S or Ube2C) in HeLa cells, siRNA-
mediated gene silencing was employed (Elbashir et al., 2001). HeLa cells were 
transfected using Lipofectamine RNAiMax (Invitrogen), according to the 
manufacturer’s instructions. Briefly, HeLa cells in a 15cm dish (40-50 % confluent 
if synchronized afterwards) were transfected with 5-10nM siRNA and 25µL 
Lipofectamine RNAiMax reagent per dish. Cells were analyzed for protein 
depletion generally 48h later by western blot. 
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For some early experiments Oligofectamine (Invitrogen) was used according to 
the manufacturer’s instructions. The amount of siRNA used with this transfection 
reagent was 100-200nM siRNA. 
 
3.3.4. Generation of stable HeLa or inducible 293 cell lines 
To generate HeLa cell lines stably expressing Ube2G2CTP, Ube2G2CTP-C89S, or 
Ube2S, transfection and selection occurred as described (Wickliffe et al., 2011a). 
Briefly untagged Ube2G2CTP, Ube2G2CTP-C89S or Ube2S was cloned into a 
vector (pCDNA3.1(+) hygro) under a CMV promoter containing the gene for 
hygromycin B phosphotransferase. After transfection of the generated plasmid 
with Lipofectamine 2000 HeLa cells were selected for expression of the 
hygromycin resistance gene and supposedly co-expression of the introduced 
sequence by treatment with 300µg/ml hygromycin B, which kills organisms by 
stabilizing the ribosomal acceptor site for tRNA, thereby inhibiting translocation 
and translation. HeLa cells expressing the introduced gene were identified by 
western blot analysis for Ube2S levels higher than present in control cells to 
identify Ube2S positive clones or appearance of a lower MW form to identify 
Ube2G2CTP positive clones using antibodies against the CTP of Ube2S (Bethyl). 
A Ube2G2CTP inducible 293 cell line was created using the Flp-In™ T-REx™ 
system according to the manufacturer’s instructions (Invitrogen). In short, 
untagged Ube2G2CTP was cloned into a vector (pCDNA5/FRT/TO) under a hybrid 
human cytomegalovirus (CMV)/TetO2 promoter for high-level, tetracycline-
regulated expression of the gene of interest. The vector also contained FLP 
Recombination Target (FRT) sites for Flp recombinase-mediated integration into 
the Flp-In™ T-REx™ 293 host cell line and a gene encoding for hygromycin B 
resistance for selection. After transfection of the generated plasmid and another 
plasmid allowing expression of Flp recombinase (pOG44) with Lipofectamine 
2000, 293 cells were selected for expression of the hygromycin resistance gene. 
293 cells were tested for expression of Ube2G2CTP upon treatment with 
tetracycline by western blot analysis. 
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3.3.5. Cell cycle synchronization of cells 
The presence of thymidine in excess leads to arrest in S phase, which can be 
alleviated by removal of the excess thymidine (Bootsma et al., 1964). Treatment 
with nocodazole leads to arrest of HeLa cells at the onset of mitosis (Zieve et al., 
1980) in a prometaphase like state as microtubule depolymerize in the presence 
of nocodazole. To enriche HeLa or HeLa S3 cells in prometaphase, dividing cells 
were treated with 2mM thymidine (Sigma) for 24h. Cells were washed and 
incubated in medium without thymidine for 3h. Nocodazole (Sigma) was added to 
a final concentration of 100ng/ml for 11h, if the cells were to be released from a 
nocodazole induced arrest for 2-4h to let them enter G1, or for 12h, if cells 
arrested in mitosis were wanted. 
Thymidine in combination with nocodazole led to reduced expression of 
exogenous proteins after transfection. Therefore cells transfected with DNA and 
to be enriched in certain phases were only treated with either 2mM thymidine for 
24h to moderately enrich for cells in S phase or with 100ng/ml nocodazole for 
16h to moderately enrich for cells in M phase. 
 
3.3.6. Immunofluorescence 
For immunofluorescence analysis of constitutively expressing Ube2S- and 
Ube2G2CTP-HeLa cells, they were grown to confluency on glass coverslips. Cells 
were fixed with 4% (w/v) formaldehyde/TBST for 10min, permeabilized with TBS, 
0.4% (v/v) Triton X-100, 2% BSA for 10min and blocked with blocking solution, 
2% (w/v) BSA in TBS, for 30min prior to application of primary antibody. Cells 
were incubated with the primary antibody diluted appropriately in blocking 
solution for 1-2h in a humid chamber, then washed three times for 5min with 
TBS, 2% (w/v) BSA. Then, cells were incubated for 0.5-1h in a humid chamber 
with Alexa488- or Alexa569-conjugated secondary antibodies (Molecular Probes) 
diluted 1:500 and Hoechst 33342 (VWR) diluted 1:1000 in blocking solution. 
Methods 
 !
! -66-!
Cells were then washed three times for 5min in PBS before mounting with 
ProLong Gold (Invitrogen) on slides. 
 
3.3.7. Analysis of cell cycle progression in cell lines by FACS 
To determine the DNA content and hence the cell cycle stage of cells with 
propidium iodide (PI) staining and fluorescence-activated cell sorting (FACS), 
cells were plated in 6-well plates and transfected with 100nM siRNA against the 
3’-UTRs of p31, UBE2C and UBE2S and oligofectamine, as described 
(Williamson et al., 2009), or with 5nM siRNA against the 3’UTR of UBE2S, as 
described here. 40h post transfection untreated or thymidine and nocodazole 
treated cells were harvested, washed and resuspended in PBS containing 2% 
(v/v) FBS. Cells were fixed by adding 75% ethanol at -20°C, washed, and stained 
in 50µg/ml propidium iodine in 3.8mM sodium citrate containing RNAse A for 
30min at 37°C. Excess dye was washed away and the cell cycle profile was 
determined using a Beckman-Coulter EPICS XL Flow Cytometer (575nm band 
pass filter). 
 
3.3.8. Determination of cell cycle distribution by automated microscopy and 
analysis 
For measuring the taxol or nocodazole response, HeLa cells or cells 
constitutively expressing Ube2S, Ube2G2CTP, Ube2G2CTP-C89S or empty vector 
were plated in a 384 well plate (Corning) at 30% confluency. The next day, taxol 
(Sigma) was diluted in medium and added in increasing concentrations. Cells 
were incubated for 14-16h, before staining with 20µM Hoechst 33342 (VWR) for 
30min at 37°C. Cells were fixed with formaldehyde at a final concentration of 
3.7% (v/v). I imaged eight sites per well with an average of 400 cells using an 
automated microscope ImageXpress Micro (Molecular Devices) and MetaMorph. 
Images were analyzed in terms of their mitotic index with CellProfiler and 
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CellProfilerAnalyst (Broad Institute) after training the software by visual input of at 
least 200 cells per mitotic or interphase morphology. When done in combination 
with siRNAs against Ube2C and Ube2S, cells were treated with siRNA using 
oligofectamine as described above and treated with 100nM taxol after 20h. In 
case of nocodazole titrations, cells were transfected using 
LipofectamineRNAimax and 10nM control or Ube2S siRNA, treated with the 
indicated nocodazole concentrations after 24h and fixed 16h later.  
 
3.3.9. Determination of substrate levels in cells 
HeLa cells stably expressing Ube2S, Ube2G2CTP, Ube2G2CTP-C89S or empty 
vector were plated in 6-well plates and transfected with 100nM siRNA against the 
3’-UTR of UBE2C and UBE2S, as described (Williamson et al., 2009b). To 
exclude off-target effects, I used a previously characterized siRNA against the 3’-
UTR of UBE2S (Dharmacon; GGCACUGGGACCUGGAUUU) (Wickliffe et al., 
2011a; Williamson et al., 2009b) and another siRNA obtained from a different 
vendor against the open reading frame (ORF) of UBE2S (Qiagen; 
CCCGAUGGCAUCAAGGUCUUU). Cells were treated with 2mM thymidine for 
24h. After a 3h release, cells were treated with 100ng/ml nocodazole (Sigma) for 
11h. Mitotic cells were harvested by shake-off and plated into fresh medium. 
Samples were taken after the indicated times post release for analysis by 
western blot. For cycloheximide (CHX) chases thymidine and nocodazole treated 
cells were left in nocodazole and treated with 50 µg/mL cycloheximide (Sigma) 
for the indicated time points. 
Tet-inducible Ube2G2CTP 293T cells were plated in a 6-well plate and transfected 
with TransIT-293 (Mirus) to express 3xHA-Cdh1 and securinΔDBOX. 24h post 
transfection, expression of Ube2G2CTP was induced with 1µg/mL doxycyclin 
(Sigma) for 24h. Cells were harvested and analyzed by western blot.   
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3.3.10. Live cell imaging of Ube2S depleted HeLa cells 
For live cell imaging, HeLa cells that constitutively express mCherry-H2B and 
GFP-tubulin (gift from Rebecca Heald) were maintained in DMEM (no phenol 
red, Gibco) containing 10% (v/v) FBS at 37 °C with 5% CO2 using 4-well 
chambered coverglass (Fisher), and imaged at a single focal plane every 3min 
for 12h beginning 36h after transfection with 15nM RNA-oligos using 
Lipofectamine RNAimax (Invitrogen). Images were taken with a 0.95 NA 40x 
objective on an Olympus Revolution XD spinning disk confocal microscope 
equipped with a charged-couple device camera (Andor technology) and a 
Yokogawa spinning disk. Image analysis was performed using MetaMorph. The 
time between NEBD and sister chromatid separation was determined by counting 
the frames between the first frame showing the beginning of chromosome 
condensation plus GFP-staining in former nucleus location and the first frame 
showing recognizable separation of sister chromatids after formation of a 
metaphase plate. Cumulative percentages were plotted using Prism6. !
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4. Results 
4.1. Ube2S enhances ubiquitylation and proteasomal degradation of 
prometaphase APC/C substrates 
The metazoan APC/C cooperates with Ube2S to assemble K11-linked chains 
that drive the degradation of cell cycle regulators during mitosis and G1. 
However as depletion of Ube2S showed few defects during mitosis, it is not fully 
understood whether K11-linked chains have essential roles for cell division 
(Garnett et al., 2009; Williamson et al., 2009a; Wu et al., 2010). To address this 
issue cells were tested, that expressed Ube2S at lower levels due to siRNA 
against Ube2S. 
 
4.1.1. Nek2A levels are increased upon depletion of Ube2S 
Using siRNA targeted against Ube2S with the transfection reagent Lipofectamine 
RNAimax the mRNA levels of Ube2S were reduced to less than 2% of its normal 
abundance in HeLa cells.  
Figure 10: Depletion of 
Ube2S by siRNA only 
changes the mRNA levels 
of Ube2S in HeLa cells. 
A. Depletion of Ube2S 
does not change Nek2A 
mRNA levels. HeLa cells 
treated with control or 
Ube2S siRNAs were 
synchronized with thymidine and nocodazole, and mRNA abundance was determined by qRT-
PCR. Depicted is the abundance relative to actin mRNA levels in control versus siUBE2S treated 
cells. Note that siRNA against Ube2S led to a reduction in Ube2S mRNA to less than ~2% of its 
normal levels (n=3; data are represented as average + standard deviation (SD)). B. Depletion of 
Ube2S does not change the cell cycle stage of synchronized cells. HeLa cells were treated with 
control or Ube2S siRNA, synchronized by thymidine and nocodazole and analyzed by FACS after 
propidium iodide staining (n=3; data are average + SD). 
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These cells were synchronized in prometaphase using thymidine and nocodazole 
(Figure 10A). Furthermore the depletion of Ube2S by RNAi in HeLa cells did not 
change the overall synchronization in prometaphase (Figure 10B). Strikingly, a 
decrease of Ube2S levels caused a strong increase in the abundance of Nek2A 
during prometaphase, a cell cycle stage in which the APC/C is mostly inhibited 
by the spindle checkpoint (Figure 11A). An even stronger stabilization of Nek2A 
can be achieved by inhibition of the 26S proteasome with the compound MG132 
during prometaphase (Figure 11A) leading to the conclusion that Ube2S, as a 
ubiquitin conjugating enzyme, contributes to the ubiquitylation and consequently 
degradation of Nek2A as a substrate of the proteasome. The accumulation of 
Nek2A was seen with two different siRNAs against Ube2S (Figure 11B) negating 
the possibility of an off-target effect caused by the Ube2S Dharmacon RNA oligo 
used in this study.  
Figure 11: Depletion of Ube2S by siRNA 
leads to stabilization of Nek2A in 
prometaphase. A. Depletion of Ube2S 
increases the levels of Nek2A during 
prometaphase. HeLa cells transfected with 
control or Ube2S siRNA using Lipofectamine 
RNAimax were synchronized in prometaphase 
using thymidine and nocodazole. If indicated, 
cells were treated with 20µM MG132 for an 
additional two hours in nocodazole containing media after the initial 11-hour nocodazole 
treatment. The abundance of endogenous proteins was measured by western blot analysis. B. 
Different RNA oligos targeting Ube2S lead to similar increases in Nek2A levels during 
prometaphase. Two siRNA oligos with different target sequences were obtained from distinct 
vendors and tested for effects on Nek2A levels after thymidine and nocodazole arrest. Nek2A 
levels were determined by western blot analysis. 
To rule out any other secondary effects caused by Ube2S mRNA depletion, 
HeLa cells constitutively expressing Ube2S were created. The introduced 
sequence of Ube2S was insensitive to the used siRNA, because the Ube2S RNA 
oligo targets a region of the gene encoding for Ube2S downstream of the stop 
codon. While control cells resistant to hygromycin B still showed stabilization of 
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Nek2A upon Ube2S depletion the effect was not observed with the stable 
expression of siRNA-resistant Ube2S (Figure 12). The slight overexpression of 
Ube2S seemed to have led to a decrease in Nek2A levels arguing a high 
sensitivity of Nek2A levels towards the amount of Ube2S present (Figure 12). In 
summary the levels of Ube2S and Nek2A are anticorrelated in prometaphase 
HeLa cells. 
 
Figure 12: Stabilization of Nek2A caused by Ube2S depletion is 
rescued by ectopic expression of Ube2S. Ube2S was depleted by 
siRNA from prometaphase HeLa cells that are resistant to 
hygromycin B (HeLa-HR) or that are resistant and constitutively 
expressing siRNA-resistant Ube2S (HeLa-Ube2S). Cells were 
transfected with Lipofectamine RNAimax, synchronized in 
prometaphase using thymidine and nocodazole, and analyzed for 
Nek2A levels by western blot analysis. 
 
4.1.2. Ube2S depletion stabilizes prometaphase APC/C substrates 
Based on these findings I used cycloheximide chase experiments to test, 
whether Ube2S was required for APC/C substrate degradation during 
prometaphase. Cycloheximide inhibits protein synthesis by inhibiting elongation 
of the polypeptide during translation through binding of the exit site of the 60S 
ribosomal unit and interfering with deacetylated tRNA (Klinge et al., 2011; 
Pestova and Hellen, 2003; Schneider-Poetsch et al., 2010). By inhibiting de novo 
protein synthesis with cycloheximide, the half-life of a protein can be determined 
giving a more sensitive readout for protein stability in the cell. Indeed the 
depletion of Ube2S resulted in a pronounced increase in the half-life of Nek2A, 
as well as the CDK inhibitor p21, another APC/C-substrate (Figure 13; Amador et 
al., 2007). At the same time levels of phospho-histone H3 (Ser10), Mad2 and 
Kif18A showed no change, leading to the assumption that the cells were not 
progressing within the cell cycle (Johansen and Johansen, 2006) and did not 
experience a general change in levels of APC/C-inhibiting MCC components 
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(Chao et al., 2012; Herzog et al., 2009; Schreiber et al., 2011) or of anaphase 
APC/C substrates (Sedgwick et al., 2013). Therefore, Ube2S is important for the 
timely degradation of APC/C substrates during prometaphase. 
 
Figure 13: The half-lives of the APC/C 
prometaphase substrates Nek2A and p21 are 
increased upon Ube2S depletion. HeLa cells 
transfected with control or Ube2S siRNA using 
Lipofectamine RNAimax were synchronized in 
prometaphase by thymidine and nocodazole, 
treated with 50µg/ml cycloheximide while still in 
nocodazole for the indicated time points, and 
analyzed for protein abundance by western blot 
analysis. The top shows an outline of the 
experimental workflow. 
 
 
 
 
 
 
 
4.1.3. Decreased ubiquitylation of prometaphase APC/C substrates caused by 
reduced Ube2S levels 
To further corroborate the effect of Ube2S depletion on the stability of 
prometaphase APC substrates, it was directly tested if the loss of the ubiquitin 
conjugating enzyme Ube2S led to a decrease of ubiquitylated APC/C substrates 
in prometaphase. HeLa cells were transfected with control or Ube2S RNA oligos 
using Lipofectamine RNAimax. After 18 hours, these cells were again transfected 
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with control or Hisubiquitin encoding expression vectors using calcium phosphate, 
synchronized with nocodazole, treated with 15 µM MG132 for two hours while 
still arrested with nocodazole and lysed. His-tagged protein complexes were 
purified with NiNTA under denaturing conditions in 8 M Urea to inhibit DUB 
activity and co-purification of other proteins leading to false-positive detection of 
ubiquitylated proteins. The purification of these ubiquitin conjugates from 
prometaphase cells revealed that Ube2S was required for the attachment of high 
molecular weight (MW) chains to endogenous Nek2A and p21 (Figure 14A,B). 
Ube2S also mediated the ubiquitylation of Cdc20 (Figure 14A, Figure 13), a 
reaction that disassembles spindle checkpoint complexes (Foster and Morgan, 
2012; Reddy et al., 2007; Uzunova et al., 2012; Williamson et al., 2009a).  
 
Figure 14: Ube2S siRNA leads to loss of 
APC/C prometaphase substrate 
ubiquitylation of Nek2A, Cdc20 and p21. A. 
HeLa cells expressing Hisubiquitin were 
transfected with control or Ube2S siRNA using 
Lipofectamine RNAimax, synchronized in 
prometaphase by 100ng/ml nocodazole and 
treated with 15µM MG132 for two hours while 
remaining in nocodazole. Purified ubiquitin 
conjugates were analyzed by αNek2A or 
αCdc20 western blot. B. HeLa cells expressing 
Hisubiquitin and transfected with control or 
Ube2S siRNA using Lipofectamine RNAimax 
were synchronized in prometaphase by 
nocodazole and treated with 15µM MG132 for 
two hours while remaining in nocodazole. 
Purified ubiquitin conjugates were analyzed by 
αp21 western blot.  
 
In contrast, another prometaphase substrate, cyclin A, was not stabilized (Figure 
11A), which might be due to incomplete Ube2S depletion or redundant 
mechanisms governing degradation of this cell cycle regulator (Kikuchi et al., 
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2014). These experiments therefore show that Ube2S is important during 
prometaphase, a time in the cell cycle when the spindle checkpoint reduces the 
overall APC/C-activity. 
 
4.1.4. Reduced levels of Ube2S cause a delay in early mitosis 
After detecting the loss of APC/C prometaphase substrate ubiquitylation and the 
increase in their protein levels upon Ube2S depletion, the overall effects of 
Ube2S siRNA on progression through early mitosis were determined. HeLa cells 
constitutively expressing GFPtubulin and mCherryhistone H2B (gift from Rebecca 
Heald’s lab) were transfected with control or Ube2S siRNA using Lipofectamine 
RNAimax for 32 hours and stills were taken every three minutes for 16 hours. 
Over 130 cells for each condition were used in analysis if they contained 
fluorescent markers, no apparent multi-nucleation and an intact bipolar spindle.  
In these cells, the time between nuclear envelope breakdown and sister 
chromatid separation was quantified. The time of nuclear envelope breakdown 
was taken at the first frame of DNA condensation based on mCherryhistone H2B 
morphology plus NEBD based on GFPtubulin localization at the position of the 
formerly intact nucleus (seen at 9 minutes in control and at 6 minutes in Ube2S 
siRNA treated cells; Figure 15A). The time of sister chromatid separation was 
taken at the first frame of apparent spatial separation of sister chromatids 
determined by mCherryhistone H2B morphology (seen at 45 minutes in control and 
51 minutes in Ube2S siRNA treated cells; Figure 15A). A significant number of 
cells was quantified showing an increase in time needed by HeLa cells depleted 
of Ube2S to progress through early mitosis (Figure 15B). On average Ube2S 
depleted cells needed 15 minutes longer to achieve sister chromatid separation 
after NEBD, while the median time increased by nine minutes. This delay in 
mitosis becomes even more obvious if HeLa cells treated with control or Ube2S 
siRNA and arrested in prometaphase by thymidine and nocodazole, are released 
from the nocodazole arrest and harvested every 30 minutes for western blot 
analysis of APC/C substrates. 
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Figure 15: Ube2S siRNA delays progression through early mitosis. A. Depletion of Ube2S 
delays anaphase initiation. HeLa cells constitutively expressing GFPtubulin and mCherryhistone H2B 
were transfected with control or Ube2S siRNA using Lipofectamine RNAimax and monitored by 
live cell imaging. The time from nuclear envelope breakdown to initiation of sister chromatid 
separation was determined. B. Quantification of live cell imaging depicted above for >130 cells 
per condition. C. HeLa cells were treated with control or Ube2S siRNA and synchronized with 
thymidine and nocodazole. After an arrest in nocodazole, cells were released into drug-free 
medium and protein levels were analyzed by western blot at the indicated time points. 
While the degradation of Nek2A can only be observed in this experiment due to 
Ube2S depletion other substrates like HURP, Aurora A, cyclin B1 and securin are 
degraded within about two hours after release from the nocodazole-induced 
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arrest in control cells. Depletion of Ube2S however causes stabilization of these 
APC/C substrates, which correlates with a general delay of mitosis seen by the 
steady levels of phospho-histone H3 (Ser10) in these cells. The delaying effect of 
Ube2S siRNA in prometaphase was also seen in asynchronous cells treated with 
increasing concentrations of the microtubule poison nocodazole. In a 384 well 
format cells were treated with control or Ube2S siRNA. Twenty-four hours after 
transfection, cells were treated with different amounts of nocodazole for another 
16 hours. The cells were stained with Hoechst and fixed with formaldehyde. After 
automated acquisition, Hoechst-stained DNA intensity and morphology was 
determined using a software-based approach, allowing for the quantification of 
mitotic cells for more than 1000 cells per condition. Cells depleted of Ube2S and 
treated with low concentrations of nocodazole showed an increased in the 
percentage of mitotic cells by up to 2.5-fold (Figure 16). This is consistent with 
the previous observation that HeLa cells depleted of Ube2S show a delay 
throughout early mitosis. Ube2S depleted cells are more prone towards stress in 
mitosis based on the increased sensitivity towards nocodazole. Ube2S is 
therefore important for proper progression of HeLa cells through mitosis. 
Figure 16: Depletion of Ube2S sensitizes cells to a 
nocodazole-dependent prometaphase arrest. HeLa 
cells transfected with control or Ube2S siRNA using 
Lipofectamine RNAimax were treated with increasing 
concentrations of nocodazole and analyzed for mitotic 
status measured by Hoechst staining and automated 
image analysis of >1000 cells/condition (n=3; data are 
represented as average +/- SD).  
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4.2. Ube2S synthesizes branched K11-linked ubiquitin chains off non-K11-
linkages  
Previous work had shown that Ube2S elongates single ubiquitin moieties or 
ubiquitin chains that were initiated by Ube2C or Ube2D with K11-linked ubiquitin 
chains (Garnett et al., 2009; Wickliffe et al., 2011a; Williamson et al., 2009a; Wu 
et al., 2010). To gain further insight into this reaction driven by Ube2S during 
prometaphase, the ubiquitylation of Nek2A and of linear ubiquitin fusion 
substrates (Ub)n=1,2,3-cyclin A or Ub3-Nek2A was reconstituted in vitro.  
 
4.2.1.  K11 in ubiquitin is not sufficient for formation of long polyubiquitin chains 
on Nek2a by Ube2C and Ube2S  
As Nek2A shows autophosphorylation due to the presence of its N-terminal 
kinase domain, a truncation consisting of residues 272-445 was created; this 
truncation includes all necessary APC/C recognition and modification sites 
(Sedgwick et al., 2013) and did not show a phophorylation pattern in SDS-PAGE 
simplifying the visualization of Nek2A ubiquitin conjugates (data not shown). 
Using 35S-radiolabeled HANek2A272-445 with immunoprecipitated APC/C, 
recombinant Ube2C and Ube2S, the modification of Nek2A with high MW 
conjugates in the presence of wild type ubiquitin, but not a K11R-mutant of 
ubiquitin (ubiR11), was observed (Figure 17A). Chains derived with ubiR11, which 
cannot be used by Ube2S for chain formation, closely mirrored those seen in 
cells lacking Ube2S (Figure 14B), recapitulating the in vivo modification of 
endogenous Nek2A. Surprisingly, the abundance of high MW of Nek2A 
conjugates was strongly reduced in reactions that contained ubiquitin mutant with 
K11 as the only site for chain formation (ubiK11; Figure 17A). This was in contrast 
to the radiolabeled model substrate UbK29,48R-cyclin A modified by Ube2S alone 
(Figure 17B) and suggested that formation of high MW chains on Nek2A by 
Ube2C and Ube2S was dependent on multiple linkages. Instead of using Ube2C 
as the initiating enzyme, Ube2D3 was used to further validate the requirement of 
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multiple linkages. While Ube2C is limited in the variety of ubiquitin linkages 
formed, mainly K11 but also K48 and K63 (Kirkpatrick et al., 2006), E2s of the 
Ube2D family show little linkage preference (Kim et al., 2007). Ubiquitylation of 
recombinant Nek2A272-445 using wt-ubiquitin with Ube2D3 and Ube2S showed 
formation of high MW species, while using ubiK11 or ubiR11 restricted the formation 
of long ubiquitin conjugates on Nek2A (Figure 17C). 
 
 
Figure 17: K11 in ubiquitin is not sufficient for high MW ubiquitin conjugate formation on 
Nek2A. A. Nek2A is modified with branched chains in vitro. 35S-labeled HANek2A272-445 was 
incubated with APC/CCdc20, Ube2C, Ube2S, and ubiquitin mutants at 30°C for 30 minutes. 
Reactions were analyzed by autoradiography. B. Ube2S elongates Ub-cyclin A efficiently with 
homogenous K11-linked chains. HisCdk2 affinity purified 35S-labeled UbK29,48R-cyclin A was 
incubated with APC/CCdc20, Ube2S, and ubiquitin mutants at 30°C for 20 minutes. Reactions were 
analyzed by autoradiography. C. Ube2D3 supports formation of branched chains. Reactions were 
performed with APC/CCdc20, Ube2D3 and Ube2S, ubiquitin mutants and recombinant Nek2A272-445 
at 30°C for 30 minutes. Reactions were analyzed by αNek2A western blot. 
 
4.2.2. Ube2S and Ube2C do not form linear mixed ubiquitin chains on Nek2A 
Conjugates with multiple linkages could be mixed chains, in which distinct 
connections are used within a single conjugate (linear mixed chain), or branched 
structures, in which at least one moiety received two or more ubiquitin molecules. 
To distinguish between these possibilities, Nek2A was incubated with mixtures of 
ubiR11 and ubiK11. If the APC/C assembled linear mixed chains, it could 
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sequentially use ubiR11 and ubiK11 to build conjugates of similar MW as seen with 
wt-ubiquitin. In contrast, branched conjugates that result from concurrent 
modification of K11 and another ubiquitin lysine could not be assembled; thus, if 
the APC/C were a branching enzyme, chains formed with ubiK11 and ubiR11 
should be of lower MW than with wt-ubiquitin. Nek2A was modified with low MW 
conjugates in the presence of ubiR11 and ubiK11, suggesting that the APC/C 
decorated this substrate with branched chains (Figure 17A,C). 
 
4.2.3. Ube2S attaches single ubiquitin moieties to N-terminally fused linear 
ubiquitin chains on cyclin A and Nek2A 
As physiological enzymes for the assembly of branched chains were unknown, 
the notion that the APC/C could produce such conjugates was tested.  
 
 
Figure 18: Ube2S introduces ubiquitin branches by modifying internal ubiquitin moieties 
of Ub-Ub-cyclin A. A. Ub-cyclin A, UbR11-cyclinA, Ub-Ub-cyclin A and UbR11-Ub-cyclin A were 
incubated with APC/C, Ube2S, and methyl-ubiquitin or wt-ubiquitin. Left: reaction products if 
Ube2S would elongate or branch chains. Pink: fused substrate-ubiquitin; red: ubiquitin added by 
Ube2S. Right: Reactions were analyzed by αHA western blot. B. Ube2S synthesizes branched 
linkages with similar efficiency as it promotes chain elongation. UbK0-cyclin AHA, Ub-cyclin AHA, 
UbR11-Ub-cyclin AHA, and Ub-Ub-cyclin AHA were incubated with APC/C, Ube2S, and methyl-
ubiquitin. Reactions were analyzed by αHA western blot. Pink ball: fused ubiquitin; red ball: 
ubiquitin added by Ube2S. 
 
The initiation step was circumvented to detect introduction of branches in a 
simplified manner. By PCR the C-terminus of ubiquitin was fused to the N-
terminus of the respective APC/C substrate, while G75 and G76 of ubiquitin were 
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omitted to inhibit accessibility by DUBs or E1. More ubiquitin moieties were 
added by fusing the C-terminus of ubiquitin again without G75 and G76 to the N-
terminus of the already substrate fused ubiquitin. Two prometaphase APC/C-
substrates were fused to these quasi-linear ubiquitin moieties: Nek2A, which 
requires Ube2S for degradation, and cyclin A, which can be robustly ubiquitylated 
in vitro (Rape et al., 2006).  
To test for branching in ubiquitylation reactions of these model substrates, 
methyl-ubiquitin was added, which allows transfer of the first ubiquitin by Ube2S, 
but interferes with further chain extension, as lysine residues are methylated. If 
Ube2S elongates preexisting chains, only the distal ubiquitin of these substrates 
should be modified, yet if it assembles branched conjugates, internal moieties 
could be ubiquitylated as well. Demonstrating the formation of branched chains, 
Ube2S added two methyl-ubiquitin molecules to Ub-Ub-cyclin A, and it attached 
one ubiquitin to a substrate variant that lacked K11 in its distal moiety (UbR11-Ub-
cyclin A; Figure 18A). Ube2S synthesized the branched linkage on UbR11-Ub-
cyclin A with the same specificity and efficiency as seen for elongation (Figure 
18A,B). 
                   
Figure 19: Ube2S is able to branch ubiquitin molecules off Ub3-cyclin A and Ub3-Nek2A. A. 
Ub-cyclin AHA, Ub-Ub-cyclin AHA, or Ub-Ub-Ub-cyclin AHA was incubated with APC/CCdh1, Ube2S 
and methyl-ubiquitin or ubiR11. Reaction products were analyzed by αHA western blot. Red dot: 
first added ubiquitin; blue dot: second added ubiquitin; green dot: third added ubiquitin. B. Ube2S 
efficiently modifies Nek2A with branched chains in vitro. Ub3-Nek2A was incubated with 
APC/CCdc20, Ube2S, and methyl-ubiquitin or ubiR11, and analyzed by αNek2A western blot. 
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Furthermore, Ube2S was able to branch ubiquitin molecules off substrates with 
longer chains, such as Ub3-cyclin A and Ub3-Nek2A, while retaining K11-
specificity shown by single modification of each present ubiquitin moiety with 
ubiR11 (Figure 19). As shown for Ub3-cyclin A and Ub3-Nek2A the ability of Ube2S 
to introduce branches within ubiquitin chains seems not be limited to an 
individual substrate (compare Figure 19 A and B). If these assays were 
performed with wt-ubiquitin, Ube2S branched a block of ~6 K11-linked molecules 
off each ubiquitin containing a free K11, thereby effectively modifying Ub-Ub-
cyclin A with chains that had twice the MW as those on Ub-cyclin A or UbR11-Ub-
cyclin A (Figure 18A). By using model substrates Ube2S was therefore shown to 
introduce branches within ubiquitin chains. 
 
4.2.4. Ube2S branches off ubiquitin chains on cyclin A preformed by Ube2C 
Next, I determined if Ube2S could also introduce these branches within short 
ubiquitin chains synthesized by the physiological initiating E2 Ube2C. Ube2C 
decorates APC/C-substrates with short chains containing ~50% K11-, but also 
K48- and K63-linkages (Kirkpatrick et al., 2006). If Ube2C produced the latter two 
linkages, Ube2S could use an internal ubiquitin to branch off a K11-linked chain. 
To test this hypothesis, Ub-cyclin A was incubated with Ube2C at concentrations 
that led to formation of short chains (Ub3-cyclin A; Figure 20).  
 
Figure 20: Ube2S synthesizes branched conjugates off chains 
initiated by Ube2C. 1µM Ub-cyclin AHA was incubated with an 
estimated 10nM APC/CCdh1 and 1µM Ube2C, which led to selective 
modification of ubiquitin in Ub-cyclin A (data not shown). After 5min 
reactions were stopped (stop); or 50µM Ube2CC114S, PBS and methyl-
ubiquitin were added to inhibit further initiation (PBS); or 50µM 
Ube2CC114S, 10µM Ube2S and methyl-ubiquitin were added (Ube2S). 
Reactions were analyzed by αHA western blot.  
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The initiation step was stopped with an excess of Ube2CC114S, which does not 
affect Ube2S activity (Wickliffe et al., 2011a), and then added methyl-ubiquitin 
and Ube2S. Ube2S attached up to three ubiquitin molecules to Ub3-cyclin A 
produced by Ube2C (Figure 20). Consequently Ube2S introduces branches, 
when Ube2C is used to synthesize the template ubiquitin chain.  
 
4.2.5. Absence of K48 and K63 in ubiquitin leads to decreased ubiquitylation of 
Ub-cyclin A by Ube2S and Ube2C 
In addition to show that Ube2C and Ube2S work together to form branched K11-
linked ubiquitin chains, single substrate-turnover reactions (Rape et al., 2006) 
with ubiR48/63 or ubiK6/K11 were performed. These mutants support formation of 
K11-linked chains, but prevent the synthesis of K48 and K63 linkages by Ube2C 
(Kirkpatrick et al., 2006), that are required for branching by Ube2S. Importantly, 
Ube2S decorated APC/C substrates with high MW chains in the presence of 
Ube2C and wt-ubiquitin, but not if Ube2C was omitted or ubiR48/63 or ubiK6/K11 
were used (Figure 21). Less Ube2S activity is seen comparing ubiK11 and 
ubiK6/K11 revealing a small caveat in the analysis of ubiquitylations performed with 
ubiK11 (Figure 21B left panel). Thus, the APC/C modifies substrates with 
branched chains in vitro. 
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Figure 21: Mutation of K48 and K63 in ubiquitin inhibit formation of longer, branched 
ubiquitin chains by Ube2S and Ube2C. A. APC/C synthesizes branched conjugates with 
Ube2C and Ube2S. Ub-cyclin AHA was incubated with APC/CCdh1, Ube2S, or Ube2C and Ube2S, 
and ubiquitin mutants. The concentrations of Ube2C used for this assay allowed modification of 
ubiquitin in Ub-cyclin A, but not lysine residues in cyclin A. Reactions were analyzed by western 
blot against HA. B. The APC/C synthesizes branched conjugates with its physiological E2s. Left 
panel: 1µM Ub-cyclin AHA was incubated with an estimated 10nM APC/CCdh1, Ube2S, and 
ubiquitin mutants. UbiK6/K11 acts as efficiently as wt-ubiquitin, as it provides residues required for 
chain formation (K11) and acceptor recognition (K6) (Wickliffe et al., 2011a). The excess of 
substrate over APC/C guarantees single turnover conditions (Rape et al., 2006). Right panel: Ub-
cyclin AHA was incubated with APC/CCdh1, Ube2C, Ube2S, and ubiquitin mutants. High MW 
conjugates indicative of branched chains were only observed with wt-ubiquitin, but not with any 
ubiquitin mutant that inhibited Ube2S (i.e. ubiK48) or branching (i.e. ubiK6/K11). Reactions were 
analyzed by αHA western blot.  
 
4.3. The APC/C synthesizes branched ubiquitin chains in cells 
To further validate these findings I established an assay that directly shows the 
existing branches within a ubiquitin chain without mutating lysine residues on 
ubiquitin, which could lead to artifacts by forcing E2s to use other lysine residues 
than the naturally preferred residues. Mass spectrometry can be used to detect 
the general kind of ubiquitin linkages (Nishikawa et al., 2004; Peng et al., 2003; 
Wang et al., 2006; Xu et al., 2009) and even to detect K6/11, K27/29 and K29/33 
branches (Kim et al., 2007). Unfortunately several trypsin digestion sites 
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separated K11/48 and K11/63 branches. Hence, mass spectrometry was only 
useful for detecting the presence of ubiquitin linkages individually. Because of 
this, ubiquitin variants with protease cleavage sites were created allowing the 
detection of K11/48 and K11/63 branches.  
 
4.3.1. Mass spectrometry shows the presence of non-K11-linkages within 
ubiquitin chains on Nek2A made by Ube2S and Ube2C 
I determined by mass spectrometry, which ubiquitin linkages are present, when 
Nek2a is ubiquitylated by APC/C, Ube2C and Ube2S. Consequently recombinant 
Nek2A272-445 was incubated with APC/CCdc20, Ube2C and Ube2S, and resolved 
by SDS-PAGE. The separating gel area between 37 and 250 kDa was excised. 
Proteins were extracted and digested with trypsin. The QB3/Chemistry Mass 
Spectrometry Facility at UC Berkeley performed mass spectrometry and 
analysis. Several independent experiments showed that the APC/C decorated 
Nek2A with chains containing K11, K48, and K63 linkages (Figure 22). Based on 
the linkage specificities of Ube2C and Ube2S (Kirkpatrick et al., 2006; Williamson 
et al., 2009), Ube2S seemed to assemble K11/K48 and K11/K63 branches, 
which - due to the multiple lysine and arginine residues separating the two 
attachment sites in the branched ubiquitin - cannot be detected by trypsin-based 
mass spectrometry. The apparent, higher amount of K11 is in line with Ube2S 
being able to efficiently synthesize long K11-linked chains using only few K48 or 
K63 linkages to add a large amount of K11 linkages.  
 
Figure 22: Mass spectrometry detects K11, K48 and K63 
linkages within Nek2A ubiquitin conjugates in vitro. 
APC/CCdc20, Ube2C and Ube2S modify Nek2A with chains 
containing K11, K48 and K63 linkages. Recombinant Nek2A272-445 
was incubated with APC/C, Ube2C, Ube2S, and ubiquitin, and 
reaction products were subjected to mass spectrometry. The sum 
of ubiquitin linkages from three independent reactions is shown.  
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Thus, agreeing with previous reports Ube2S and Ube2C build K11 and non-K11-
linkages on an APC/C substrate (Kirkpatrick et al., 2006; Williamson et al., 
2009a). 
 
4.3.2. Ube2S modifies Ub-cyclin A with TEV-cleavable ubiquitin derivatives 
Because of the shortcomings of mass spectrometry an alternative method was 
developed to monitor formation of branched chains to track the synthesis of such 
conjugates in cells (Figure 23A). To directly identify the attachments of the C-
termini of several donor ubiquitin moieties to one acceptor ubiquitin molecule, I 
decided to take a similar approach to the mass spectrometry method. Instead of 
using trypsin, which creates fragments that are too small to detect K11/48 or 
K11/63 branches, a single protease cleavage site was placed within ubiquitin, C-
terminal of K48 to detect K11/48 branches or C-terminal of K63 to detect both 
K11/48 and K11/63 branches. Once the fragments are created by protease 
cleavage, the branches will be detected based on an increase in their apparent 
mass observed by SDS-PAGE. As ubiquitin is fragmented in the process, 
western blot analysis with ubiquitin antibodies is not feasible and a tag was 
placed C-terminal of the protease cleavage site. This allows for detection of N-
terminal ubiquitin fragments modified with tagged C-terminal ubiquitin fragments.  
C-terminal of two ubiquitin residues, G53 and E64, located in loop regions of 
ubiquitin, insertion of a TEV-cleavage site (ubi53TEV) plus a FLAG-epitope in the 
case of E64 (ubi64TEV/FLAG) was successful. The resulting derivatives were still 
recognized by E1, Ube2S and APC/C (Figure 23B). Ub-cyclin A was modified 
with ubi53TEV or ubi64TEV/FLAG and treated with TEV protease. Almost complete 
cleavage was observed for ubi53TEV and complete cleavage for ubi64TEV/FLAG. A 
mixture of ubi53TEV and ubi64TEV/FLAG seemed to give the most turnover of Ub-
cyclin A and highest amount of ubi53TEV or ubi64TEV/FLAG cleaved fragments on Ub-
cyclin A (Figure 23B). Addition of a TEV cleavage site C-terminal of L71 was 
detrimental towards ubiquitylation activity (Figure 23B) likely due to blocked 
recognition of the ubiquitin C-terminus by E1 (Olsen and Lima, 2013). 
Results 
 !
! -86-!
 
            
Figure 23: APC/C and Ube2S can use ubiquitin with an internal cleavage site and FLAG 
epitope. A. Outline of a method to monitor synthesis of branched chains. A TEV-site and FLAG-
epitope (ubiTEV/FLAG) were introduced into ubiquitin. Cleavage of ubiTEV/FLAG-conjugates reveals a 
~2kDa stamp for elongation or multiple stamps for branching. B. UbiTEV/FLAG is recognized by 
Ube2S and APC/C, and sensitive to TEV cleavage. Ub-cyclin AHA was incubated with APC/CCdh1, 
Ube2S, and wt-ubiquitin or ubiTEV mutants. Reactions were treated with TEV and analyzed by 
αHA-Western.  
To further validate this new system 35S-radiolabeled cyclin A was modified with 
ubi53TEV or ubi64TEV/FLAG and subsequently the reaction products were treated with 
TEV-protease. This led to the collapse of long chains and the emergence of 
supposedly diagnostic FLAG-reactive peptides, when ubi64TEV/FLAG was present: 
while modification of a distal moiety produced a small cleavage product (Figure 
23B), ubiquitin branches or multiple ubiquitylation sites on cyclin A were detected 
as additional species of higher MW (Figure 24A). Use of both ubi53TEV and 
ubi64TEV/FLAG proved to be most efficient for detecting ubiquitin branches (data not 
shown). A time course showed that the addition of ubi53TEV or ubi64TEV/FLAG to an 
already present ubiquitin moiety does not impede the transfer of ubiquitin by 
Ube2S compared to addition of wt-ubiquitin (Figure 24B). 
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Figure 24: APC/C, Ube2C and Ube2S can use ubi53TEV or ubi64TEV/FLAG to modify cyclin A 
with polyubiquitin chains. A. 35S-cyclin A was incubated with APC/CCdh1, Ube2C, Ube2S, and 
wt-ubiquitin, ubi53TEV or ubi64TEV/FLAG proteins. Reactions were treated with TEV and analyzed by 
autoradiography. B. The APC/C and Ube2S are able to use ubi53TEV or ubi64TEV/FLAG. Ub-cyclin AHA 
was incubated with APC/CCdh1, Ube2S, and ubiquitin mutants, and reaction products were 
analyzed by αHA western blot. 
 
4.3.3. Detection of branched ubiquitin fragments on cyclin A and Nek2A in vitro 
Next I determined if the developed assay was suitable to detect branches within 
ubiquitin chains. To exclude the detection of artifacts the formation of 
homogenous chains with Ube2S and ubiquitin fusions of cyclin A and Nek2A272-
445 were monitored at the same time (Figure 25A). Additionally a control reaction 
was performed without addition of TEV after ubiquitylation, checking for the 
occurrence of artifacts when using ubi53TEV and ubi64TEV/FLAG. Mixing recombinant 
cyclin A, APC/CCdh1, Ube2S, Ube2C, ubi53TEV and ubi64TEV/FLAG led to the 
formation of branched ubiquitin conjugates, which were detected by FLAG 
western blot analysis after TEV treatment (Figure 25B). The same was observed 
when Nek2A272-445 was tested (Figure 25C). In both cases the lanes not 
containing TEV show the presence of free intact ubi64TEV/FLAG at the bottom.  
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Figure 25: Detection of branched ubiquitin fragments on cyclin A and Nek2A in vitro. A. 
Cartoon depicting the outcome compared between control reaction of Ube2S with ubiquitin fusion 
of a substrate producing homogenous chains and test reaction of Ube2C and Ube2S with 
substrate producing branched chains. B. Ub-cyclin AHA was incubated with APC/CCdh1, Ube2S, 
ubi53TEV and ubi64TEV/FLAG to add homogenous K11-linked chains; alternatively, cyclin A was 
modified by APC/CCdh1, Ube2C, Ube2S, ubi53TEV and ubi64TEV/FLAG with branched chains. 
Reactions were treated with TEV and analyzed by 20% tricine gels and αFLAG western blot. C. 
Ub3-Nek2A272-445 was incubated with APC/CCdh1, Ube2S, ubi53TEV and ubi64TEV/FLAG to add 
homogenous K11-linked chains; alternatively, Nek2A272-445 was modified by APC/CCdh1, Ube2C, 
Ube2S, ubi53TEV and ubi64TEV/FLAG with branched chains. Reactions were treated with TEV and 
analyzed by 20% tricine gels and αFLAG western blot. D. Nek2A272-445 was incubated with 
APC/C, Ube2C, Ube2S, ubi53TEV and ubi64TEV/FLAG. APC/C was purified from G1 phase, when it is 
active, or S phase, when APC/C-activity is low. APC/CCdh1 was also inhibited by Emi1. Reactions 
were treated with TEV and analyzed by 20% tricine gels and αFLAG western blot. E. Branching is 
impeded by a ubiquitin mutant that does not have lysine residues used by Ube2C and Ube2S. 
Nek2A272-445 was incubated with APC/CCdh1, Ube2C, Ube2S, ubi53TEV and ubi64TEV/FLAG. In the right 
reaction, ubiquitin with mutant K11R, K48R, and K63R was utilized. Reaction products were 
treated with TEV and analyzed by 20% tricine gels and αFLAG western blot.  
The lanes containing TEV show a band at similar MW to intact ubi64TEV/FLAG either 
because of modification of one ubiquitin moiety by another single moiety or 
incomplete cleavage of free ubi64TEV/FLAG, which is unlikely due to the high excess 
of used TEV. Any band at a slightly higher MW represents the introduction of 
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branches in the former ubiquitin conjugates. The combinatorial possibilities of 
multiple branches and presence of ubi53TEV and ubi64TEV/FLAG led to multiple higher 
MW species (Figure 25C). The formation of ubiquitin branches on Nek2A were 
only observed if active APC/C was present, as inhibition by the APC/C-inhibitor 
Emi1 (Reimann et al., 2001) or usage of inactive APC/C immunoprecipitated 
from HeLa cell extract synchronized in S-phase by a double thymidine arrest 
(Rape and Kirschner, 2004) ablated formation of ubiquitin branches (Figure 25D). 
The majority of detected fragments were K11/48, K11/63 or theoretically 
K48/K63, because the mutation of K11, K48 and K63 to arginine in the used 
ubiquitin variants inhibited the detection of these branched ubiquitin fragments 
(Figure 25E). Therefore the here-described assay detects the presence of 
K11/48 and K11/63 branched ubiquitin conjugates on APC/C substrates.  
 
4.3.4. K11-linked ubiquitin chains co-purify with the APC/C 
To determine whether the APC/C synthesizes branched chains in vivo, significant 
amounts of ubiquitin conjugates that were made in prometaphase by APC/C had 
to be purified. Strikingly αK11 western blot analysis revealed the co-purification 
of enriched K11-linked ubiquitin conjugates in APC/C immunoprecipitations from 
thymidine and nocodazole arrested HeLa cells (Figure 26A; Matsumoto et al., 
2010). Immunoprecipitations were performed with an antibody against Cdc27, 
which is an integral subunit of the APC/C (Barford, 2011). The presence of these 
ubiquitin conjugates was dependent on Ube2S as depletion of Ube2S by siRNA 
decreased the amount of ubiquitin conjugates in APC/C immunoprecipitations 
(Figure 26A). To confirm the existence of K11-linked ubiquitin conjugates co-
purifying with the APC/C and to exclude the detection of artifacts by the K11 
antibody, APC/C immunoprecipitations were treated with the K11-specific DUB 
Cezanne (Bremm et al., 2010). The disappearance of signal in the αK11 western 
blot over time due to Cezanne, corroborates the isolation of K11-linked ubiquitin 
conjugates from HeLa cells in prometaphase (Figure 26B). 
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Figure 26: APC/C substrate K11 ubiquitin conjugates can be co-purified by APC/C 
immunoprecipitation. A. APC/C was purified from nocodazole arrested HeLa cells transfected 
with control or Ube2S siRNA and analyzed for co-purifying K11-linked chains using αK11 western 
blot analysis. B. Chains co-purifying with mitotic APC/C are disassembled by the K11-specific 
DUB Cezanne. Immunoprecipitated APC/C from nocodazole arrested HeLa cells was treated with 
50nM Cezanne and binding of K11-modified proteins was determined by αK11-western blot 
analysis C. Chains co-purifying with mitotic APC/C can be washed off by high-salt buffers. 
Immunoprecipitated APC/C from nocodazole arrested HeLa cells was treated with buffers 
containing increasing concentrations of sodium chloride and binding of K11-modified proteins was 
determined by αK11 western blot analysis.  
The purified ubiquitin conjugates could either be attached to APC/C subunits 
itself due to autoubiquitylation or to APC/C substrates. Sodium chloride at 
increasing concentrations should be able to inhibit the interaction of APC/C 
substrates with the APC/C, as this interaction is relatively weak and mainly 
electrostatic (da Fonseca et al., 2011). Indeed, the amount of K11-linked 
ubiquitin conjugates is drastically lowered at 600 or 750mM salt, while the APC/C 
stays intact based on the Cdc16 levels in a Cdc27 immunoprecipitation (Figure 
26C). APC/C cofactors and E2s could technically be washed off as well, but are 
considered substrates of the APC/C as well (Ge et al., 2009; Listovsky et al., 
2004; Rape and Kirschner, 2004; Williamson et al., 2009a). Consequently K11-
linked ubiquitin conjugates were attached to endogenous substrates that 
remained bound to the APC/C following their modification. Hence mitotic APC/C 
co-purifies with its K11 modified substrates.  
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4.3.5. Detection of branched ubiquitin chains co-purifying with the APC/C in vivo 
I developed an approach to detect ubiquitin branches directly in vitro and showed 
that the isolation of ubiquitin conjugates on APC/C substrates in cells was 
possible. These two methods were therefore combined to show if ubiquitin 
branching on APC/C substrates would occur in cells. Consequently FLAGubi53TEV 
and Hisubi64TEV/FLAG were expressed in 293T cells, which did not change general 
ubiquitin levels (Figure 27A). Asynchronous 293T cells were used instead of 
synchronized HeLa cells, as 293T cells allow higher expression of exogenous 
proteins in general.  
 
Figure 27: Detection of branched ubiquitin chains co-purifying with the APC/C in vivo A. 
Expression of ubiTEV/FLAG does not change ubiquitin levels in cells. Lysates of 293T cells 
transfected with FLAGubi53TEV and Hisubi64TEV/FLAG were probed for ubiquitin and the FLAG epitope 
by western blot. B. APC/C synthesizes branched chains in vivo. APC/C was purified from 293T 
cells expressing FLAGubi53TEV and Hisubi64TEV/FLAG, treated with TEV, and analyzed by  αFLAG 
western blot. Upper panel: conjugates co-purifying with APC/C. Lower panel: MW range for 
diagnostic peptides (longer exposure). Ubiquitin detected in reactions without TEV is produced by 
DUBs that co-precipitate with APC/C. C. APC/C was purified from 293T cells expressing wt- or 
Lys-mutant FLAGubi53TEV and Hisubi64TEV/FLAG, treated with TEV, and analyzed for co-purifying 
conjugates (upper panel) or diagnostic peptides (lower panel). D. APC/C was precipitated from 
293T cells expressing FLAGubi53TEV and Hisubi64TEV/FLAG, treated with TEV as shown and analyzed 
by αFLAG western blot. As indicated, APC/C was purified from cells enriched in S phase by 
thymidine treatment (thy). 
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The APC/C was purified from 293T cells expressing FLAGubi53TEV and 
Hisubi64TEV/FLAG with co-precipitating substrates, and the samples were treated 
with TEV. These experiments showed that endogenous APC/C-substrates were 
modified with branched chains, while the branching pattern reflecting that of the 
in vitro analyses (Figure 27B). The formation of branched linkages was severely 
reduced upon expression of ubiR11/48/63 in the FLAGubi53TEV and Hisubi64TEV/FLAG 
background (Figure 27C), a mutant that obliterated branching in vitro (Figure 
25E), showing that also in vivo mainly K11/48 and K11/63 ubiquitin branches are 
formed. Furthermore was APC/C activity needed in vivo, as 293T cells 
overexpressing FLAGubi53TEV and Hisubi64TEV/FLAG showed reduced levels of the 
predominant branching fragment, when arrested in S phase by thymidine 
treatment (Figure 27D). In summary APC/C introduces ubiquitin branches in 
cells, which were detected in APC/C co-purifying ubiquitin conjugates of 
endogenous substrates. 
 
4.3.6. Detection of branched ubiquitin chains attached to APC/C substrates in 
vivo 
To test whether the APC/C modifies Nek2A with branched chains in cells, the 
newly developed approached was used in combination with exogenously 
expressed HANek2A and a classical approach with expressing ubiquitin mutants 
was used with other APC/C substrates, namely geminin and NuSAP (Li et al., 
2007a; McGarry and Kirschner, 1998). First, 293T cells were transfected with 
HANek2A, FLAGubi53TEV and Hisubi64TEV/FLAG and treated for six hours with 20 µM 
MG132. Treatment of HA-immunoprecipitations with TEV revealed a fraction of 
branched chains, similar to the modification of Nek2A with such conjugates in 
vitro (Figure 28A). These findings were supported by the second approach 
showing that expression of HisubiK6/11 and similarly HisubiK11, a mutant that allows 
formation of K11-linked chains, but prevents branched conjugates, strongly 
impaired the modification of APC/C-substrates in cells (Figure 28B). Expression 
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of GFP was used to control for equal transfection efficiency. Hence, the APC/C 
assembles branched chains in cells and Nek2A is a substrate for this 
modification. 
 
               
Figure 28: Detection of branched ubiquitin chains attached to APC/C substrates in vivo. A. 
Nek2A is modified with branched chains in cells. HANek2A was purified from cells expressing 
FLAGubi53TEV and Hisubi64TEV/FLAG and treated with TEV. Reactions were analyzed by αFLAG 
western blot. B. APC/C requires multiple ubiquitin lysine residues for efficient substrate 
modification in vivo. 293T cells were transfected with geminin or NuSAP, His-tagged wt- or 
mutant ubiquitin, and GFP as control. Ubiquitylated proteins were purified under denaturing 
conditions and detected by western blotting. Probably due to high activity of DUBs 
monoubiquitylation or short chains cannot be detected under these conditions (see the ubi-noK 
control).  
 
4.4. Altering the linkage-specificity of metazoan APC/C 
To determine specific functions of branched chains, another experimental system 
was required, which allowed me to compare the fate of a substrate decorated 
with different distinct homogenous chains or branched conjugates that resulted 
from a combination of these distinct chain types respectively. Such experiments 
are difficult to perform with Ube2C, as this E2 produces chains of mixed 
topology. To overcome this limitation, a K48-specific APC/C-E2 was engineered, 
which together with the physiological E2s enabled me to modify substrates either 
with K11-, K48-linked, or K11/K48 branched chains.  
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4.4.1. Ube2S without its CTP does not bind APC/C 
To generate an APC/C E2 with new linkage specificity, Ube2S was imitated, in 
the way it stably binds to APC/C (Williamson et al., 2009a). Ube2S consists of a 
catalytic N-terminal ubiquitin conjugating (UBC) domain connected to a stretch of 
positively charged residues at the C-terminus (CTP) via a linker region (Figure 
29A).  
                   
Figure 29: The CTP of Ube2S is essential for binding to the APC/C. A. Ube2S consists of a 
catalytic UBC domain and a C-terminal peptide (CTP) connected by a linker region. B. The CTP 
is required and sufficient for APC/C-binding of Ube2S in vitro. 35S-labeled APC/C-subunits were 
incubated with immobilized MBP, MBPCTP, MBPUbe2S, or MBPUbe2S∆CTP. Binding reactions were 
analyzed by autoradiography. C. The CTP is required for APC/C-binding of Ube2S in cells. 
HAUbe2S or HAUbe2S∆CTP were precipitated from HeLa cells, and co-purifying APC/C was 
detected by αCdc27 western blot analysis.  
 
To determine the main binding surface on Ube2S, MBP as a control, MBPUbe2S 
or MBPUbe2S∆CTP were immobilized on amylose-resin, as shown in the 
Coomassie stained gel (Figure 29B), and incubated with 35S-radiolabeled APC/C 
subunits (APC2, Cdc27, APC4 and APC5) or an APC/C coactivator Cdh1. 
Autoradiography showed that MBPUbe2S was able to bind all APC/C components, 
which is likely due to incorporation of radiolabeled proteins into APC/C 
complexes present in the reticulocyte lysate (Figure 29B). On the other hand 
binding of all APC/C components was lost if the region C-terminal of the UBC 
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domain in Ube2S was deleted (Figure 29B) showing that the main binding motif 
of Ube2S for the APC/C lies within its C-terminus. To further validate this finding 
in cells, 293T cells were transfected with either full-length (FL) HAUbe2S or a C-
terminal deletion HAUbe2S∆CTP. HA-immunoprecipitations showed that only the FL 
version pulled down endogenous Cdc27 (Figure 29C). Consequently the CTP of 
Ube2S is essential for binding to APC/C in cells. 
 
4.4.2. The CTP is sufficient for APC/C-binding 
The next step to generate an APC/C E2 with new linkage specificity was to test, if 
the CTP was not only essential for binding to the APC/C, but if it was also 
sufficient for targeting to the APC/C. To determine this in vitro the CTP was 
coupled to biotin (Williamson et al., 2009a), immobilized on streptavidin agarose 
and incubated with 35S-radiolabeled APC/C components.  
 
Figure 30:! The CTP is sufficient for 
APC/C binding A. The CTP is sufficient for 
APC/C binding in vitro. Biotinylated CTP was 
immobilized on streptavidin agarose, 
incubated with 35S-labeled APC/C subunits 
and analyzed by autoradiography. B. The 
CTP is sufficient for APC/C-binding in cells. 
APC/C was purified from 293T cells 
expressing HACTP and binding reactions were analyzed by western blot against the respective 
APC/C component or HA. 
 
Autoradiography revealed enrichment of APC/C components on CTP coupled 
beads compared to the streptavidin resin control, showing the CTP is sufficient 
for binding to the APC/C in vitro (Figure 30A). This was further validated by using 
MBPCTP (Figure 29B). To determine if the CTP is also enough for binding to 
endogenous APC/C in cells, HACTP was expressed in 293T cells. By western blot 
analysis the presence of HACTP was only observed in APC/C 
immunoprecipitations showing the capability of the CTP for binding to the APC/C 
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in vivo (Figure 30B). Thus the CTP is sufficient for APC/C targeting in vitro and in 
vivo. 
 
4.4.3. Ube2G2CTP binds the APC/C in vitro and in vivo 
Several UBC domains of E2s were tested to engineer a novel APC/C E2 with a 
ubiquitin linkage specificity distinct from the K11 specificity of Ube2S (data not 
shown). In the end it was decided respectively to fuse FL Ube2G2 to the CTP 
(Ube2G2CTP). Ube2G2 is a K48 specific E2 normally working with the E3 gp78 to 
degrade substrates of the endoplasmic-reticulum-associated protein degradation 
(ERAD) pathway (Fang et al., 2001; Li et al., 2007b). First it had to be 
determined, if Ube2G2CTP can actually bind the APC/C. MBP, MBPUbe2S, 
MBPUbe2G2CTP, MBPUbe2S∆CTP and MBPUbe2G2 were bound to amylose-resin 
(Figure 31A: Coomassie stained gel) and incubated with 35S-radiolabeled APC/C 
components Cdc27 or Cdh1. Autoradiography revealed that only MBPUbe2S and 
MBPUbe2G2CTP bind the APC/C (Figure 31A), showing that Ube2G2 by itself does 
not interact with the APC/C, while Ube2G2CTP is able to bind the APC/C in vitro. 
To test if Ube2G2CTP is targeted to the APC/C in vivo as well, HeLa cells 
constitutively expressing untagged Ube2G2CTP were generated. The predicted 
MW of Ube2S is 23.8kDa, but the apparent MW of Ube2S in SDS PAGE seems 
to be slightly above 25kDa. The predicted MW of Ube2G2CTP is 22.5kDa, which 
seems to be in line with its apparent MW in SDS PAGE allowing clear separation 
and detection of both Ube2S and Ube2G2CTP by Ube2S western blot analysis 
(Figure 31B). An extract of a generated Ube2G2CTP cell line was used for 
immunoprecipitation of APC/C. Ube2S and Ube2G2CTP both co-purified with 
precipitated APC/C, while a control immunoprecipitation (CD3) excluded 
unspecific binding (Figure 31B). Taken together, this indicates that Ube2G2CTP 
binds APC/C in vitro and in cells. 
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 Figure 31: Ube2G2CTP binds the APC/C in vitro and in vivo. A. Ube2G2CTP binds APC/C in 
vitro. Binding of 35S-labeled Cdc27 or Cdh1 to immobilized MBP, MBPUbe2S, MBPUbe2G2, 
MBPUbe2G2CTP, or MBPUbe2S∆CTP was analyzed by autoradiography. B. Ube2G2CTP binds APC/C 
in cells. APC/C was immunoprecipitated from extracts of HeLa cells constitutively expressing 
Ube2G2CTP with αCD3- or αCdc27-antibodies, and co-purifying Ube2S and Ube2G2CTP were 
detected by the Ube2S antibodies recognizing the CTP. 
 
4.4.4. Ube2G2CTP ubiquitylates APC/C substrates 
After confirming the ability of Ube2G2CTP to interact with APC/C, I tested, if the 
newly engineered E2 was able to modify APC/C substrates with ubiquitin. 35S-
labeled cyclin A, APC/CCdh1, and either no E2, Ube2G2 or Ube2G2CTP with the 
other necessary ubiquitylation components were incubated. Autoradiography 
visualized the outcome of the reaction. The presence of an E2 was necessary for 
ubiquitylation of cyclin A (Figure 32A). Luckily the designed Ube2G2CTP was able 
to polyubiquitylate cyclin A. Ubiquitylation activity of Ube2G2CTP was dependent 
on the CTP, as Ube2G2 did not modify cyclin A (Figure 32A). Furthermore 
catalyzed Ube2G2CTP the formation of ubiquitin chains on geminin at a rate 
similar to Ube2S (Figure 32B). Ube2C had to be added to these reactions at 
100nM, as Ube2G2CTP shows slower ubiquitylation of substrate lysine residues 
than Ube2C (data not shown). Ubiquitylation reactions of cyclin A with 
Ube2G2CTP were sensitive to inhibition by Emi1 or excess of another APC/C 
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substrate (Rape et al., 2006), here securin, the same way Ube2S is inhibited 
under these conditions (Figure 32C). Respectively, Ube2G2CTP ubiquitylates 
APC/C substrates similar to Ube2S in vitro.  
 
 
Figure 32: Ube2G2CTP ubiquitylates APC/C substrates. A. Ube2G2CTP ubiquitylates cyclin A. 
35S-cyclin A was incubated with APC/CCdh1 and no E2, Ube2G2, or Ube2G2CTP for 30min at 30°C. 
Reactions were analyzed by autoradiography. B. Ube2G2CTP catalyzes ubiquitylation of geminin 
with similar efficiency as Ube2S. 35S-labeled geminin was incubated with APC/CCdh1, low levels of 
Ube2C for initiation, and either Ube2G2CTP or Ube2S for the indicated time points at 25°C. 
Reactions were analyzed by autoradiography and quantified using ImageJ. C. 35S-labeled cyclin 
A was incubated with APC/CCdh1, low levels of Ube2C, and Ube2G2CTP or Ube2S. APC/C was 
inhibited by Emi1 or an excess of recombinant securin, an APC/C-substrate. Reactions were 
analyzed by autoradiography.  
 
4.4.5. Ube2G2CTP requires a functional catalytic E2 domain and APC/C substrate 
recognition motifs  
Next I investigated if engineered Ube2G2CTP still catalyzed ubiquitin transfer in 
the same way Ube2G2 and other E2s do regarding its catalytic site. The most 
obvious requirement for ubiquitin transfer within an E2 is its active site cysteine 
residue. Mutation of the active site cysteine C89 to serine (C89S) led to the 
abrogation of Ub-cyclin A ubiquitylation activity of Ube2G2CTP detected by K48 
western blot analysis (Figure 33A). Mutating the catalytic domain of Ube2G2CTP 
further corroborated this. Deletion of the acidic loop (A95-A107) close to the 
active site of Ube2G2CTP inhibited ubiquitin transfer (Figure 33B) as reported for 
Ube2G2 (Li et al., 2007b).  
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Figure 33: Ube2G2CTP requires a functional catalytic E2 domain and APC/C substrate 
recognition motifs for ubiquitylation. A. The catalytic cysteine is required for Ube2G2CTP-
activity towards APC/C-substrates. Ub-cyclin A was incubated with APC/CCdh1 and Ube2G2CTP or 
Ube2G2CTP-C89S, and reactions were analyzed by αK48-linkage specific western blot. B. 
Ube2G2CTP requires its RING-domain interaction loop for activity with APC/C. 35S-labeled cyclin A 
was incubated with APC/CCdh1 and indicated Ube2G2CTP-mutants. Reactions were analyzed by 
autoradiography. C. 35S-geminin or mutants in its D-box (DBOX) or initiation motif (IM) were 
incubated with APC/CCdh1, low levels of Ube2C, and Ube2G2CTP or Ube2S. Reactions were 
analyzed by autoradiography.  
 
Mutation of the surface responsible for interaction with the RING finger also 
inhibited Ube2G2CTP activity (Figure 33B) as published (Das et al., 2009). 
Therefore, Ube2G2CTP supposedly interacts with the APC/C RING finger to 
ubiquitylate APC/C substrates. Addition of a peptide representing the portion of 
gp78 that interacts with Ube2G2 (Das et al., 2009) reduced ubiquitylation by 
Ube2G2CTP indicating that this allosterically activated conformation of Ube2G2CTP 
is reduced in its ability to bind the APC/C RING domain or that the peptide is 
competing with the APC/C RING for binding to Ube2G2CTP. Additionally 
Ube2G2CTP needed the same APC/C substrate recognition motifs as the 
physiological APC/C E2s. Geminin with mutations in its destruction box (DBOX) 
or initiation motif (IM) was used for this purpose (Williamson et al., 2011). Wt-
geminin or its mutants were incubated with no E2s as a control, Ube2S as the 
physiological E2 or Ube2G2CTP. Autoradiography showed that Ube2G2CTP relies 
on the same APC/C substrate interactions as Ube2S (Figure 33C). In summary 
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Ube2G2CTP requires an active site cysteine, RING finger interaction and APC/C 
substrate recognition motifs to ubiquitylate APC/C substrates. 
 
4.4.6. Ube2G2CTP synthesizes K48-linked ubiquitin chains on cyclin A 
As Ube2G2CTP was shown to be active with the APC/C, it was determined if it 
retained the K48 linkage specificity of the original Ube2G2 or if the APC/C could 
change its linkage specificity. Radiolabeled cyclin A was incubated with APC/C, 
the respective ubiquitin mutants and Ube2S or Ube2G2CTP. The use of wt-
ubiquitin or ubiquitin mutants with only a single lysine residue (all other lysine 
residues were mutated to arginine) revealed that the linkage specificity of the 
APC/C switched from K11 to K48 using Ube2G2CTP instead of Ube2S, as Ube2S 
supported formation of ubiquitin chains using ubiK11, while Ube2G2CTP 
ubiquitylated cyclin A using ubiK48 (Figure 34A). Remarkably the linkage 
specificity of the 1.5MDa large APC/C is consequently determined by the 15kDa 
large UBC domain of its E2. At this point it should be mentioned, that APC/C 
immunoprecipitations as the source in these reactions had to be washed with 
500mM sodium chloride to isolate almost Ube2S free APC/C (data not shown). A 
small amount of Ube2S possibly still remained bound explaining negligible 
amounts of K11-linked chains in the ubiK11 lane of Ube2G2CTP (Figure 34A). The 
same result is achieved, if the experiment is done with the reverse ubiquitin 
mutants. Instead of using mutants with a single lysine residue, ubiquitin mutants 
with a single lysine to arginine substitution were employed. Again Ube2S 
synthesized K11 chains on cyclin A shown by the inhibition of ubiquitylation in the 
presence of ubiR11, while Ube2G2CTP ubiquitylated cyclin A with K48 chains 
based on inhibition by ubiR48 (Figure 34B). Ubiquitin linkage specific antibodies 
(Matsumoto et al., 2010; Newton et al., 2008) allow to determine the linkage of 
wt-ubiquitin conjugates. This approach becomes important as E2s can change 
their linkage specificity if used in combination with ubiquitin mutants (Wickliffe et 
al., 2011a). Hence, recombinant Ub-cyclin A was incubated with either Ube2S or 
Ube2G2CTP and the resulting reaction products were analyzed by αK11, αK48 or 
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αcyclin A western blot. In the presence of APC/C, both Ube2S and Ube2G2CTP 
form substrate attached ubiquitin conjugates linked through K11 or K48 (Figure 
34C). Use of ubiquitin mutants or linkage specific antibodies demonstrated that 
Ube2G2CTP modified APC/C-substrates with K48-linked chains switching the 
linkage specificity of the APC/C from K11 to K48.  
 
Figure 34: Ube2G2CTP synthesizes K48-linked ubiquitin chains on cyclin A. A. Ube2G2CTP 
catalyzes chain formation with ubiK48. 35S-cyclin A was incubated with APC/CCdh1, low levels of 
Ube2C, Ube2S or Ube2G2CTP, and ubiquitin mutants. Reactions were analyzed by 
autoradiography. B. Ube2G2CTP requires K48 of ubiquitin for chain formation. 35S-cyclin A was 
incubated with APC/CCdh1, low levels of Ube2C, Ube2S or Ube2G2CTP, and ubiquitin variants. 
Reactions were analyzed by autoradiography. C. Ube2G2CTP catalyzes K48-linked chain 
formation with APC/C. Ub-cyclin A was incubated with APC/CCdh1, either Ube2S or Ube2G2CTP, 
and ubiquitin. Reaction products were analyzed by western blot.  
 
 
Results 
 !
! -102-!
4.5. Ube2G2CTP and Ube2S synthesize branched K11/K48-linked chains 
I created a novel E2 producing K48 ubiquitin conjugates on APC/C substrates. 
Using this tool it was tested if the combination of both K11 and K48 linkages 
would lead to the attachment of larger ubiquitin conjugates to APC/C substrates 
as an additional and elegant proof of principle for ubiquitin chain branching. It 
was carefully analyzed, if K11 and K48 linkages could be detected within the 
same APC/C substrate ubiquitin conjugates, if it was due to mixing or branching 
of different ubiquitin linkages and if it would also occur in cells and not only in an 
in vitro system. 
 
4.5.1. Ube2S and Ube2G2CTP produce ubiquitin chains containing K11 and K48 
linkages on cyclin A in vitro 
First I tested, what happens when K11 and K48 producing enzymes, here Ube2S 
and Ube2G2CTP, would both be present in APC/C ubiquitylation reactions. 
Recombinant Ub-cyclin A was used as a substrate for Ube2S and Ube2G2CTP. 
Furthermore was Ub-cyclin A in excess over immunoprecipitated APC/C for 
single substrate turnover (Rape et al., 2006) to ensure that the outcome of the 
reaction could potentially take place in cells and is not a result of overcrowding in 
vitro. While Ube2S alone transferred about six ubiquitin moieties, a combination 
of Ube2S and Ube2G2CTP added K11 polyubiquitin chains of a drastically higher 
MW (Figure 35A). The combination of Ube2G2CTP-C89S and Ube2S did not 
recapitulate the formation of these long ubiquitin chains excluding activation of 
Ube2S by the presence of Ube2G2CTP. Next it was checked, if the high MW 
polyubiquitin chains made by Ube2S and Ube2G2CTP were comprised of K11 and 
K48 linkages within the same ubiquitin conjugates or if they were a mixture of 
substrates modified with either K11 or K48 chains. Ub-cyclin A and FLAGubiquitin 
were incubated with or without Ube2G2CTP allowing the formation of K48-linked 
chains on Ub-cyclin A (Figure 35B).  
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Figure 35: Ube2S and Ube2G2CTP produce ubiquitin chains containing K11 and K48 
linkages on cyclin A in vitro. A. High MW chains are seen in single substrate turnover assays. 
An excess of Ub-cyclin A (1µM) over APC/CCdh1 (~10nM) was incubated with Ube2S, 
Ube2S/Ube2G2CTP, or Ube2S and Ube2G2CTP-C89S. Reactions were analyzed by western blot. 
B. Ube2S and Ube2G2CTP catalyze formation of high MW conjugates that contain K11 and K48 
linkages. Ub-cyclin A was incubated under single turnover conditions with APC/C, Ube2G2CTP 
and a low concentration of FLAGubiquitin. After 5min, reactions were supplemented with an excess 
of ubiR48, which blocks Ube2G2CTP-activity, but does not affect Ube2S. Then, Ube2S was added 
to allow formation of K11-linkages. To purify conjugates that contained both K48 and K11 
linkages, the final reactions were subjected to affinity purification on FLAG-agarose, and peptide-
eluates were analyzed with αK11 specific western blotting. C. Long chains formed by Ube2G2CTP 
and Ube2S contain K11 linkages. Chains produced by APC/CCdh1, Ube2S and Ube2G2CTP were 
incubated with the K11 specific DUB Cezanne and analyzed by αK11 specific western blot.  
 
Adding excessive amounts of ubiR48 stopped the incorporation of FLAGubiquitin. At 
the same time Ube2S was added allowing the modification of Ube2S with K11-
linked chains. Detection of ubiquitin species after FLAG immunoprecipitation, 
elution with FLAG peptide and αK11 western blot analysis meant that these 
ubiquitin conjugates were created by incorporation of FLAGubiquitin through 
Ube2G2CTP in form of K48 linkages and sequential attachment of K11-linked 
chains by Ube2S in the presence of ubiR48. Indeed only high MW polyubiquitin 
chains gave a strong signal for this analysis and therefore consist of K11 and 
K48 ubiquitin linkages (Figure 35B). The combination of the two linkages made 
by Ube2S and Ube2G2CTP was validated by another approach. High MW species 
synthesized by Ube2S and Ube2G2CTP were treated with the K11 specific DUB 
Cezanne. If these species existed because of the modification with long 
homogenous K48 chains introduced by the engineered Ube2G2CTP, incubation 
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with Cezanne should show no change in the abundance of K11-linked chains. 
The contrary was the case, as Cezanne hydrolyzed the high MW ubiquitin chains 
made by Ube2S and Ube2G2CTP in a similar manner to homogenous K11 chains 
made by Ube2S alone (Figure 35C). Together these data show that combination 
of K11 and K48 linkages leads to the formation of high MW polyubiquitin chains 
on an APC/C substrate. 
 
4.5.2. Ube2S and Ube2G2CTP form K11/K48-branched ubiquitin chains in vitro 
Next, I determined if the ubiquitin species by Ube2S and Ube2G2CTP contained 
K11- and K48-linked chains due to mixing or branching of K11 and K48 linkages. 
Ub-cyclin A incubated with wt-ubiquitin, Ube2S and Ube2G2CTP produced high 
MW ubiquitin conjugates positive for K11 and K48 linkages based on αK11 and 
αK48 western blot analysis (Figure 36A).  
 
 
Figure 36: Ube2S and Ube2G2CTP modify cyclin A with K11/K48-branched ubiquitin chains. 
A. High MW conjugates assembled by Ube2S and Ube2G2CTP are branched chains. Ub-cyclin A 
was incubated with APC/CCdh1, Ube2S, Ube2G2CTP, and ubiquitin mutants under single substrate-
turnover conditions and analyzed by Western. Mixtures of ubiR11 and ubiR48 allow Ube2S and 
Ube2G2CTP to synthesize mixed chains, yet prevent introduction of branches. B. Ube2S 
elongates K48-linked chains by Ube2G2CTP with K11-linked chains. Ub-cyclin A was mixed with 
APC/CCdh1, Ube2G2CTP and low levels of ubiquitin, which leads to addition of two K48-linked 
ubiquitin molecules (Ub3-cyclin A). Next, an excess of ubiR48 and Ube2S were added. Ub-cyclin A 
was also directly incubated with Ube2S and ubiR48. Reactions were analyzed by western blot.  
Results 
 !
! -105-!
Using ubiR11 or ubiR48 inhibited the formation of these conjugates showing that 
both K11 and K48 linkages are needed. Even more importantly Ube2S and 
Ube2G2CTP did not produce high MW chains, if incubated with mixtures of ubiR11 
and ubiR48 (Figure 36A). Under these conditions mixed chains with K11 and K48 
linkages can be synthesized, but K11/K48-branched chains cannot be produced, 
as no ubiquitin contains K11 and K48 at the same time. To further test whether 
the engineered E2 could be used to produce branched chains, Ub-cyclin A was 
incubated with APC/CCdh1, Ube2G2CTP, and wt-ubiquitin at a low concentration for 
a short time, which led to attachment of two K48-linked ubiquitin molecules (Ub3-
cyclin A). An excess of ubiR48 then inactivated Ube2G2CTP, before Ube2S was 
added. As expected for the assembly of branched chains Ube2S decorated Ub3-
cyclin A with conjugates of much higher MW than those formed on Ub-cyclin A, a 
substrate that can only be modified with a single K11-linked chain (Figure 36B). 
Thus, these experiments show that Ube2S and Ube2G2CTP produce K11/K48-
branched chains on APC/C-substrates.  
 
4.5.3. Presence of Ube2G2CTP, Ube2C and Ube2S in extracts and cells leads to 
formation of high MW ubiquitin chains 
To check if the physiological E2s and the engineered E2 would also form 
K11/K48-branched high MW ubiquitin conjugates in cells two different 
experiments were performed. First the ubiquitylation of geminin, as a model 
APC/C substrate, by the physiological E2s, Ube2C and Ube2S and the 
engineered E2, Ube2G2CTP was analyzed separately in extracts made from HeLa 
cells synchronized in prometaphase by thymidine and nocodazole. Endogenous 
Ube2S is present and further addition of Ube2S does not lead to improved 
ubiquitylation (data not shown). The concentration of active APC/C in these 
extracts is limiting and the substrate ubiquitin transfer activity of Ube2G2CTP is 
weak compared to Ube2C (data not shown). Therefore addition of Ube2G2CTP to 
these extracts did not result in significant ubiquitylation of geminin compared to 
the control (Figure 37A). Addition of a high concentration of Ube2C on top of low 
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levels of endogenous Ube2C already present in the control, led to ubiquitylation 
of geminin, which became detectable in the presence of high amounts of GST 
tagged UBA domains (Hjerpe et al., 2009; Raasi et al., 2004). When Ube2C and 
Ube2G2CTP were added together the formation of high MW ubiquitin species was 
detected (Figure 37A).  
      
Figure 37: Ube2G2CTP, Ube2C and Ube2S cooperate in extracts and cells. A. Cooperation of 
K11 and K48 specific APC/C E2s results in high MW conjugates. Extracts of prometaphase HeLa 
cells synchronized with thymidine and nocodazole were supplemented with 35S-labeled geminin 
and 200µM MG132, or recombinant GST tagged UBA domains of HHR23A (to capture 
ubiquitylated substrates and thereby inhibiting deubiquitylation). Reactions were incubated for two 
hours and analyzed by autoradiography. B. Ube2S and Ube2G2CTP cooperate in vivo. 
Prometaphase HeLa cells synchronized with thymidine and nocodazole expressing Hisubiquitin, 
Ube2G2CTP, or dominant-negative E2s (Ube2G2CTP-C89S, Ube2C-C114S and Ube2S-C95S) 
were released into anaphase, and treated with 15µM MG132 for 2 hours to enrich for ubiquitin 
conjugates. Conjugates were purified under denaturing conditions with NiNTA, and K11-linked 
chain formation was monitored by αK11 western blot analysis. 
To determine if Ube2G2CTP, Ube2C and Ube2S also cooperate in cells to form 
K11/K48-branched chains, HeLa cells were transfected with Hisubiquitin, 
synchronized in anaphase after release from thymidine and nocodazole into 
MG132 containing medium and enriched for ubiquitin conjugates by NiNTA pull 
down under denaturing conditions. As revealed by αK11 western blot analysis 
co-expression of Ube2G2CTP increased the amount and MW of ubiquitin 
conjugates (Figure 37B). This increase relied on the presence of active 
Ube2G2CTP, Ube2C or Ube2S, as co-expression of dominant negative 
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Ube2G2CTP, Ube2C or Ube2S abolished significant detection of high MW species 
(Figure 37B). Hence Ube2G2CTP, Ube2C and Ube2S collaborate in the formation 
of K11/K48 branched high MW ubiquitin conjugates in extracts and cells. 
 
4.6. Branched ubiquitin chains show improved binding to ubiquitin binding 
proteins 
After establishing that the physiological E2s Ube2C and Ube2S and the 
engineered E2 Ube2G2CTP and Ube2S were able to produce branched chains, it 
was now possible to investigate the effects of homogenous versus branched 
ubiquitin chains in terms of interaction with ubiquitin binding proteins. 
Furthermore Ube2G2CTP making specifically K48-linked chains gives the 
opportunity to test for differences in K11 versus K48 ubiquitin linked chains for 
binding to ubiquitin receptors. 
 
4.6.1. Cyclin A modified with either K11- or K48-linked ubiquitin chains shows 
similar binding to S5a, HHR23A and p97 cofactor complexes 
To compare chains of certain linkages versus branched chains resulting from a 
combination of these linkages in terms of ubiquitin receptor affinities, I tested first 
to what extent the different linkages bind individually. Chains made by Ube2C 
and Ube2S were considered mainly K11 chains and chains made by Ube2C and 
Ube2G2CTP were considered mainly K48 chains. The proteasomal delivery factor 
HHR23A, the major ubiquitin receptor within the 26S proteasome S5a and 
complexes of p97 with its ubiquitin binding cofactors involved in ubiquitin 
dependent processes were analyzed for binding to K11- and K48-linked chains. 
Radiolabeled cyclin A was modified using Ube2C for efficient chain initiation and 
either Ube2S or Ube2G2CTP for efficient attachment of K11- or K48-linked chains. 
The modified cyclin A was incubated with HHR23A, S5a or p97, which were 
immobilized on amylose resin via their N-terminal MBP tags. In the case of 
MBPp97 the His tagged cofactors were indirectly bound to amylose resin through 
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MBPp97. After visualization of cylin A ubiquitin conjugate binding to HH23A, S5a 
or p97 complexes by autoradiography, no significant differences in the affinities 
of K11- or K48-linked chains were determined (Figure 38).  
 
    
Figure 38: HHR23A, S5a and p97 cofactor complexes bind with similar efficiency to cyclin 
A modified with either K11- or K48-linked chains. A. The proteasomal substrate adaptors 
HHR23A and S5a bind with similar efficiency to APC/C-substrates modified with either K11- or 
K48-linked chains. 35S-labeled cyclin A was incubated with APC/CCdh1, low concentrations of 
Ube2C, and Ube2S or Ube2G2CTP for modification with K11- or K48-linked chains, respectively. 
Reaction products were added to immobilized MBP, MBPHHR23A, or MBPS5a, and binding was 
detected by autoradiography. B. APC/C-substrates decorated with either K11- or K48-linked 
chains are recognized similarly by p97 substrate adaptors. 35S-labeled cyclin A was modified with 
K11- or K48-linked chains, incubated with immobilized complexes between MBPp97 and His-
tagged substrate adaptors, and analyzed by autoradiography.  
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4.6.2. Cyclin A modified with either K11- or K48-linked ubiquitin chains does not 
compete for binding to S5a or p97/SAKS1  
Additionally it was investigated, if in the presence of both chain types, K11 or K48 
ubiquitin chains might show enhanced binding over the other.  
      
Figure 39: K11- or K48-linked ubiquitin chains do not compete for binding to ubiquitin 
binding proteins. A. Ub-cyclin A was modified by the APC/CCdh1 and Ube2S or Ube2G2CTP with 
either K11- or K48-linked chains. Reaction products were incubated with immobilized MBPS5a 
either alone or together, and analyzed by western blot. B. K11- and K48-linked chains mediate 
substrate binding to p97/SAKS1. Ub-cyclin A was modified with K11- or K48-linked chains. 
Products were added to immobilized MBPp97/HisSAKS1-complexes, and binding was analyzed by 
western blot using K11 or K48 specific antibodies.  
 
Therefore, recombinant Ub-cyclin A was modified with either homogenous K11 
chains by Ube2S or homogenous K48 chains by Ube2G2CTP. Reaction products 
either individually or in combination were incubated with immobilized MBPS5a or 
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MBPp97/HisSAKS1. Binding of ubiquitylated cyclin A was determined by αK11 or 
αK48 western blot analysis and quantified with ImageJ. While K11- and K48-
linked ubiquitin chains similarly bind to S5a, the presence of both chain types 
seems not to negatively interfere with binding of the respective chain type (Figure 
39A).  
Competition for interaction with p97/SAKS1 was observed neither (Figure 39B). 
To the contrary a significant enhancement of binding was detected in the 
presence of cyclin A modified with K11 chains and cyclin A modified with K48 
chains. This was not further investigated. Consequently K11- or K48-linked 
ubiquitin chains on an APC/C substrate do not compete for binding to S5a or 
p97/SAKS1. 
 
4.6.3. High MW branched ubiquitin chains show enhanced binding compared to 
shorter ubiquitin chains 
After determining that K48- and K11-linked chains show similar binding I 
determined if K11/K48-branched chains would enhance binding to S5a or 
p97/SAKS1 compared to shorter K11-linked chain. Ub-cyclin A was either 
modified with about six K11-linked ubiquitin moieties by Ube2S or with a mixture 
of similar shorter chains possibly either K11 or K48 and high MW K11/K48-
branched chains by combining Ube2S and Ube2G2CTP. The reaction products 
were incubated with MBPS5a immobilized on amylose resin and binding was 
visualized by αK11 western blot. While short K11 chains interact weakly with 
S5a, large K11/K48 branched chains bind relatively strong (Figure 40A). The 
same was observed when 35S-radiolabeled cyclin A was modified with Ube2S, 
Ube2G2CTP and low levels of Ube2C. Detecting all ubiquitin conjugates by 
autoradiography a mixture of shorter chains and long K11/K48-branched chains 
were seen on cyclin A. A preference for the branched chains was determined 
when ubiquitin conjugates were incubated with MBPp97/HisSAKS1 and MBPS5a 
(Figure 40B). Thus, these experiments show the enhanced binding of K11/K48-
branched chains to ubiquitin receptors. 
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Figure 40: High MW branched ubiquitin chains show enhanced binding compared to 
shorter ubiquitin chains A. Proteins decorated with K11/K48-linked branched chains bind more 
efficiently to S5a than those modified with single chains. Ub-cyclin A modified with K11-linked or 
K11/K48-branched chains were incubated with MBPS5a in the presence of 300mM sodium 
chloride, and binding was monitored by αK11 western blot. B. Branched chains are recognized 
with higher affinity by S5a or p97 than single chains. 35S-labeled cyclin A modified with a mixture 
of homogenous or K11/K48-branched chains (generated with APC/CCdh1, low levels of Ube2C, 
Ube2S, and Ube2G2CTP) were incubated with immobilized MBP, MBPS5a, or MBPp97/HisSAKS1. 
Binding was analyzed by autoradiography.  
 
4.6.4. Branched ubiquitin chains show better binding than homogenous chains of 
similar length on cyclin A or Nek2A 
Next I investigated if the binding difference observed between homogenous and 
branched chains were caused by difference in length or by the presence of 
branches. 35S-labeled cyclin A was modified with a combination of Ube2S, 
Ube2G2CTP and low levels of Ube2C, resulting in the attachment of either 
branched chains using wt-ubiquitin, homogenous K11-linked chains using ubiK11 
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or homogenous K48-linked chains using ubiK48. Cyclin A attached to branched or 
homogenous K48 chains appeared to be of similar MW (Figure 41A).  
        
Figure 41: Enhanced binding of branched ubiquitin chains. A. Preferential binding of 
branched chains is independent of chain length. 35S-labeled cyclin A was modified by APC/CCdc20, 
low levels of Ube2C, Ube2S and/or Ube2G2CTP, and wt-ubiquitin, ubiK11, or ubiK48 to assemble 
K11-, K48-linked, or K11/K48-branched chains, and incubated with MBPS5a. Reactions were 
analyzed by autoradiography. B. Branched chains increase the affinity of Nek2A for the 
proteasomal receptor S5a. 35S-labeled Nek2A272-445 was modified by APC/CCdc20, Ube2C and 
Ube2S with homogenous or branched chains (using ubiK11 or wt-ubiquitin) and incubated with 
MBPS5a. Reactions were analyzed by autoradiography.  
 
When tested for binding to immobilized MBPS5a though, branched chains seemed 
to be more effective. Subsequently it was determined if modification of the 
prometaphase substrate Nek2A by APC/CCdc20, Ube2C and Ube2S with 
branched chains results in stronger binding to ubiquitin receptors. 35S-
radiolabeled Nek2A272-445 was attached to branched chains using wt-ubiquitin or 
homogenous K11-linked chains using ubiK11. The reaction products were 
incubated with MBPS5a and analyzed by autoradiography. Only Nek2A modified 
with high MW branched chains showed significant binding to the proteasomal 
ubiquitin receptor (Figure 41B). The difference between ubiquitylation of Nek2A 
with wt-ubiquitin or ubiK11 compared to earlier experiments is not as pronounced 
(Figure 17A), as the reaction was incubated longer to increase product formation, 
more substrate was used to create more product and the gel was contrasted 
differently to see binding of Nek2A ubiquitin conjugates to S5a. In summary 
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enhanced binding of branched ubiquitin chains was not a mere function of the 
number of ubiquitin molecules attached to the respective APC/C substrates. 
 
4.6.5. Branched ubiquitin chains are hydrolyzed by DUBs  
To exclude that branched ubiquitin chains were an in vitro artifact, which could 
interact with ubiquitin binding domains but not be hydrolyzed by DUBs, the 
turnover of branched chains by DUBs was tested. Ub-cyclin AHA or UbR11-Ub-
cyclin AHA was modified with APC/CCdh1, Ube2S and methyl-ubiquitin, creating 
K11 linkages in an either linear or branched fashion.  
 
               
Figure 42: DUBs hydrolyze branched and homogenous chains similarly. A. Deubiquitinases 
recognize branched conjugates. Ub-cyclin AHA or UbR11-Ub-cyclin AHA was modified with 
APC/CCdh1, Ube2S, and methyl-ubiquitin to generate linear or branched substrates, before 
incubation with the K11-specific DUB Cezanne. In the bottom panel, Ub-cyclin AHA or Ub-Ub-
cyclin AHA was modified by APC/CCdh1, Ube2S, and wt-ubiquitin with one or two ubiquitin chains. 
Reactions were analyzed by αHA western blot. B. Usp37 deubiquitylates substrates modified with 
linear or branched conjugates with similar efficiency. As described above, Ub-cyclin AHA, UbR11-
Ub-cyclin AHA, or Ub-Ub-cyclin AHA were modified by APC/C, Ube2S, and methyl-ubiquitin. 
Deubiquitylation by Usp37 was analyzed by αHA western blot.  
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Both substrates are hydrolyzed similarly in a titration of Cezanne, as detected by 
disappearance of higher MW species in αHA western blot (Figure 42A). Titrations 
with Ub-cyclin AHA or Ub-Ub-cyclin AHA modified by wt-ubiquitin and Ube2S 
showed similar hydrolysis of single homogenous K11-linked chain and two 
branched K11-linked by Cezanne (Figure 42A). Besides the K11 specific 
Cezanne, which contains an ovarian tumor (OTU) domain as its catalytic domain, 
hydrolysis of branched chains was tested with Usp37, a DUB containing a 
ubiquitin specific protease (USP) domain and supposedly being an APC/C DUB 
(Huang et al., 2011). Ub-cyclin AHA, UbR11-Ub-cyclin AHA or Ub-Ub-cyclin AHA was 
modified by APC/CCdh1, Ube2S and methyl-ubiquitin, and used as substrates in 
titrations with Usp37. Hydrolysis of linear or branched ubiquitin chains occurred 
at similar Usp37 concentrations (Figure 42B). Concomitantly the DUBs similarly 
process homogenous or branched linkages.  
 
4.7. Modification of APC/C substrates with branched chains leads to an 
increase in substrate degradation 
As branched chains on APC/C substrates allow an enhanced binding to 
proteasomal delivery factors, I tested whether proteasomal degradation was 
enhanced as well. While branched chains could enhance degradation based on 
the higher proteasomal retention times in vitro, it could be possible that branches 
do not allow for proper processing of the ubiquitylated substrate in the context of 
the full proteasome. With the different ubiquitin mutants and the different APC/C 
E2s at my disposal I compared the in vitro degradation efficiencies of APC/C 
substrates modified with ubiquitin chains of different topologies in the presence of 
purified human 26S proteasome. In HeLa cell extracts stability of APC/C 
substrates was observed upon addition of the different ubiquitin variants and 
E2s. Furthermore the formation of ubiquitin aggregates might occur in cells due 
to high local ubiquitin concentrations. The presence of cellular DUBs might 
negate the enhanced binding of branched ubiquitin chains; consequently the 
levels of APC/C substrates were detected in HeLa cells, upon increased ubiquitin 
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chain branching due to expression of Ube2G2CTP. The inhibition of branching 
was investigated by depletion of Ube2S. A caveat of Ube2S siRNA was the 
simultaneous inhibition of elongation; this was fully addressed with the in vitro 
characterization above and can be neglected.   
 
4.7.1. Branched ubiquitin chains improve Nek2A ubiquitin conjugate turnover by 
the 26S proteasome in vitro 
I tested first if branched chains on Nek2A lead to differences in degradation by 
purified 26S proteasomes compared to homogenous chains on Nek2A. 35S-
radiolabeled HANek2A272-445 was modified with branched chains by APC/CCdc20, 
Ube2C, Ube2S and wt-ubiquitin or with homogenous K11-linked chains using 
ubiK11. The reaction products were supplemented with glycerol and ATP to 
prevent the added proteasomes from dissociating into CP and RP (Beckwith et 
al., 2013).  
 
Figure 43. Branched chains improve the efficiency of proteasomal degradation in vitro. 
35S-HANek2A272-445 was modified with branched or homogenous K11-linked chains and added to 
increasing concentrations of 26S proteasomes. A representative gel is shown. Five independent 
titrations were monitored by autoradiography and quantified using ImageJ (n=5; data are average 
+/- SD; ** p<0.002 in paired t-test; *** p<0.001). The asterisk marks background degradation by 
proteasomes that co-purify with APC/C.  
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After incubation with different amounts of 26S proteasomes, abundance of 
ubiquitin conjugates on Nek2A were determined by autoradiography and 
quantified with ImageJ. Homogenous K11-linked chains on Nek2A were shorter 
and less abundant than the high MW branched chains and the degradation of 
conjugates was measured relative to the initial products. This analysis showed 
that branched chains led to faster degradation than homogenous chains (Figure 
43). While at the highest proteasome concentration only about 25% branched 
chains were left over, K11-linked chains were still at levels of slightly more than 
40%. In agreement with the previous binding experiments branched chains were 
more efficient than linear K11-linked conjugates in driving the degradation of 
Nek2A by purified proteasomes.  
 
4.7.2. K11- and K48-linked ubiquitin chains lead to APC/C substrate degradation 
in cell extracts 
Subsequently the distinct chain types were compared in cell extracts. To 
understand differences between degradation of K11-linked and K11/K48-
branched chains, it was first tested how K11- and K48-linked ubiquitin chains 
compare in extracts. Extracts of HeLa cells synchronized in early G1 by 
thymidine and nocodazole arrest and release from nocodazole for two hours, 
were used to show degradation of a standard APC/C substrate, geminin, by K11-
linked chains (Figure 44A) in line with previous publication (Jin et al., 2008). 
Ube2G2CTP was used to modify APC/C substrates with K48-linked chains and it 
was investigated, whether this would lead to degradation at a similar rate. As it 
was shown above Ube2C, Ube2S and Ube2G2CTP together modify APC/C 
substrates. Therefore a cell extract free of Ube2C and Ube2S was used. Extract 
prepared from serum starved T98G cells does not contain Ube2C or Ube2S (Jin 
et al., 2008; Williamson et al., 2009a). Supplementing this extract with 
Ube2G2CTP led to degradation of another standard APC/C substrate, securin 
(Figure 44B). K48- and not K11-linked ubiquitin chains drove securin degradation 
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as ubiR48 inhibited degradation while ubiR11 had no effect. Therefore K11 and K48 
chains individually mediate degradation of APC/C substrates. 
 
Figure 44: Degradation of APC/C 
substrates is mediated by K11 or 
K48 chains individually A. The 
physiological APC/C E2s drive K11 
specific degradation. 35S-geminin 
was incubated in endogenous 
Ube2S containing G1 extracts that 
were supplemented with Ube2C 
and the indicated ubiquitin mutants. 
Reactions were analyzed by 
autoradiography. B. K48-linked 
chains drive APC/C-substrate degradation in extracts. 35S-labeled securin was added to extracts 
of serum starved T98G cells, which do not contain endogenous K11-specific APC/C-E2s. 
Extracts were supplemented with Ube2G2CTP or Ube2G2, respectively, and wt-ubiquitin or 
ubiquitin mutants. Reactions were analyzed by autoradiography. 
 
4.7.3. Branched ubiquitin chains enable degradation of weaker binding 
substrates or under low APC/C activity 
APC/C substrates therefore are degraded due to K11 or K48 chains individually. I 
determined next, if the combination of K11 and K48 to form K11/K48-branched 
chains would lead to enhanced degradation. Degradation was measured in 
prometaphase synchronized HeLa cell extracts, in which APC/C activity should 
be fairly low due to the presence of MCC. Indeed, even though Ube2S and 
Ube2C are present in these extracts (Williamson et al., 2009a), no degradation of 
endogenous geminin is observed (Figure 45A). Addition of Ube2G2CTP allowed 
degradation that was APC/C specific based on the inhibition by Emi1 and 
Ube2CC114S, and RING finger dependent based on inhibition by Ube2CC114S. The 
degradation of geminin in the presence of active APC/C and Ube2G2CTP was 
therefore dependent on K48-linked ubiquitylation. 
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Figure 45: Enhanced APC/C substrate degradation by branched ubiquitin chains in HeLa 
cell extracts. A. Branched chains promote degradation more efficiently. Prometaphase extracts 
with endogenous Ube2S and Ube2C were treated with Ube2G2CTP in the presence of ubiquitin 
mutants. The stability of geminin was monitored by αgeminin western blot analysis. Geminin was 
stable in extracts containing mixtures of ubiR11 or ubiR48, a condition that allows Ube2S and 
Ube2G2CTP to assemble mixed, but not branched chains. B. Branched chains accelerate 
substrate degradation. Extracts of early G1 HeLa cells containing endogenous Ube2S and 
Ube2C were supplemented with 35S-securin∆DBOX, Ube2G2CTP as indicated on the left, and 
various ubiquitin mutants or degradation controls, shown on the right. The stability of securin∆DBOX 
was analyzed by autoradiography. Presence of ubiR11 or ubiR48 allows Ube2S and Ube2G2CTP to 
form homogenous or mixed chains but prevent branching, and securin∆DBOX was stable under 
these conditions.  
 
UbiR11 inhibited degradation though, which means that Ube2S must be needed 
under these conditions. Combination of ubiR11 and ubiR48 did not rescue geminin 
turnover. Consequently only branched chains permitted degradation of an APC/C 
substrate in prometaphase cell extracts. I additionally checked if branched chains 
enhance protein degradation by measuring the degradation of an APC/C 
substrate that only weakly interacts with the APC/C, securin∆DBOX. This allowed 
the use of G1 HeLa cell extract instead of prometaphase cell extract excluding 
secondary effects caused by the presence of MCC. Radiolabeled securin∆DBOX 
was not degraded in the presence of endogenous Ube2C and Ube2S, but the 
addition of Ube2G2CTP led to its degradation (Figure 45B). The different controls 
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showed that degradation is dependent on APC/C and proteasome. Degradation 
only took place, when branching was possible according to the use of ubiquitin 
mutants. Together, these experiments show that artificial ubiquitin chain 
branching allows APC/C substrate degradation, even though APC/C activity is 
low due to presence of MCC or due to weakened interaction with its substrate. 
Therefore branched ubiquitin chains enhance protein degradation in cell extracts.  
 
4.7.4. Decrease of ubiquitin conjugates co-purifying with the APC/C in the 
presence of Ube2G2CTP due to turnover by the proteasome 
I investigated whether Ube2G2CTP expressed in cells could achieve a similar 
increase in protein degradation. The constitutively Ube2G2CTP expressing HeLa 
cell line, described above, was used to look at general levels of APC/C ubiquitin 
conjugates upon enhanced ubiquitin chain branching. Substrate ubiquitin 
conjugates co-purify with APC/C immunoprecipitations (Figure 26), which was 
considered as readout for the overall presence of ubiquitylated APC/C 
substrates. HeLa cells were enriched in the presence of ubiquitylated APC/C 
substrates by release from thymidine and nocodazole into MG132 containing 
medium. In control cells ubiquitylated substrates were detected in APC/C 
immunoprecipitations based on αK11 western blot analysis (Figure 46).  
 
Figure 46: Decrease of ubiquitin conjugates co-purifying with 
the APC/C in the presence of Ube2G2CTP due to turnover by the 
proteasome. HeLa cells constitutively expressing Ube2G2CTP were 
released from thymidine and nocodazole induced mitotic arrest and 
treated with 20  µM proteasome inhibitor MG132 for two hours as 
indicated. Co-purifying K11-conjugates were monitored by western 
blot analysis.  
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By contrast, in cells expressing Ube2G2CTP and therefore assembling K11/K48-
branched chains relatively little conjugates were observed. The absence of 
ubiquitin conjugates was rescued by MG132 treatment, suggesting that an 
increased formation of branched chains facilitated substrate degradation by the 
proteasome (Figure 46). Inhibition of the APC/C by Ube2G2CTP could explain this 
result but the in vitro experiments above showed enhanced ubiquitylation and no 
significant growth defect was observed in this cell line, which would be expected 
upon APC/C inhibition.  
 
4.7.5. Co-expression of Cdh1 and Ube2G2CTP decreases levels of a weakly 
binding APC/C substrate 
Instead of measuring the level of all ubiquitylated APC/C substrates at once, it 
was tested if expression of Ube2G2CTP would augment degradation of a specific 
APC/C substrate by enabling enhanced K11/K48-branching. 
 
Figure 47: Ube2G2CTP enhances substrate degradation in 
293T cells. Securin∆DBOX was expressed with Cdh1 in 293T cells 
or in 293T cells stably expressing Ube2G2CTP under a Tet-
inducible promoter. Levels of securin∆DBOX were measured by 
western blot.  
 
A Ube2G2CTP inducible 293 cell line was created using the Flp-In™ T-REx™ 
system. The model substrate securin∆DBOX was used as degradation readout 
under weakened APC/C activity, as securin∆DBOX has only little affinity towards 
APC/C. Degradation was triggered by co-expression of Cdh1 (Jin et al., 2008). 
While co-expression of Cdh1 lowered the levels of securin∆DBOX in not induced 
cells as expected, additional induction of Ube2G2CTP led to enhanced 
degradation. Thus the augmented formation of branched chains on a model 
APC/C substrate enhances protein destruction in cells. 
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4.7.6. Depletion of Ube2S leads to stabilization of the proteasomal substrate 
Nek2A 
HeLa cells were depleted of Ube2S to inhibit branching, which is normally 
catalyzed by Ube2C and Ube2S. It was tested if this inhibition of branching had 
an effect on the stability of certain APC/C substrates in cells. As depletion of 
Ube2S seemed to have a pronounced effect on Nek2A levels in prometaphase, 
HeLa cells were depleted of Ube2S and synchronized by thymidine and 
nocodazole arrest. Arrested cells were treated for the indicated times with 
50µg/ml cycloheximide. Nek2A levels were determined in cell extract and in 
APC/C immunoprecipitations. The cycloheximide chase showed that Ube2S 
depletion leads to slower turnover of Nek2A in prometaphase HeLa cells (Figure 
48A).  
  
Figure 48: Ube2S depletion or proteasome inhibition increase APC/C bound Nek2A levels. 
A. Ube2S RNAi increases APC/C bound Nek2A levels. HeLa cells transfected with control or 
Ube2S siRNA using Lipofectamine RNAimax were synchronized in prometaphase by thymidine 
and nocodazole, and treated with 50µg/ml cycloheximide. APC/C was purified at indicated times 
after cycloheximide addition, and co-purifying proteins were analyzed by western blot. B. MG132 
treatment increases APC/C bound Nek2A levels. The levels of Nek2A bound to the APC/C were 
analyzed in prometaphase HeLa cells treated with 50µg/ml cycloheximide and 20µM MG132 
proteasome inhibitor by western blot. C. Ube2S RNAi increases APC/C bound Nek2A and cyclin 
B1 levels coinciding with hyperphosphorylation of Cdc27. APC/C was purified from prometaphase 
HeLa cells treated with control or Ube2S siRNA and Lipofectamine RNAimax, and levels of co-
purifying proteins were determined by western blot analysis.  
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Nek2A was only detected on the APC/C if cells were depleted of Ube2S, while 
the overall level of MCC components seemed unaffected. The increase of Nek2A 
on the APC/C might be due to higher Nek2A levels or based on reduced active 
removal of Nek2A from the APC/C by UPS components. Nek2A stabilization and 
binding to the APC/C caused by inhibition of branching, seemed to be 
proteasome dependent, as treatment with 15µM MG132 led to similar increases 
of Nek2A levels within prometaphase cells and on the APC/C (Figure 48B). 
Furthermore I showed that binding of Nek2A is APC/C specific compared to an 
control immunoprecipitation. The increased levels of Nek2A on the APC/C 
caused by Ube2S depletion coincided with higher amounts of cyclin B1 on 
prometaphase APC/C (van Zon et al., 2010). An upward shift in MW of the 
APC/C subunit Cdc27 was seen upon Ube2S depletion (Figure 48C), probably 
related to its phosphorylation status, which is important for regulation of the cell 
cycle and proliferation (Huang et al., 2007; Kraft et al., 2003; Zhang et al., 2011). 
Importantly presence of Ube2S, a mediator for branching, is detrimental for 
APC/C bound prometaphase substrate levels and phosphorylation status of 
Cdc27.  
 
4.8. Presence of Ube2G2CTP causes cell cycle defects 
Decoration of APC/C substrates with branched ubiquitin chains by the 
physiological E2s is important for substrate stability. Inhibition of ubiquitin chain 
branching caused by Ube2S depletion also delays cell cycle progression. The 
introduction of Ube2G2CTP in cells leads to enhanced branching and increased 
APC/C substrate degradation. Hence, I investigated whether the presence of 
Ube2G2CTP and consequently constitutive K11/K48-branching interfered with 
proper cell cycle regulation. It was tested first, if Ube2G2CTP alone would support 
APC/C activity in cells based on APC/C substrate levels in anaphase and mitotic 
indices of RNAi treated cells. HeLa cells were treated with taxol and analyzed for 
aberrant cell divisions to check for proper cell cycle regulation in the presence of 
enhanced K11/K48-branching by Ube2S and Ube2G2CTP.  
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4.8.1. Ube2G2CTP enables cell cycle progression and degradation of APC/C 
substrates 
Depletion of Ube2C, Ube2S and p31Comet was performed in HeLa cells to test 
whether Ube2G2CTP contributes to APC/C activity in cells. This depletion leads to 
a significant increase in the number of mitotic cells due to APC/C inactivation 
(Reddy et al., 2007; Summers et al., 2008; Williamson et al., 2009a). Control 
hygromycin resistant HeLa cells or constitutively Ube2S or Ube2G2CTP 
expressing HeLa cells were transfected with a combination of siRNAs against 
Ube2C, Ube2S and p31Comet and Oligofectamine. After 48 hours the cells were 
fixed in ethanol and stained with fluorescent propidium iodide, which intercalates 
into DNA. FACS analysis revealed the DNA content of single cells and 
consequently the cell cycle stage of the treated cells. Control cells showed an 
increase of cells in G2/M by about 30% upon triple depletion (Figure 49A).  
 
Figure 49: Ube2G2CTP 
rescues APC/C activity in 
cells. A. Ube2G2CTP 
rescues a cell cycle defect 
caused by depletion of 
APC/C-E2s and p31comet. 
HeLa cells were treated 
with Ube2C, Ube2S and 
p31comet siRNA at the same 
time using Oligofectamine 
for 48 hours, stained with propidium iodide and analyzed by FACS (n=3; data are average + SD). 
B. K48-linked chains support APC/C substrate degradation in vivo. APC/C E2s Ube2C and 
Ube2S were depleted from HeLa cells by Ube2C and Ube2S siRNA with Oligofectamine. HeLa 
cells were constitutively expressing siRNA resistant Ube2S, Ube2G2CTP, or Ube2G2CTP-C89S as 
indicated. Degradation of the APC/C-substrate Aurora A in anaphase was monitored by western 
blot analysis.  
 
Presence of RNAi resistant Ube2S mostly rescued this phenotype showing that 
reintroduction of a physiological APC/C E2 is restoring APC/C activity to 
sufficient levels. Strikingly, active Ube2G2CTP was able to greatly rescue G2/M 
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enrichment by contributing to APC/C activity in cells, while inactive Ube2G2CTP-
C89S showed no significant difference.  
The stable cell lines were also treated with a combination of Ube2C and Ube2S 
RNAi using Oligofectamine. They were arrested in prometaphase by thymidine 
and nocodazole treatment and released into nocodazole free medium. Cells were 
analyzed by western blot at the indicated times after nocodazole release. The 
anaphase APC/C substrate Aurora A is stabilized upon Ube2S/Ube2C RNAi 
treatment (Williamson et al., 2009a). This phenotype seemed to be completely 
rescued in a Ube2S stable cell line and reduced in a Ube2G2CTP cell line, while 
inactive Ube2G2CTP-C89S showed no effect (Figure 49B). Together these two 
experiments show that K11 or K48 specific E2s promote substrate degradation 
and cell cycle progression during mitosis.  
 
4.8.2. Ube2G2CTP rescues a mitotic arrest induced by depletion of Ube2C and 
Ube2S 
Additionally I tested if Ube2G2CTP could rescue the synergistic increase of mitotic 
cells upon Ube2C and Ube2S depletion (Williamson et al., 2009a). This 
experiment is more direct, as only Ube2C and Ube2S need to be depleted to 
detect a raise in the number of mitotic cells. Using software-based analysis of 
Hoechst stained cells, it was possible to differentiate between G2 and mitotic 
cells.  
 
 
Figure 50: Ube2G2CTP rescues a cell cycle delay caused by 
depletion of APC/C-E2s. HeLa cells or HeLa cell lines 
constitutively expressing Ube2G2CTP were treated with control or 
Ube2C/Ube2S siRNAs. Mitotic index was determined by 
automated image capture and analysis (n=3; >1000 cells per n; 
data are average + SD).  
 
Results 
 !
! -125-!
To determine the mitotic index for different treatments, control or Ube2G2CTP 
constitutively expressing HeLa cells were seeded in a 384-well format and 
transfected with control or Ube2C and Ube2S siRNA using Oligofectamine. 
Analysis in this format was described above. A significantly higher percentage of 
cells were in mitosis due to synergy between reduced levels of Ube2C and 
Ube2S, while presence of Ube2G2CTP negated this effect (Figure 50). Therefore 
Ube2G2CTP seems to show E2 activity with the APC/C in mitosis. 
 
4.8.3. Ube2G2CTP causes bypass of a taxol induced mitotic arrest 
Taxol treatment and the subsequent mitotic arrest of HeLa cells, is established 
as a sensitive readout for properly regulated APC/C activity by the spindle 
assembly checkpoint (Ikui et al., 2005; Stegmeier et al., 2007). Thus, HeLa cells 
constitutively expressing Ube2G2CTP were tested for their response upon 
treatment with taxol to determine if enhanced ubiquitin chain branching in the 
presence of Ube2C, Ube2S and Ube2G2CTP interferes with a taxol induced arrest 
indicating a change in APC/C activity. Therefore hygromycin resistant HeLa cells, 
HeLa cells constitutively expressing Ube2G2CTP or Ube2G2CTP-C89S were plated 
in a 384-well format and treated with different taxol concentrations of 0 to 100nM 
the next day. After 18 hours the cells were fixed, stained with Hoechst and the 
percentage of mitotic cells was determined by software based image analysis. 
While control cells showed more than 80% enrichment in mitotic cells at 100nM 
taxol, the Ube2G2CTP expressing cells would only arrest to about 40% (Figure 
51A). Cells expressing Ube2G2CTP were less sensitive to taxol over the whole 
range of concentrations used. This effect was only observed in the presence of 
active Ube2G2CTP and not with catalytically inactive Ube2G2CTP-C89S. The 
multilobed morphology of the Hoechst stained DNA, indicated spindle assembly 
checkpoint bypass (Figure 51A). The extent of Ube2G2CTP dependent taxol 
bypass was reduced upon depletion of Ube2S and Ube2C by siRNA using 
Oligofectamine (Figure 51B), showing that bypass only occurs in the presence of 
increased ubiquitin branching.  
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Figure 51: Ube2G2CTP 
causes bypass of a 
taxol induced mitotic 
arrest. A. Stable 
expression of 
Ube2G2CTP, but not 
Ube2G2CTP-C89S, 
causes spindle 
checkpoint bypass. 
Upper panel: HeLa 
cells constitutively 
expressing indicated 
proteins were treated with taxol at concentrations from 0-100 nM for 18 hours. Mitotic arrest was 
scored by automated microscopy (n=3; >1000 cells/condition; data are average +/- SD; unpaired 
t- tests p<0.0005). Lower panel: Images of representative cells stained with Hoechst. B. 
Checkpoint bypass requires Ube2G2CTP and Ube2C/Ube2S. HeLa cells or stable cell lines 
expressing Ube2G2CTP were treated with siRNAs against Ube2C and Ube2S as well as 100 nM 
taxol, and the mitotic index was determined by automated microscopy (n=3; 1000 cells/condition; 
data are average +SD; paired t-test p<0.02).  
 
4.8.4. Extent of taxol bypass correlates with the expression level of Ube2G2CTP  
To further corroborate that the observed taxol bypass depends on the degree of 
ubiquitin chain branching, HeLa cells expressing Ube2G2CTP at different levels 
were tested for taxol bypass assuming that expression levels correlate with 
ubiquitin branching. Hence, cell lines with varying concentrations of Ube2G2CTP 
were analyzed after taxol treatment (Figure 52A). The higher the expression level 
of Ube2G2CTP was the weaker was the response to taxol. This was not due to 
overall increased levels of E2s working with the APC/C, as raised levels of 
Ube2S in HeLa cells did not lead to taxol bypass (Figure 52B). Consequently the 
amount of K11/K48-branched chain formation determined the degree of spindle 
checkpoint bypass, which is a known consequence of increased APC/C activity. 
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Figure 52: Correlation between taxol bypass and Ube2G2CTP levels. A. Stable expression of 
Ube2G2CTP along with endogenous Ube2S and Ube2C results in concentration dependent 
spindle checkpoint bypass. Different clones of Ube2G2CTP expressing stable cell lines were 
analyzed for cell cycle arrest by taxol, as measured by Hoechst staining and automated image 
analysis (n=3; >1000 cells/n; data are average +/- SD). Protein expression was monitored by 
western blot analysis. B. Constitutive expression of Ube2S does not cause spindle checkpoint 
bypass. HeLa cells constitutively expressing additional exogenous Ube2S were subjected to 
increasing concentrations of taxol, and the number of mitotic cells was determined as described 
above (n=3, >1000 cells per n; data are average +/- SD). 
 
4.8.5. Expression of Ube2G2CTP leads to aneuploidy in HeLa cells 
Enabling the APC/C to form K11/K48-branched increases APC/C activity and 
desensitizes the APC/C towards inhibition by the spindle assembly checkpoint, 
which was determined in taxol bypass assays. The inability of the SAC to 
regulate the APC/C leads to aneuploidy, as cells are not able to halt progression 
into anaphase before chromosomes are properly aligned. Expression of high 
levels of Ube2G2CTP in HeLa cells caused extensive multinucleation after 
extensive periods of time in culture, as was seen in cells stained by 
immunofluoresence, while expression of additional Ube2S did not show 
multinucleation (Figure 53). To quantify aneuploidy in these cells the relative 
amount of DNA based on propidium iodide fluorescence was measured. FACS 
detected a significant, more than twofold increase of cells beyond the G2/M 
population. Accordingly aberrant ubiquitin chain branching leads to aneuploidy. 
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Figure 53: Ube2G2CTP causes 
aneuploidy. Left: Expression of 
Ube2G2CTP with endogenous Ube2S 
results in multinucleation. HeLa cells 
constitutively expressing an extra 
copy of Ube2S or Ube2G2CTP were 
imaged for tubulin (red), Tpx2 
(green), and DNA (blue). Right: The 
stable cell lines described above 
were subjected to propidium iodide staining and FACS (n=3; 30000 cells per n; data are average 
+ SD).  
 
4.9. Branching of ubiquitin chains seems to be applicable to other E2/E3 
pairs 
At last it was tested if the formation of K11-branched chains by Ube2S on short 
chains made by Ube2C was unique to the way K11 chains are built by the 
APC/C. The ability of other lysine specific E2s to introduce ubiquitin branches 
was investigated, to determine if these could extent chains of a different linkage 
type. Ube2G2 activated by the cytosolic domain of the ERAD E3 ligase gp78 and 
the heterodimeric E2 complex of Ube2N and Ube2V1 activated by the E3 TRAF6 
(Deng et al., 2000) are know to specifically synthesize K48- or K63-linked 
ubiquitin chains (Eddins et al., 2006; Li et al., 2009). The linear ubiquitin fusions 
of cyclin A were used as a template for branching. Modification of these fusions 
with the respective E3 activated E2s using methyl-ubiquitin, showed the 
introduction of branches (Figure 54A). The introduction of branches was linkage 
specific as the respective ubiquitin mutants, ubiR48 or ubiR63, led to attachment of 
single ubiquitin moieties (Figure 54A). The rate for elongating a distal or a 
proximal ubiquitin moiety seemed to be similar for K48 and K63 ubiquitylation 
enzymes (Figure 54B), which was shown to be the case for the K11 specific 
Ube2S above. Theoretically the branching of ubiquitin chains could therefore be 
a general cellular mechanism for other kinds of ubiquitin linkages.  
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Figure 54: K48 and K63 specific ubiquitylation enzymes are able to branch ubiquitin 
chains. A. Ube2G2-gp78 and Ube2N/Ube2V1-TRAF6 catalyze branching, and branched chains 
have K48 or K63 linkage specificity. Ub-cyclin AHA, Ub2-cyclin AHA or Ub3-cyclin AHA was 
incubated with Ube2G2 and gp78 in the presence of methyl-ubiquitin or ubiR48. Reactions were 
analyzed by αHA western blots. The E2s Ube2N/Ube2V1 and its E3 TRAF6 catalyze branching, 
and branched chains have K63 specificity. Ub-cyclin AHA, Ub2-cyclin AHA, or Ub3-cyclin AHA was 
incubated with Ube2N/Ube2V1 and TRAF6 in the presence of methyl-ubiquitin or ubiR63. 
Reactions were analyzed by αHA western blots. B. Ube2G2-gp78 and Ube2N/Ube2V1-TRAF6 
catalyze branching as efficiently as chain elongation. Ub-cyclin AHA, Ub2-cyclin AHA or Ub3-cyclin 
AHA was incubated with Ube2G2-gp78 or Ube2N/Ube2V1-TRAF6 and methyl-ubiquitin for the 
indicated time points and the reaction products were analyzed by αHA western blot. !
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5. Discussion 
The posttranslational modification of proteins with ubiquitin is a powerful tool for 
the cell to modulate crucial processes in eukaryotes and is therefore essential for 
signaling, proliferation, differentiation and survival of cells (Deshaies and 
Joazeiro, 2009; Schulman and Harper, 2009). Besides attachment of a single 
ubiquitin molecule to a substrate, ubiquitin chain formation can occur through 
seven lysine residues (K6, K11, K27, K29, K33, K48, K63) or the N-terminus of 
ubiquitin (M1), leading to the assembly of multiple chains with distinct topology 
(Komander and Rape, 2012). While all different topologies exist within cells 
(Peng et al., 2003; Xu et al., 2009) it is not completely understood how much the 
modification of a certain protein with a specific ubiquitin chain topology actually 
matters. Much progress had recently been made in the characterization of K11-
linked ubiquitin chains synthesized by the APC/C, sometimes still referred to as 
an atypical or non-canonical chain type (Meyer and Rape, 2011; Wickliffe et al., 
2011b). In this study the formation of ubiquitin chains by the APC/C on its 
substrates and the outcome of changing the topology of ubiquitin chains was 
closely investigated. The reported findings above are further discussed regarding 
the current literature and remaining open questions. 
 
5.1. The APC/C synthesizes branched ubiquitin chains. 
Branched chains were detected for the first time in yeast about ten years ago 
(Peng et al., 2003). In this case, K29/K33 branched ubiquitin peptides were 
detected by mass spectrometry of a NiNTA pull down of untreated yeast cells 
expressing Hisubiquitin. The same branch and two others, K11/K27 and K27/K29, 
were reported three years later, again using mass spectrometry and this time 
tandem purification with NiNTA and streptavidin of His/Biotinubiquitin from yeast 
(Tagwerker et al., 2006). Further evidence for the existence of branched chains 
was given in vitro four years later (Kim et al., 2007), when denatured luciferase 
was modified by the E3 carboxy terminus of Hsp70-interacting protein (CHIP) 
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and Ube2D or in autoubiquitylation of the E3s Muscle-specific RING finger 
protein 1 (MuRF1) or Double minute 2 protein (Mdm2). Branches of K6/K11, 
K27/K29 and K29/K33 were detected by mass spectrometry. Ube2D in 
combination with different RING E3 ubiquitin ligases seems to be mainly 
unspecific regarding the linkage of ubiquitin chains (Komander and Rape, 2012). 
Therefore, branches could occur randomly involving any of the seven lysine 
residues on ubiquitin. Due to methods-based limitations, only K6/K11, K27/K29 
and K29/K33 ubiquitin branches might have been detected. Four years later a 
combination of linkage specific immunoprecipitation and mass spectrometry of 
samples from human cells was used for quantitative analysis of ubiquitin 
linkages, which indicated branched chains mainly consisting of K11, K48 and 
K63 linkages (Phu et al., 2011).  
Furthermore, the presence of S5a in vitro was shown to inhibit the formation of 
branched chains by Ube2D (Kim et al., 2009); this has not been tested in the 
case of the APC/C in vitro and in general in vivo. Hence it is unclear if free S5a is 
changing the abundance of branched chains in the cell. If this were the case, it 
would be an example of how the formation of branched chains might be 
regulated in cells.  
 
Figure 55: Enhanced protein degradation by branched ubiquitin chains. Ube2C initially 
modifies APC/C substrates with short chains containing mainly K11, K48 and K63 linkages. 
Ube2S adds blocks of about six K11-linked ubiquitin molecules to each chain moiety with an 
unmodified K11. This process leads to the formation of branched ubiquitin chains that increase 
the proteolytic capacity of the initial ubiquitylation mark.  
 
The synthesis of branched chains by the APC/C seems to be different from the 
Ube2D/E3 pairs discussed above. The assembly of branched chains in this study 
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depends upon the cooperation of ubiquitylation enzymes with different linkage 
specificities, a condition fulfilled by the E2s of metazoan APC/C. Ube2C initiates 
chain formation by modifying substrates with short conjugates containing 50% 
K11-, but also K48- and K63-linkages (Kirkpatrick et al., 2006). At least in vitro, 
the APC/C is also able to nucleate chains with E2s of the Ube2D-family, which 
synthesize ubiquitin chains with little linkage preference (Kirkpatrick et al., 2006). 
The collaboration of APC/C and Ube2C versus Ube2D is still controversial, but it 
seems Ube2C is the main E2 specifically working with the APC/C (Summers et 
al., 2008). If the initiating E2s use K48- or K63-linkages, K11 of an internal 
ubiquitin remains unmodified and provides a site for Ube2S to branch off a K11-
linked chain (Figure 55). Ube2S is also able to modify ubiquitin molecules 
embedded in linear or completely K48-linked chains. This is in line with published 
structures of K48, K63 or M1 polyubiquitin. K11 is surface exposed in these chain 
types and should be accessible by Ube2S (Figure 56). Ube2S might additionally 
be able to induce changes in the conformation of a present ubiquitin chain. It has 
been shown that ubiquitin dimers undergo conformational transitions (Ye et al., 
2012). Binding to Ube2S could lead to a polyubiquitin conformation favorable for 
K11-linked ubiquitin chain modification. It seems the presence of a free K11, but 
not overall chain linkage or structure, determines formation of a branch point. 
Consistent with this notion, Ube2S synthesized a branch with the same efficiency 
and specificity, as it promoted chain elongation at the distal ubiquitin. It is 
interesting to note that Ube2S synthesizes a branched linkage with such high 
efficiency. As documented with linkage-specific antibodies, the accumulation of 
K11-linked chains during mitosis depends entirely on Ube2S (Matsumoto et al., 
2010; Wickliffe et al., 2011), indicating that its linkage specificity is different from 
most, if not all mitotic ubiquitylation enzymes. Combined with its efficiency in 
synthesizing branched linkages, this observation implies that Ube2S could also 
branch K11-linked chains off conjugates initiated by other enzymes that interact 
with the APC/C. Indeed several APC/C substrates are shown to be substrates of 
other E3s as well (Donzelli et al., 2002; Emanuele et al., 2011; Fujii et al., 2006; 
Germani et al., 2000; Hsu et al., 2004; Meyer and Rape, 2011).  
Discussion 
 !
! -133-!
 
 
Figure 56: Conformations of differently linked ubiquitin chains. K11 is accessible in K48, 
K63 and M1 chains. A. K48-linked ubiquitin tetramers show a closed conformation. Lysine 11 
residues are accessible in a closed conformation (PDB 2O6V). Position 48 in every moiety is 
shown in yellow. B. K63-linked ubiquitin tetramers show an open conformation. Lysine 11 
residues are accessible in an open conformation (PDB 3HM3). K63 in every moiety is shown in 
yellow. C. M1-linked ubiquitin dimers show an open conformation. Lysine 11 residues are 
accessible in linear chains (PDB 2W9N). The C-terminus and M1 in every moiety is shown in 
yellow. Ubiquitin moieties are numbered increasingly from proximal to the very distal ubiquitin (C-
terminal residues within the single moieties are orange; K11 residues are colored green). 
 
Whether APC/C activity overlaps spatially and temporally with these other E3s 
needs to be analyzed in more detail. If this were the case, it raises the interesting 
possibility that the K11 specificity of metazoan APC/C did not arise due to a 
particular function of this topology, but because it allowed the formation of 
branched chains on as many initial ubiquitin conjugates as possible.  
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Mixed linkages are a general term for ubiquitin chains containing different 
linkages. In this study it was determined that the APC/C mainly produces K11-
linked ubiquitin chains, but uses non-K11 linkages made by Ube2C to branch off 
K11-linked chains produced by Ube2S. Technically, therefore ubiquitin 
conjugates on APC/C substrates consist of mixed chains. Here it was analyzed in 
more detail that these particular chains are branched chains, which are 
technically a subcategory of mixed chains. A significant number of reports 
suggest the presence of mixed chains made by other E2s and E3s (Blankenship 
et al., 2009; Boname et al., 2010; Emmerich et al., 2013; Huang et al., 2013; 
Kirkpatrick et al., 2006; Newton et al., 2008; Phu et al., 2011; Ben-Saadon et al., 
2006; Winborn et al., 2008). Unfortunately the topology of these conjugates was 
not analyzed in more detail. It can be speculated that at least some of these 
systems might be due to ubiquitin chain branching as well. For instance the 
modification of key players in the NF-κB pathway are ubiquitylated by K63-linked 
chains and subsequently by M1-linked chains (Emmerich et al., 2013), raising the 
possibility of a combination of the two linkage types in a branched manner to 
enhance signaling. Additional experiments regarding these cellular processes 
need to be done to differentiate between mixed chains containing branches or 
not.    
 
5.2. Enhanced protein degradation by branched ubiquitin chains. 
To decipher the information encoded by branched chains, we generated a toolkit 
of E2s that allowed us to modify substrates with K11-, K48-linked or K11/K48-
branched chains. Engineering Ube2G2CTP to produce K48-linked ubiquitin chains 
with the APC/C showed that an RING E3 can be reprogrammed to form different 
ubiquitin topologies. Consequently the E3 and in particular the RING show no 
substantial restraint for a certain ubiquitin linkage. RING E3 reprogramming is 
consistent with a study of HECT E3s. Instead of the E2, only the C-terminal lobe 
of the HECT domain had to be switched out to reprogram the linkage specificity 
of these E3s (Wang et al., 2006). Ube2G2 is known to assemble ubiquitin chains 
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on its catalytic site and transfer them to the substrate en bloc (Li et al., 2007b). It 
was not fully determined if Ube2S might modify these pre-formed K48 chains on 
Ube2G2CTP with K11-linked chains or if both E2s worked sequentially. To allow 
for modification with K11 and K48 ubiquitylation in a single binding event both 
E2s, Ube2S and Ube2G2CTP, had to be bound to the APC/C at the same time. 
The exact binding sites and stoichiometry of Ube2S on the APC/C are not 
known, giving room to the assumption that multiple E2s are able to bind 
simultaneously to APC/C complexes via the CTP. Ube2G2CTP though seems to 
work differently with the APC/C compared to Ube2S. While Ube2S does not 
seem to interact with the RING domain of APC/C in a canonical manner like 
Ube2C (Williamson et al., 2009a), Ube2G2CTP requires its RING finger interaction 
sites and is inhibited by the presence of dominant negative Ube2C blocking the 
RING domain. Interestingly, Ube2G2CTP is able to interact with the RING 
probably because of the raised affinity towards the APC/C due to the CTP, as 
Ube2G2 is inactive with the APC/C. This raises the question if RING finger 
interacting UBC domains would show activity with a variety of RING domains if 
they had additional binding motifs for the respective E3.  
As a key result of this study it was shown for the same protein that K11- and 
K48-linked chains mediate substrate binding to the proteasome with similar 
efficiency, and accordingly both chain topologies trigger degradation at times 
when the APC/C is fully active. These findings confirm that K11-linked chains are 
powerful degradation signals (Jin et al., 2008; Matsumoto et al., 2010). Moreover 
they show that the K11 specificity of the APC/C is not essential for the turnover of 
anaphase substrates, while K48-linked chains are not a prerequisite for substrate 
targeting to the proteasome. Interestingly it was recently reported that different 
ubiquitin linkages show different kinetics for chain formation; the closed K48-
linked chain was elongated slower than the open K63-linked chain (Kovacev et 
al., 2014). In this study the formation of both closed K11- and K48-linked chains 
seemed comparable leading to the assumption that the observed differences 
were caused by the conformation of the ubiquitin chain. This will need to be 
further tested with more precise kinetic measurements. The same report showed 
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slower rates for longer ubiquitin chain synthesis. If that were the case, branching 
would be beneficial for faster ubiquitin transfer of more ubiquitin moieties. 
Ube2G2CTP mediated K48-linked chain formation though was not able to catalyze 
degradation of a weakly binding APC/C substrate or of a standard APC/C 
substrate under conditions of low APC/C activity. It is possible, that Ube2G2CTP 
mediated K48-linked chain formation could not be quite as active as formation of 
homogenous K11-linked chains by Ube2C/Ube2S. In this particular case, 
inhibition by the MCC might be different regarding the engineered E2 or K11-
linked chains as they do fulfill a more specific purpose under those conditions. 
Nevertheless the observations presented here thus support studies that found 
most linkages to accumulate in response to proteasome inhibition, indicative of a 
proteolytic role for the majority of chain topologies (Dammer et al., 2011; Peng et 
al., 2003; Xu et al., 2009). This finding is particularly interesting in light of the 
ongoing debate whether K63 chains can catalyze degradation by the proteasome 
similarly to K48-linked chains (Saeki et al., 2009; Thrower et al., 2000): A recent 
study postulated inhibition of K63 mediated proteasomal degradation by 
endosomal sorting complexes required for transport 0 (ESCRT0; Nathan et al., 
2013). Others report preferred hydrolysis of K63 chains by DUBs (Cooper et al., 
2009; Jacobson et al., 2009). On the other hand an E3 ligase making K63 chains 
is directly bound to the proteasome enhancing its degradation processivity 
(Aviram and Kornitzer, 2010; Crosas et al., 2006). Unfortunately attempts to 
reprogram the APC/C to make K63-linked chains by fusing Ube2N or Ube2V1 to 
the CTP failed suggesting that a heterodimeric E2 seems not to work in this 
case. However lessons learned from the debate regarding K48- and K63-linked 
chains were applied to the conundrum of K11- and K48-linked chains both 
targeting proteins to the proteasome. The ubiquitin-interacting proteins used in 
this study showed no apparent difference between K11- and K48-linked chains in 
line with similar affinities for proteasomal delivery factors determined in vitro 
(Sokratous et al., 2012). No major differences in DUB sensitivity of K11 and K48 
chains were encountered, while a reported K11 specific DUB has not been 
shown to be involved in cell cycle regulation (Bremm et al., 2010). Additionally a 
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recent study presented that the DUB Rpn10 in the proteasomal lid showed no 
preference for a certain ubiquitin linkage (Worden et al., 2014). Nevertheless the 
presence of such specific proteins is still possible and needs to be further 
addressed in future experiments, but at the same time it seems that multiple 
polyubiquitin topologies mediate proteasomal degradation.  
Providing a potential explanation for this apparent redundancy, it is proposed that 
the combination of different chain types allows formation of branched conjugates 
with improved signaling capacity. Branched conjugates with multiple blocks of 
K11-linked chains, as generated by the APC/C, increased the efficiency of 
substrate recognition by the proteasome, and accordingly promoted degradation 
in purified systems, extracts or cells even under conditions of low APC/C activity. 
Thus, distinct from randomly branched chains that impair degradation (Kim et al., 
2007), the branched conjugates assembled by the APC/C act as particularly 
powerful proteolytic signals. In particular Kim and colleagues showed that 
branched chains were less efficiently hydrolyzed by the 26S proteasome, 
resulting in the enrichment of K6/K11 branches after treatment of branched 
chains with purified proteasome. This might not be due to branches per se, but 
because of the modification of K6, which has been reported to inhibit 
proteasomal processing (Shang et al., 2005). More generally they also measured 
that substrates being decorated with branched chains were degraded slower by 
the 26S proteasome. This data was acquired in vitro and still needs to be 
validated in cells showing that Ube2D would modify substrates with branched 
ubiquitin chains causing a slow degradation by the 26S proteasome. Another 
study gives further clarification regarding branched chains and the proteasome, 
as K48/K63 branches are reported to be processed by the proteasome 
(Nakasone et al., 2013). It seems that branched chains could encode different 
information dependent upon the linkages that were used to form these branches. 
Branched chains are not weaker degradation signals in general though. 
Why branched chains with multiple blocks of K11 linkages facilitate proteasomal 
degradation requires further analysis. Here the idea is postulated that the higher 
signal capacity of branched chains originates from increased levels of substrate-
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attached ubiquitin, which overcomes the modest affinity of effectors towards 
ubiquitin. Furthermore even if linkages are being mixed, the individual linkages 
are still read independently (Nakasone et al., 2013), which makes the presence 
of factors specifically recognizing the branch less likely. As longer ubiquitin 
chains do not provide a similar effect (Thrower et al., 2000), ubiquitin probably 
has to be concentrated close to the substrate, thus promoting multivalent 
recognition by effectors with several ubiquitin-binding domains in the same 
complex. Indeed, the proteasome and p97, both of which efficiently bind 
branched chains, contain multiple binding domains for ubiquitylated substrates 
(Finley, 2009; Lander et al., 2012; Richly et al., 2005). Especially the proteasome 
has been suggested to have other ubiquitin binding sites besides its already two 
postulated ubiquitin receptors (Archer et al., 2008; Finley, 2009; Lam et al., 
2002). If these hypotheses were correct, it would be expected that multiple 
ubiquitin moieties or short chains attached to neighboring substrate lysine 
residues should also stimulate degradation. This is the case for cyclin B, which 
can be degraded under such conditions (Dimova et al., 2012). Thus branching 
might only be necessary when the number of ubiquitylation sites on a substrate is 
limited similar to dependency on Ube2S for degradation of single lysine 
substrates (Dimova et al., 2012). This would open up ways of regulating ubiquitin 
chain branching on substrates by posttranslational modifications such as 
acetylation limiting the number of available lysine residues (Choi et al., 2009). 
Moreover, attachment of the first ubiquitin to a substrate lysine is often the rate 
limiting step of chain formation (Pierce et al., 2009), and cleavage of the proximal 
ubiquitin represents the rate-limiting step of degradation (Finley, 2009). The 
capacity of branched chains to increase the ubiquitin density without introducing 
more rate limiting steps could provide an explanation for why these conjugates 
generate a particularly powerful proteolytic signal.  
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5.3. Why did branched chains evolve in metazoans? 
Our discovery that human APC/C assembles branched chains might provide 
insights into the changes in linkage specificity that occurred between yeast and 
metazoan APC/C. The APC/C in Saccharomyces cerevisiae initiates chain 
formation in mitosis with Ubc4, which seems to add single ubiquitin molecules to 
substrates (Rodrigo-Brenni and Morgan, 2007; Stoll et al., 2011), while the 
metazoan APC/C initiates chain formation with Ube2C leading to the introduction 
of monoubiquitylations and of short chains containing K11, K48 and K63 linkages 
(Dimova et al., 2012; Kirkpatrick et al., 2006). Based on the reports in yeast it 
seems unlikely that yeast APC/C catalyzes formation of ubiquitin branches, as 
only single ubiquitin moieties are present after initiation. Metazoan APC/C 
synthesizes branched chains with Ube2C and Ube2S. While Ube2S does not 
have a homologue in Saccharomyces cerevisiae, the Ube2C homologue Ubc11 
is only poorly expressed in cycling Saccharomyces cerevisiae cells (Chu et al., 
1998). In this study it was shown that Ube2S plays an important role in 
prometaphase, a cell cycle stage that might not be present at all or is present in a 
different form in S.cerevisiae, which undergoes closed mitosis, and metazoans, 
where nuclear envelope breakdown dictates that spindle assembly occurs 
without the chromosomes being confined to a subcellular compartment. 
Interestingly Nek2A activity correlates with phosphorylation of the nuclear pore 
complex protein 98 (Nup98) homologue and its dispersal from the nuclear pore 
complex in mitosis leads to partial disassembly of the nuclear envelope 
(Güttinger et al., 2009; De Souza et al., 2004). At the same time Nek2A was one 
of the APC/C substrates that was the most sensitive to inhibition of branching by 
Ube2S depletion. Also possibly reflecting these differences but highly speculative 
is that maybe only few substrates are degraded during early mitosis in 
S.cerevisiae, whereas in metazoans several examples of APC/C substrate 
degradation have been reported at this cell cycle time (Amador et al., 2007; 
Chow et al., 2012; Gabellini et al., 2003; Hayes et al., 2006; Peart et al., 2010; 
Sedgwick et al., 2013; Song and Rape, 2010; Wolthuis et al., 2008). In addition 
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prometaphase APC/C continuously disassembles spindle checkpoint complexes, 
which results in a dynamic interplay between the APC/C and the checkpoint. 
Checkpoint disassembly is strongly promoted by a metazoan specific protein, 
p31comet, which might point to an increased extent of checkpoint disassembly in 
these organisms (Foster and Morgan, 2012; Reddy et al., 2007; Uzunova et al., 
2012; Varetti et al., 2011; Williamson et al., 2009a). It is therefore speculated that 
the increased proteolytic capacity of branched chains, formation of which 
required the emergence of Ube2C producing short chains and Ube2S branching 
off K11-linked chains, allowed the metazoan APC/C to cope with higher demands 
on its activity during early stages of cell division.  
 
5.4. Concluding remarks and perspectives 
In this study the APC/C was identified as an enzyme that synthesizes branched 
ubiquitin chains. I also discovered a critical role for such conjugates in driving 
efficient proteasomal degradation. Branched conjugates are synthesized during 
mitosis when Ube2S adds multiple K11-linked chains to mixed assemblies 
produced by the initiating E2s of APC/C (Figure 55). Branched chains strongly 
improve proteasomal substrate recognition and accordingly are required for 
degradation at times of limited APC/C activity. Similar branching activities for K48 
and K63 specific enzymes were observed, suggesting that branched chains 
might frequently be employed in ubiquitin dependent signaling. Regarding the 
K11 branching activity of the APC/C, it will be interesting to determine if other 
E3s synthesizing non-K11-linked chains collaborate with the APC/C in building 
branched ubiquitin chains on common substrates. In future experiments other 
ways have to be developed to detect branched chains, i.e. raising antibodies 
specifically against branched chains or further improving mass spectrometry 
based approaches. This would allow the identification of other cellular processes 
regulated by ubiquitin chain branching. The presence of E4s in cells, enzymes 
elongating existing ubiquitin chains (Crosas et al., 2006; Huang et al., 2014; 
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Koegl et al., 1999; Liu et al., 2011; Shi et al., 2009), will have to be further 
investigated in the light of the results published in this study. !
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6. Abbreviations 
General abbreviations 
3’UTR Three prime untranslated region 
293T Human Embryonic Kidney 293 cells with large T antigen  
aa amino acids 
A adenine in context of DNA and RNA 
AMP adenosine-5’-monophosphate 
APC/C anaphase-promoting complex/cyclosome 
APS ammonium persulfate 
ATP adenosine-5’-triphosphate 
Aurora A Aurora A kinase = serine/threonine protein kinase 6 
C cytosine in context of DNA and RNA 
C- Carboxyl-, in context of proteins 
cDNA complementary DNA 
CD3 cluster of differention 3 
Cdc Cell-division cycle protein 
Cdh1 Cdc homologue twenty 1 
C.elegans Caenorhabditis elegans 
CHX cycloheximide 
CMV cytomegalovirus 
CRL cullin-RING based Ubiquitin E3 ligase  
Da Dalton 
∆ deletion of 
DBOX destruction box of APC/C substrates (RxxL) 
DMEM Dulbecco’s Modified Eagle Medium 
DMSO dimethylsulfoxide 
DNA deoxyribonucleic acid 
dNTP deoxynucleotide triphosphate 
DTT dithiothreitol 
DUB deubiquitinating enzyme 
E1 ubiquitin-activating enzyme 
E2 ubiquitin-conjugating enzyme 
E3 ubiquitin ligase 
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E.coli Escherichia coli 
EDTA ethylenediaminetetraacetic acid 
EGTA ethylene glycol tetraacetic acid 
Emi1 Early mitotic inhibitor 1 
ER Endoplasmic reticulum 
ERAD Endoplasmic-reticulum-associated protein degradation 
FACS Fluorescence-activated cell sorting applied in flow cytometry  
FAF1 FAS-associated factor 1 
FAF2 FAS-associated factor 3 
FCS fetal calve serum 
Flp flippase recombinase 
FRT flippase recognition target 
G guanine in context of DNA and RNA  
G0 gap zero phase 
G1 gap one phase 
G2 gap two phase 
GFP green fluorescent protein 
GST Glutathione-S-transferase 
HA Human influenza hemagglutinin 
HCl hyrdrochloric acid 
HeLa Henrietta Lacks human cervical cancer cell line  
HECT Homologous to the E6-AP Carboxyl Terminus 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HHR23A human UV excision repair protein RAD23 homolog A 
His- Hexahistidine tagged 
HURP Hepatoma up-regulated protein 
IF Immunofluorescence 
IM Initiation motif 
LB Luria-Bertani broth 
M  mitotic phase 
Mad2 mitotic arrest deficient 2 
MBP maltose-binding protein 
MCC mitotic checkpoint complex 
mRNA messenger ribonucleotide acid 
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MW molecular weight 
N- Amino-, in context of proteins 
NaCl sodium chloride 
NEBD nuclear envelope breakdown 
Nek2A Never in mitosis A-related kinase 2 
Ni-NTA nickel nitrilotriacetic acid 
NP40 Nonidet P-40 
NuSAP Nucleolar and spindle-associated protein 1 
oligo DNA or RNA oligonucleotide 
ORF open reading frame 
OTU ovarian tumor domain 
p47 NSFL1 cofactor p47 
p97 Transitional endoplasmic reticulum ATPase 
PAGE Polyacrylamide gel electrophoresis 
PBS phosphate buffered saline 
PCR polymerase chain reaction 
qRT-PCR real-time quantitative PCR 
RING really interesting new gene 
RNA ribonucleotide acid 
RNAi RNA interference 
S synthesis phase 
S5A 26S proteasome non-ATPase regulatory subunit 4 
SAC spindle assembly checkpoint 
SAKS1 SAPK substrate protein 1 
S.cerevisiae Saccharomyces cerevisiae 
SCF Skp1-Cul1-F-box 
SD standard deviation 
SDS sodium dodecyl sulfate 
siRNA small interfering RNA 
TAE Tris acetate EDTA 
TEMED Tetramethylethylenediamine 
Tet tetracycline 
TEV tobacco etch virus 
Tris tris(hydroxymethyl)aminomethane) 
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Triton X-100 4-octylphenol polyethoxylate 
thy thymidine 
U uracile in context of RNA 
Ub ubiquitin 
UBC ubiquitin-conjugating domain 
UBDX7 UBX domain-containing protein 7 
Ube2C ubiquitin-conjugating enzyme E2 C 
Ube2S ubiquitin-conjugating enzyme E2 S 
ubi ubiquitin 
UPS ubiquitin proteasome pathway 
Usp37 ubiquitin-specific-processing protease 37 
v/v volume per volume 
w/v weight per volume 
wt wildtype 
  
Units  
°C  degree Celsius 
g gram 
g acceleration of gravity on earth in the context of centrifuges 
h hour 
l/L litre 
m meter 
M molar (mol/L) 
min minute 
OD optical density 
pH negative common logarithm of the proton concentration 
rpm rounds per minute 
s second 
V Volt 
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Prefixes  
M mega- 106 
k kilo- 103 
c centi- 10-2 
m milli- 10-3 
µ micro- 10-6 
n nano- 10-9 
p pico- 10-12 
  
Code for amino acids 
A Ala alanine 
C Cys cysteine 
D Asp aspartate 
E Glu glutamate 
F Phe phenylalanine 
G Gly glycine 
H His histidine 
I Ile isoleucine 
K Lys lysine 
L Leu leucine 
M Met methionine 
N Asn asparagine 
P Pro proline 
Q Gln glutamine 
R Arg arginine 
S Ser serine 
T Thr threonine 
V Val valine 
W Trp tryptophane 
Y Tyr tyrosine 
X  any amino acid !
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